cancers

IMPACT FACTOR 6.575

Indexed in: PubMed

Anticancer Drugs and Herbal Products: From Interactions to Synergic Activity

Volume 14 · Issue 21 | November (I) 2022

MDPI

mdpi.com/journal/cancers
ISSN 2072-6694

cancers (/journal/cancers)

(https://www.ncbi.nlm.nih.gov/pubmed/?term=2072-6694)

Submit to *Cancers* (https://susy.mdpi.com/user/manuscripts/upload?form[journal_id]=23)

Review for *Cancers* (https://susy.mdpi.com/volunteer/journals/review)

Journal Menu

► Journal Menu

- *Cancers* Home (/journal/cancers)
- Aims & Scope (/journal/cancers/about)
- **Editorial Board (/journal/cancers/editors)**
- Reviewer Board (/journal/cancers/submission_reviewers)
- Topical Advisory Panel (/journal/cancers/topical_advisory_panel)
- Instructions for Authors (/journal/cancers/instructions)
- Special Issues (/journal/cancers/special_issues)
- Topics (/topics?query=&journal=cancers&status=all&category=all)
- Sections & Collections (/journal/cancers/sections)
- Article Processing Charge (/journal/cancers/apc)
- Indexing & Archiving (/journal/cancers/indexing)
- Editor's Choice Articles (/journal/cancers/editors_choice)
- Most Cited & Viewed (/journal/cancers/most_cited)
- Journal Statistics (/journal/cancers/stats)
- Journal History (/journal/cancers/history)
- Journal Awards (/journal/cancers/awards)
- Society Collaborations (/journal/cancers/societies)
- Conferences (/journal/cancers/events)
- Editorial Office (/journal/cancers/editorial_office)

Journal Browser

► Journal Browser

volume

issue

Back to TopTop

Editorial Board

- Molecular Cancer Biology Section (/journal/cancers/sectioneditors/Molecular_Cancer_Biology)
- Cancer Immunology and Immunotherapy Section (/journal/cancers/sectioneditors/Cancer_Immunology_Immunotherapy)
- Cancer Biomarkers Section (/journal/cancers/sectioneditors/Cancer_Biomarkers)
- Cancer Epidemiology and Prevention Section (/journal/cancers/sectioneditors/Cancer_Epidemiology_Prevention)
- Cancer Pathophysiology Section (/journal/cancers/sectioneditors/Cancer_Pathophysiology)
- Tumor Microenvironment Section (/journal/cancers/sectioneditors/Tumor_Microenvironment)
- Cancer Causes, Screening and Diagnosis Section (/journal/cancers/sectioneditors/Cancer_Causes_Screening_Diagnosis)
- Transplant Oncology and Cancer Nursing Care Section (/journal/cancers/sectioneditors/Cancer_Nursing_Care)
- Cancer Therapy Section (/journal/cancers/sectioneditors/Cancer_Therapy)
- Clinical Trials of Cancer Section (/journal/cancers/sectioneditors/Clinical_Trials_Cancer)
- Systematic Review or Meta-Analysis in Cancer Research Section (/journal/cancers/sectioneditors/Systematic_Review_Meta-Analysis)
- Methods and Technologies Development Section (/journal/cancers/sectioneditors/Methods_Technologies_Development)
- Cancer Informatics and Big Data Section (/journal/cancers/sectioneditors/Cancer_Informatics_Big_Data)
- Pediatric Oncology Section (/journal/cancers/sectioneditors/Pediatric_Oncology)
- Infectious Agents and Cancer Section (/journal/cancers/sectioneditors/Infectious_Agents_Cancer)
- Cancer Drug Development Section (/journal/cancers/sectioneditors/Cancer_Drug_Development)
- Cancer Metastasis Section (/journal/cancers/sectioneditors/Cancer_Metastasis)

Members (2116)

Search by first name, last name, affiliation,

Prof. Dr. Samuel C. Mok (https://sciprofiles.com/profile/148565)
Website (https://faculty.mdanderson.org/profiles/samuel_mok.html)
Editor-in-Chief
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Interests: gynecologic cancers; tumor microenvironment; diagnostic and prognostic biomarkers discovery; stomal-epithelial interaction; exosomes
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Mary Frances McMullin (https://sciprofiles.com/profile/1110906)
Website (https://pure.qub.ac.uk/en/persons/mary-frances-mcmullin)
Associate Editor-in-Chief
Centre for Medical Education, Queen's University Belfast, Belfast BT9 7BL, UK
Interests: myeloproliferative disorders; polycythaemia vera; idiopathic erythrocytosis; acute myeloid leukaemia; chronic myeloid leukaemia; clinical trials

Dr. Deepak Nagrath (https://sciprofiles.com/profile/531186)
Website (https://nagrath.bme.umich.edu/)
Associate Editor-in-Chief
Department of Biomedical Engineering, Department of Chemical Engineering, University of Michigan, NCRC, Bldg 28, Room 3048W, 2800 Plymouth Rd, Ann Arbor, MI 48109, USA
Interests: cancer metabolism; tumor microenvironment; metabolic profiling; systems biology; metabolomics
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. David Wong (https://sciprofiles.com/profile/277684)
Website1 (https://www.mbi.ucla.edu/archives/faculty/david-wong) Website2 (https://people.ctsi.ucla.edu/institution/personnel?personnel_id=46846)
Associate Editor-in-Chief
Director, Center for Oral/Head & Neck Oncology Research, School of Dentistry, Felix & Mildred Yip Endowed Professor & Associate Dean of Research, University of California Los Angeles, 10833 Le Conte Avenue, 73-034 CHS, Los Angeles, CA 90095, USA
Interests: oral cancer; salivary diagnostics; salivaomics; liquid biopsy; early detection
Special Issues, Collections and Topics in MDPI journals

Dr. J. Chad Brenner (https://sciprofiles.com/profile/790322) *
Website (https://medicine.umich.edu/dept/otolaryngology/j-chad-brenner-phd)
Associate Section Editor-in-Chief
Department of Otolaryngology—Head and Neck SurgeryDirector, Michigan Otolaryngology and Translational Oncology LaboratoryUniversity of Michigan Health Systems, Ann Arbor, MI 48109, USA
Interests: functional genomic; proteomic and bioinformatics approaches in cancer; sequencing the exomes and transcriptomes of head and neck cancer; drug sensitivities
* Section: Cancer Informatics and Big Data
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Dario Marchetti (https://sciprofiles.com/profile/93152) *
Website (https://hsc.unm.edu/directory/marchetti-dario-cc.html)
Associate Section Editor-in-Chief
1. Division of Molecular Medicine, Department of Internal Medicine, The University of New Mexico Health Sciences Center, Albuquerque, NM 87120, USA
2. Department of Pathology, The University of New Mexico Health Sciences Center, Albuquerque, NM 87120, USA
3. Full Member, UNM Comprehensive Cancer Center, Albuquerque, NM 87131, USA
Interests: the biology and therapeutic utility of circulating tumor cells (CTCs); liquid biopsies; mechanisms of brain metastasis and dormancy in breast and melanoma cancers; molecular crosstalks between dormant bone-marrow (BM) cells and CTCs; roles of BM and BM cellular heterogeneity interplaying with metastasis and dormancy
* Section: Tumor Microenvironment
Special Issues, Collections and Topics in MDPI journals

Dr. Subbaya Subramanian (https://sciprofiles.com/profile/37647) *
Website (http://subreelab.umn.edu/people/subree-subramanian)
Associate Section Editor-in-Chief
Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA
Interests: colorectal cancer; tumor immunology; T cells; immune cells; microbiome
* Section: Cancer Immunology and Immunotherapy
Special Issues, Collections and Topics in MDPI journals

Back to TopTop

Dr. Giovanna Tosato (https://sciprofiles.com/profile/83832) *
Website (https://ccr.cancer.gov/Laboratory-of-Cellular-Oncology/giovanna-tosato)
Associate Section Editor-in-Chief
Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20982, USA
Interests: endothelial cells; hematopoietic cells; cell signaling; ephrins; Ephs
* Section: Tumor Microenvironment

Dr. Maen Abdelrahim (https://sciprofiles.com/profile/1088402) *
Website (https://www.houstonmethodist.org/faculty/maen-abdelrahim/)
Section Editor-in-Chief
1. Section of Gastrointestinal Oncology - Houston Methodist Cancer Center and Institute of Academic Medicine. 6445 Fannin, OPC-24., Houston, TX 77030, USA
2. Cockrell Center for Advanced Therapeutics (CCAT) – Phase I Program, Houston Methodist Research Institute, Houston, TX 77030, USA
3. Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA
Interests: pancreatic cancer; liver cancer; cholangiocarcinoma; biliary cancer; transplant oncology; Phase I drugs; targeted therapy; drug discovery; immunotherapy
* Section: Transplant Oncology and Cancer Nursing Care
Special Issues, Collections and Topics in MDPI journals

Dr. Nicola Amodio (https://sciprofiles.com/profile/380363)
Website (https://scholar.google.com/citations?user=xu-0uusAAAAJ&hl=en)
Section Editor-in-Chief
Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy
Interests: cancer; epigenetics; miRNA; non-coding RNA; hematological malignancies
Special Issues, Collections and Topics in MDPI journals

Dr. Farrukh Aqil (https://sciprofiles.com/profile/1208998)
Website (http://louisville.edu/medicine/research/cancer/f0aqil01)
Section Editor-in-Chief
Department of Medicine, University of Louisville, Louisville, KY 40202, USA
Interests: drug delivery; nanotechnology; cancer chemoprevention and treatment; breast; lung and ovarian cancers; exosomes
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Anupam Bishayee (https://sciprofiles.com/profile/50407)
★(https://clarivate.com/highly-cited-researchers/2022) **Website (https://lecom.edu/faculty/anupam-bishayee/)**
Section Editor-in-Chief
College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, FL 34211, USA
Interests: bioactive natural compounds; cancer prevention; phytopharmacology; molecular mechanisms
Special Issues, Collections and Topics in MDPI journals

Dr. Kevin Camphausen (https://sciprofiles.com/profile/1107309)
Website (https://irp.nih.gov/pi/kevin-camphausen)
Section Editor-in-Chief
Radiation Oncology Branch, National Cancer Institute National Institutes of Health, Bethesda, MD 20892, USA
Interests: Radiation oncology; Radiation sensitizers; Glioblastoma; Grade 4 astrocytoma; Radiation Biomarkers

Back to TopTop

Dr. Ronald de Krijger (https://sciprofiles.com/profile/753762)
Website (https://www.umcutrecht.nl/en/ziekenhuis/zorgverleners/krijger-r-de)
Section Editor-in-Chief
Princess Máxima Center for Pediatric Oncology, Laboratory for Childhood Cancer Pathology, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands
Interests: solid pediatric tumors; endocrine tumors; molecular genetics
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Massimo Di Maio (https://sciprofiles.com/profile/1157210)
Website (https://www.oncology.unito.it/do/docenti.pl/Alias?massimo.dimaio#tab-profilo)
Section Editor-in-Chief
Department of Oncology, University of Turin, at SCDU Medical Oncology, Ordine Mauriziano Hospital, 10128 Turin, Italy
Interests: methodology of clinical trials; systematic reviews; meta-analyses; patient-reported outcomes.
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Alexandre Escargueil (https://sciprofiles.com/profile/667393)
Website (https://cvscience.aviesan.fr/cv/1946/alexandre-escargueil)
Section Editor-in-Chief
Centre de Recherche Saint-Antoine, Sorbonne Université, INSERM U938, F-75012 Paris, France
Interests: cancer cell pharmacology; anticancer drugs; drug resistance; predictive biomarkers; DNA damage response; cell signaling; tumor microenvironment
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Sanjay Gupta (https://sciprofiles.com/profile/161277)
Website (https://case.edu/medicine/bstp/research/trainers-directory?combine=&page=6)
Section Editor-in-Chief
Department of Urology, Case Western Reserve University, Cleveland, OH 44106, USA
Interests: cancer biomarkers; cancer therapeutics and drug repurposing; cancer chemoprevention; diet-nutrition and cancer; drug delivery; toxicology; oncogenes; cell signaling; epigenetic and cancer prevention; inflammatory responses; cancer stem cells
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Donat Kögel (https://sciprofiles.com/profile/820237)
Website (https://www.izn-frankfurt.de/mitglied/koegel/)
Section Editor-in-Chief
Experimental Neurosurgery, Neuroscience Center, Goethe-University Frankfurt, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany
Interests: brain tumors; intrinsic and acquired therapy resistance; apoptosis; autophagy; mitochondria as targets for cancer therapy; mechanisms of tumor cell migration and invasion
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Fiona Lyng (https://sciprofiles.com/profile/92083) *
Website (https://arrow.tudublin.ie/ditres/3/)
Section Editor-in-Chief
1. School of Physics and Clinical and Optometric Sciences, Technological University Dublin, City Campus, Dublin 8, Ireland
2. Radiation and Environmental Science Centre, Focas Research Institute, Technological University Dublin, Camden Row, Dublin 8, Ireland
Interests: low dose radiation; non-targeted effects; out of field effects; individual radiosensitivity; biophotonics for cancer diagnosis

Back to TopTop

* Section: Methods and Technologies Development

Special Issues, Collections and Topics in MDPI journals

(/toggle_desktop_layout_cookie)

Dr. Sam Mbulaiteye (https://sciprofiles.com/profile/399590) *

Website (https://dceg.cancer.gov/about/staff-directory/mbulaiteye-sam)

Section Editor-in-Chief

Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Dr., Room 6E-118, MSC 330, Rockville, MD 20850, USA

Interests: epidemiology; Burkitt lymphoma; Kaposi sarcoma; HIV-related cancers; Epstein-Barr virus; plasmodium falciparum malaria; genome-wide association studies; Africa, global oncology

* Section: Infectious Agents and Cancer

Prof. Dr. Massoud Mirshahi (https://sciprofiles.com/profile/271830) *

Website (https://www.emedevents.com/speaker-profile/massoud-mirshahi)

Section Editor-in-Chief

Lariboisière Hospital, INSERM U965, 41 Bd de la Chapelle, University of Sorbonne Paris Cité - Paris 7, 75010 Paris, France

Interests: cancer and throbosis; ovarian cancer; digestive carcinomatosis; cancer and immunity

* Section: Cancer Causes, Screening and Diagnosis

Special Issues, Collections and Topics in MDPI journals

Dr. Carlos S. Moreno (https://sciprofiles.com/profile/275203)

Website (https://open.library.emory.edu/profiles/cmoreno/)

Section Editor-in-Chief

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA

Interests: prostate cancer; breast cancer; bioinformatics; genomics; transcription; biomarkers

Special Issues, Collections and Topics in MDPI journals

Dr. Jason Roszik (https://sciprofiles.com/profile/687578) *

Website (https://faculty.mdanderson.org/profiles/janos_roszik.html)

Section Editor-in-Chief

Departments of Melanoma Medical Oncology and Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Interests: computational cancer genomics; next generation sequencing; targeted therapy; immunotherapy; target discovery; drug repurposing; rare cancers

* Section: Cancer Informatics and Big Data

Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Sanjay K. Srivastava (https://sciprofiles.com/profile/30889)

Website (https://www.ttuhsc.edu/pharmacy/directory/details.aspx?eRaiderUserName=sansriva)

Section Editor-in-Chief

Department of Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center, 1718 Pine Street, Abilene, TX 79601, USA

Interests: development of phytochemicals for cancer prevention and therapeutics; targeting STAT-3, NF-kB, HER2, MCL-1, AKT/FOXO, GLI1/2, and related signaling pathways with agents such as capsaicin, piperlongumine, penfluridol, isothiocyanates, diindolylmethane, panabinostat, cucurbitacin B, and deguelin in pancreatic, ovarian, breast, melanoma, and brain cancer; drug repurposing

Special Issues, Collections and Topics in MDPI journals

Dr. Barbara Wegiel (https://sciprofiles.com/profile/1574930)

Website (https://connects.catalyst.harvard.edu/Profiles/display/Person/64760)

Section Editor-in-Chief

Back to TopTop

Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Interests: innate immunity; macrophage; heme metabolism; cancer biology; immunometabolism
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Prasad S. Adusumilli
Website (https://www.mskcc.org/cancer-care/doctors/prasad-adusumilli)
Advisory Board Member
1. Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
2. Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Interests: CAR T-cell therapy; cancer immunology and immunotherapy; tumor microenvironment

Prof. Dr. Benjamin Bonavida (https://sciprofiles.com/profile/493189)
Website (https://www.mimg.ucla.edu/people/benjamin-e-bonavida-ph-d/)
Advisory Board Member
Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA 90095, USA
Interests: cancer biology; immunotherapy; chemotherapy; resistance; RKIP; YY1; NO; metastasis; suppressors; cytotoxicity
Special Issues, Collections and Topics in MDPI journals

Dr. Sean P. Collins
Website (https://gufaculty360.georgetown.edu/s/contact/00336000014RVJeAAO/sean-collins)
Advisory Board Member
Department of Radiation Medicine, Medstar Georgetown University Hospital, Washington, DC 20007, USA
Interests: prostate cancer; radiation therapy
Special Issues, Collections and Topics in MDPI journals

Prof. Francesco Di Meco
Website (https://invivox.com/profile/6639)
Advisory Board Member
Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
Interests: neuro-oncology; brain tumor surgery

Prof. Dr. Emanuela Esposito (https://sciprofiles.com/profile/436796)
Website (http://www.unime.it/it/persona/emanuela-esposito/curriculum)
Advisory Board Member
Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy
Interests: neuroinflammation; neuromodulation; astrocytes; spinal cord injury; brain trauma; cytokines; neurodegenerative disorders; brain tumors
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Jon Glass (https://sciprofiles.com/profile/2685082)
Website (https://hospitals.jefferson.edu/find-a-doctor/g/glass-jon.html)
Advisory Board Member
Department of Neurology, Vickie and Jack Farber, Institute for Neuroscience at Jefferson Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
Interests: primary cns lymphoma; gliomas; brain metastases

Prof. Dr. Bill Greenhalf (https://sciprofiles.com/profile/1834960)
Website (https://www.liverpool.ac.uk/systems-molecular-and-integrative-biology/staff/william-greenhalf/)
Advisory Board Member
Liverpool Experimental Cancer Medicine Centre, 2nd Floor Sherrington Building, Ashton St, University of Liverpool, Liverpool L69 3GE, UK
Interests: pancreatic cancer; pancreatitis; Hsp90

Back to TopTop

Prof. Dr. Frank Grünwald (https://sciprofiles.com/profile/2251171)
Website (https://www.kgu.de/einrichtungen/kliniken/zentrum-der-radiologie/nuklearmedizin/team)
Advisory Board Member
Department of Nuclear Medicine, University Hospital, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany
Interests: radioiodine; thyroid cancer; PSMA; prostate cancer; Lutetium; PRRT

Prof. Dr. Samir M. Hanash (https://sciprofiles.com/profile/839654)
Website (https://faculty.mdanderson.org/profiles/samir_hanash.html)
Advisory Board Member
Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Interests: cancer biomarkers; proteomics; cancer surfaceome; immunooncology
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Dave S.B. Hoon (https://sciprofiles.com/profile/1777178)
Website (https://www.saintjohnscancer.org/about-us/people/dave-hoon/)
Advisory Board Member
Department of Translational Molecular Medicine, Saint John's Cancer Institute (SJCI), Providence Saint John's Health Center (SJHC), Santa Monica, CA 90404, USA
Interests: Circulating Tumor Cells (CTC); circulating cell-free DNA/miRNA biomarkers; molecular blood biomarkers; epigenetic; ubiquitin; solid tumors

Prof. Dr. Eugen B. Hug
Website (https://www.pharmig-academy.at/die-pharmig-academy/fachexperten/hug-eugen-b/)
Advisory Board Member
MedAustron Ion Therapy Center, 2700 Wiener Neustadt, Austria
Interests: radiotherapy

Dr. Anita Kloss-Brandstätter (https://sciprofiles.com/profile/2416587)
Website (https://www.widsvillach.org/profile/anita-kloss-brandstaetter-ambassador/)
Advisory Board Member
Department of Engineering & IT, Carinthia University of Applied Sciences, 9524 Villach, Austria
Interests: oral cancer; oral squamous cell carcinoma; OSCC; heteroplasmy; mitochondrial DNA; mtDNA; next generation sequencing; NGS; survival analysis; haplogroup

Dr. Simon Langdon (https://sciprofiles.com/profile/75504)
Website (https://www.ed.ac.uk/pathology/people/staff-students/simon-langdon)
Advisory Board Member
Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, UK
Interests: ovarian cancer; cell signaling; experimental therapeutics
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Kiyoshi Maeda (https://sciprofiles.com/profile/2570445)
Website (https://researchmap.jp/read0185575?lang=en)
Advisory Board Member
Department of Gastroenterological Surgery, Osaka Metropolitan University, Osaka, Japan
Interests: surgical oncology; minimally invasive surgery; robotic surgery; prognostic factor; systemic inflammation; nutritional prognostic index

Back to TopTop

Dr. Yutaka Midorikawa (https://sciprofiles.com/profile/1093586)
Website (https://nrid.nii.ac.jp/nrid/1000010292905/)
Advisory Board Member
1. Department of Digestive Surgery, Nihon University School of Medicine, 30-1, Oyaguchikami-machi, Itabashi-ku, Tokyo 173-8610, Japan
2. Department of General Surgery, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan
Interests: colorectal cancer; hepatocellular carcinoma; colorectal cancer liver metastasis; genome; pathology; drug sensitivity; carcinogenesis; machine learning method; personalized medicine

Prof. Dr. Nasir Rajpoot
Website (https://www.pathlake.org/team/professor-nasir-rajpoot/)
Advisory Board Member
Department of Computer Science, Tissue Image Analytics Centre, University of Warwick, Coventry, UK
Interests: pattern recognition; digital pathology; cancer biomarkers; image analytics; applied machine learning

Prof. Dr. John Seymour (https://sciprofiles.com/profile/233949)
★(https://recognition.webofsciencegroup.com/awards/highly-cited/2020/) Website (https://findanexpert.unimelb.edu.au/profile/66765-john-seymour)
Advisory Board Member
1. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia
2. Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia
3. Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Australia
Interests: lymphoproliferative disorders; early drug development; clinical trials; targeting apoptosis
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Georg T. Wondrak (https://sciprofiles.com/profile/40421)
Website (https://www.pharmacy.arizona.edu/directory/profile/georg-wondrak-phd)
Advisory Board Member
Department of Pharmacology and Toxicology, College of Pharmacy and UA Cancer Center, University of Arizona, Tucson, AZ 85724, USA
Interests: oxidative stress; melanoma; skin cancer
Special Issues, Collections and Topics in MDPI journals

Dr. Erik H.J.G. Aarntzen
Website (https://www.radboudumc.nl/en/people/erik-aarntzen)
Editorial Board Member
Department of Medical Imaging, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands
Interests: nuclear medicine; molecular diagnostics; radiology; imaging; immunology

Dr. Tarek Abbas (https://sciprofiles.com/profile/1161396)
Website (https://med.virginia.edu/faculty/faculty-listing/ta8e/)
Editorial Board Member
Department of Radiation Oncology, University of Virginia, 1300 Jefferson Park Avenue, Charlottesville, VA, USA
Interests: genomic instability and human cancer; ubiquitin-dependent regulation of DNA replication; cellular responses to DNA damage; DNA damage repair
Special Issues, Collections and Topics in MDPI journals

Dr. Mohamed H. Abdel-Rahman
Website (https://wexnermedical.osu.edu/departments/ophthalmology/team/mohamed-abdel-rahman)
Editorial Board Member
Department of Ophthalmology, Division of Human Genetics, The Ohio State University, Columbus, OH 43210, USA
Interests: cancer genetics; cancer susceptibility; BAP1; ocular tumors; liver tumors

Prof. Dr. Amir Abdollahi
Website (https://www.dkfz.de/en/molekulare-radioonkologie/index.php)
Editorial Board Member

Back to TopTop

1. Division of Molecular and Translational Radiation Oncology, Heidelberg University Hospital (UKHD) Heidelberg Ion-Beam Therapy Center (HIT) Im Neuenheimer Feld 450 and Clinical Cooperation Unit Translational Oncology, 69120 Heidelberg, Germany
2. Cancer Consortium (DKTK), National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany
Interests: tumor evolution; translational research; radiation oncology; particle therapy; personalized oncology; tumor-stroma-communication; antiangiogenic therapy; tumor resistance

Prof. Dr. Bassam S. Abdulkarim
Website (https://www.mcgill.ca/oncology/bassam-abdulkarim)
Editorial Board Member
Division of Radiation Oncology, Department of Oncology, McGill University, Montreal, QC, Canada
Interests: basic and translational cancer research; radiation oncology; breast cancer; brain tumour

Dr. Ghassan Abou-Alfa
Website (https://www.mskcc.org/cancer-care/doctors/ghassan-abou-alfa)
Editorial Board Member
1. Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
2. Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA
Interests: liver cancer; HCC; cholangiocarcinoma; gallbaldder cancer; biliary cancer

Prof. Dr. Roger Abounader (https://sciprofiles.com/profile/467800)
Website (https://med.virginia.edu/faculty/faculty-listing/ra6u/)
Editorial Board Member
Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA 22903, USA
Interests: basic and translational brain tumor research
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Dietmar Abraham (https://sciprofiles.com/profile/55197)
Website (https://anatomieundzellbiologie.meduniwien.ac.at/abteilungen-wissenschaft-forschung/abteilung-fuer-zell-u-entwicklungsbiologie/cell-and-tissue-biology/group-abrahamzins/people/)
Editorial Board Member
Division of Cell and Developmental Biology, Center for Anatomy and Cell Biology, Medical University of Vienna, A-1090 Vienna, Austria
Interests: tumor-host interaction; tumor microenvironment; tumor-associated macrophage; signal transduction; tumor angiogenesis; CSF-1; IL-34; tumor invasion and metastasis; preclinical cancer therapeutics
Special Issues, Collections and Topics in MDPI journals

Dr. Elisabetta Abruzzese (https://sciprofiles.com/profile/1154919)
Website (https://www.hsangiovanni.roma.it/allegati/11712/CV_Abruzzese-9c40ade187af860dede7490698eeea52.pdf)
Editorial Board Member
Hematology, S. Eugenio Hospital, Tor Vergata University, ASL ROma2, 00144 Rome, Italy
Interests: Chronic Myeloid Leukema; Tyrosin kinase inhibitors in hematologic diseases (CML; ALL; mastocytosis; hypereosinophilia); myeloproliferative disorders; myelofibrosis; Hodgkin lymphoma; aggressive non -Hodgkin Lymphomas; pregnancy in hematologic diseases

Prof. Dr. Lynne V. Abruzzo (https://sciprofiles.com/profile/2651882)
Website (https://cancer.osu.edu/find-a-researcher/search-researcher-directory/lynne-v-abruzzo)
Editorial Board Member
Department of Pathology, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA
Interests: hematopathology; lymphoid leukemias and lymphomas; cytogenetics; molecular diagnostics

Dr. Farrukh Afaq (https://sciprofiles.com/profile/231748)
Website (https://scholars.uab.edu/display/fafaq)

Back to TopTop

Editorial Board Member
Department of Dermatology, The University of Alabama at Birmingham, Birmingham, AL 35294-0019, USA
Interests: cancer chemoprevention; photocarcinogenesis; melanoma; targeted therapies; psoriasis; biochemical toxicology; cell signaling pathways

Prof. Dr. Abbas Agaimy (https://sciprofiles.com/profile/1156878)
Website (https://thepathologist.com/power-list/2020/a-solid-foundation/abbas-agaimy)
Editorial Board Member
Institute of Pathology, University Hospital Erlangen, 91054 Erlangen, Germany
Interests: head & neck cancer with focus on salivary gland and sinonasal tract neoplasms; GI stromal tumors (GIST) with focus on molecular progression pathways, therapy effects and drug resistance; GI & pancreatobiliary cancer with focus on neuroendocrine and poorly differentiated/dedifferentiated neoplasms; soft tissue tumors/sarcoma; undifferentiated malignancies with focus on dedifferentiated melanoma; hereditary tumor syndromes with focus on neurofibromatosis type 1 & hereditary GI & urological cancer syndromes; SWI/SNF-deficient neoplasia with focus on the role of SWI/SNF complex in the initiation, progression and dedifferentiation of neoplasms of different organs

Prof. Dr. Sofia Agelaki (https://sciprofiles.com/profile/932843)
Website (https://www.hazliseconomist.com/en/past_speakercv/sofia_agelaki)
Editorial Board Member
1. Laboratory of Translational Oncology, School of Medicine, University of Crete, 71003 Heraklion, Crete, Greece
2. Department of Medical Oncology, University General Hospital of Heraklion, 71110 Heraklion, Crete, Greece
Interests: Circulating tumor cells; ctDNA; liquid biopsy; biomarkers; lung cancer; breast cancer

Prof. Dr. Massimo Aglietta (https://sciprofiles.com/profile/938281)
Website (https://medchirurgia.campusnet.unito.it/do/docenti.pl/Alias?massimo.aglietta#profilo)
Editorial Board Member
Department of Medical Oncology, Candiolo Cancer Institute, FPO—IRCCS—Str. Prov.le 142, km 3.95, 10060 Candiolo (TO), Italy
Interests: Sarcoma; gastrointestinal cancers; early clinical trials
Special Issues, Collections and Topics in MDPI journals

Dr. Massimiliano Agostini (https://sciprofiles.com/profile/1093482)
Website (https://centrotor.uniroma2.it/prof-massimiliano-agostini/)
Editorial Board Member
Department of Experimental Medicine, TOR, University of Rome Tor Vergata, Rome, Italy
Interests: p53 family; genes and metabolism; cancer

Prof. Dr. Manmeet Singh Ahluwalia (https://sciprofiles.com/profile/2225314)
Website (https://doctors.baptisthealth.net/provider/Manmeet+Singh+Ahluwalia/1832154)
Editorial Board Member
Department of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA
Interests: brain metastases; glioblastoma; clinical trial; neuro-oncology; glioma

Dr. Aamir Ahmad (https://sciprofiles.com/profile/857165)
Website (https://orcid.org/0000-0003-1784-5723)
Editorial Board Member
Department of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA
Interests: cancer epigenetics; metastasis; cancer drug resistance; tumor microenvironment; miRNA; non-coding RNAs; cancer stem cells
Special Issues, Collections and Topics in MDPI journals

Back to TopTop

Prof. Dr. Nihal Ahmad (https://sciprofiles.com/profile/232517)
Website (https://dermatology.wisc.edu/staff/ahmad-nihal/)
Editorial Board Member
Department of Dermatology, University of Wisconsin, 1300 University Avenue, Madison, WI 53706, USA
Interests: cancer biology; cancer prevention; resveratrol; experimental therapeutics of cancer

Prof. Dr. Myung-Ju Ahn
★(https://clarivate.com/highly-cited-researchers/2022) **Website (https://www.samsunghospital.com/gb/language/english/departments/departmentsDoctor.do?DP_CODE=IM6&DP_ENGNM=Hematology%20and%20Oncology)**
Editorial Board Member
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul135-710, Korea
Interests: lung cancer; head and neck cancer; translational research; targeted agents; immunotherapy; molecular biology

Dr. Sikander Ailawadhi (https://sciprofiles.com/profile/1489599)
Website (https://www.mayo.edu/research/faculty/ailawadhi-sikander-m-d/bio-20490027)
Editorial Board Member
Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL 100151, USA
Interests: Multiple myeloma; Healthcare disparities; Health services and outcomes research

Prof. Dr. Jaffer A. Ajani (https://sciprofiles.com/profile/588460)
Website (https://faculty.mdanderson.org/profiles/jaffer_ajani.html)
Editorial Board Member
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, TX 77030, USA
Interests: gastroesophageal cancer; peritoneal carcinoma of GI origin; clinical trials; multidisciplinary care; multimodality therapy
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Yukihiro Akao (https://sciprofiles.com/profile/57871)
Website (https://www1.gifu-u.ac.jp/~rensou/english/03outline/03_05.html)
Editorial Board Member
United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan
Interests: roles of microRNAs in carcinogenesis; anti-cancer effect of phytochemicals; anti-cancer effect of fatty acid-analogues
Special Issues, Collections and Topics in MDPI journals

Dr. Bertal Aktas
Website (https://connects.catalyst.harvard.edu/Profiles/display/Person/48593)
Editorial Board Member
Department of Medicine, Hematology, Brigham and Women's Hospital, Boston, MA 02115, USA
Interests: translation initiation; cellular transformation; Ras Oncogenes; anti-cancer drug discovery; high throughput screening

Prof. Dr. Rita Alaggio
Website (https://research.uniroma1.it/researcher/9eac9c44b294db0e653199f6031c5ae5435255ba65ae3681746df440)
Editorial Board Member
IRCCS Ospedale Pediatrico Bambino Gesù, 00165 Rome, Italy
Interests: paediatric pathology; soft tissue tumors

Back to TopTop

Prof. Dr. Suresh K Alahari (https://sciprofiles.com/profile/107731)
Website (http://www.medschool.lsuhsc.edu/biochemistry/lab_alahari.aspx)
Editorial Board Member
Department of Biochemistry and Molecular Biology, LSU School of Medicine, CSRB 406, 533 Bolivar Street, New Orleans, LA 70112, USA
Interests: cell adhesion; Nischarin; tumor cell migration; invasion, microRNA, lncRNA
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Saverio Alberti (https://sciprofiles.com/profile/66643)
Website (https://www.spandidos-publications.com/checkEbmUserDetails/998906)
Editorial Board Member
Laboratory of Cancer Pathology, CeSI-MeT, University ‘G. d’Annunzio’, 66013 Chieti, Italy; Unit of Medical Genetics, BIOMORF Department of Biomedical Sciences, University of Messina, 98100 Messina, Italy
Interests: medical genetics; medical oncology; molecular biology; flow cytometry; immunology; genomic analyses; next-generation DNA sequencing

Prof. Dr. Adriana Albini (https://sciprofiles.com/profile/1110662)
Website (https://moh-it.pure.elsevier.com/en/persons/adriana-albini)
Editorial Board Member
Laboratory of Vascular Biology and Angiogenesis, IRCCS MultiMedica, 20138 Milan, Italy
Interests: innate immunity; angiogenesis; invasion

Prof. Dr. Luca Antonio Aldrighetti (https://sciprofiles.com/profile/1298432)
Website1 (http://www.hsr.it/strutture/ospedale-san-raffaele/chirurgia-epatobiliare) **Website2 (https://www.hsr.it/dottori/luca-aldrighetti)**
Editorial Board Member
San Raffaele Hospital, Hepatobiliary Surgery Division, Head Vita-Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy
Interests: Hepatocellular Carcinoma; Cholangiocarcinoma; Liver Metastases

Prof. Dr. Peccatori Fedro Alessandro (https://sciprofiles.com/profile/1049860)
Website (https://www.ieo.it/en/PNA/doctorSection/Peccatori-Fedro-Alessandro-AFBCBCB9ADB3C9CCBCCEC9B9CDCFCAAC/)
Editorial Board Member
Division of Gynecologic Oncology, European Institute of Oncology IRCCS Via Ripamonti 435, 20141 Milan, Italy
Interests: gynecological malignancies, breast cancer, fertility preservation, cancer in pregnancy

Dr. Krystallenia Alexandraki (https://sciprofiles.com/profile/809429)
Website (https://www.jelsciences.com/editor-biography.php?id=812&eName=%C2%A0%C2%A0%C2%A0Krystallenia-Alexandraki-------)
Editorial Board Member
2nd Department of Surgery, Aretaieion University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Interests: endocrine neoplasms; neuroendocrinology; thyroid disease
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Roberta Alfieri (https://sciprofiles.com/profile/982575)
Website (https://www.unipr.it/ugov/person/18129?__cf_chl_captcha_tk__=TSclxgWluit1yx3t12hytvADwQLNj5bfUyRa9scL4Q0-

1640161128-0-gaNycGzNCGU)
Editorial Board Member
Department of Medicine and Surgery, University of Parma, Parma, Italy
Interests: non-small cell lung cancer; EGFR; TKI; drug resistance; PD1-PDL1

Prof. Dr. Francis Ali-Osman (https://sciprofiles.com/profile/2579287)
Website (https://neurosurgery.duke.edu/profile/francis-ali-osman)
Editorial Board Member
1. Department of Neurosurgery, Duke University School of Medicine, Durham, NC, USA
2. Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA
Interests: diethyldithiocarbamic acid; nepicastat; antineoplastic activity stem cell factor; proto-oncogene proteins C-kit; kits

Prof. Dr. Marco Alifano (https://sciprofiles.com/profile/940972)
★(https://clarivate.com/highly-cited-researchers/2022) Website (https://scholar.google.com/citations?hl=zh-CN&user=jH1VAp8AAAAJ&view_op=list_works&sortby=pubdate)
Editorial Board Member
Thoracic Surgery, Cochin Hospital, AP-HP Centre-University of Paris, 75014 Paris, France
Team Cancer, Immune Control and Escape, Cordeliers Research Center, INSERM UMRS 1138, 75006 Paris, France
Interests: Thoracic Surgery; Lung Cancer; morphomics; inflammation; nutrition; host-disease interaction
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Heike Allgayer (https://sciprofiles.com/profile/1406402)
Website (https://tgh.amegroups.com/user/view/59786)
Editorial Board Member
Department of Experimental Surgery - Cancer Metastasis, Medical Faculty Mannheim, Ruprecht Karls University of Heidelberg, 68167 Mannheim, Germany
Interests: cancer metastasis; translational research; tumor-associated proteases; microRNAs; molecular staging; gastrointestinal cancers
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Lucia Altucci (https://sciprofiles.com/profile/407181)
Website (https://www.medicinadiprecisione.unicampania.it/dipartimento/docenti?MATRICOLA=057968)
Editorial Board Member
Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138 Napoli, Italy
Interests: leukaemia; epigenetic; personalized medicine; networking approaches
Special Issues, Collections and Topics in MDPI journals

Dr. Arnaud Alves (https://sciprofiles.com/profile/2433713)
Website (https://orcid.org/0000-0002-7280-8688)
Editorial Board Member
Calvados Digestive Cancer Registry, University Hospital of Caen, 14000 Caen, France
Interests: colorectal surgery; oncology; chronic inflammatory bowel disease and socio-economic and territorial inequalities

Dr. Stefan Ambs (https://sciprofiles.com/profile/1618135)
Website (https://irp.nih.gov/pi/stefan-ambs)
Editorial Board Member
Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
Interests: breast cancer; prostate cancer; epidemiology; health disparity; metabolism; inflammation

Back to TopTop

Prof. Dr. Lesley Anderson
Website (https://www.abdn.ac.uk/people/lesley.anderson)
Editorial Board Member
School of Medicine, Medical Science and Nutrition, University of Aberdeen, Aberdeen AB24 3FX, UK
Interests: epidemiology; public health; aetiology; data science

Dr. Paul R. Andreassen (https://sciprofiles.com/profile/619117)
Website (https://www.cincinnatichildrens.org/bio/a/paul-andreassen)
Editorial Board Member
Division of Experimental Hematology & Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229 USA
Interests: DNA damage responses; fanconi anemia; breast cancer susceptibility proteins

Prof. Dr. Adriano Angelucci (https://sciprofiles.com/profile/320218)
Website (http://discab.univaq.it/index.php?id=915)
Editorial Board Member
Department of Biotechnological and Applied Clinical Science, University of L'Aquila, 67100 L'Aquila, Italy
Interests: cell pathology; cancer progression; cancer metastasis; targeted therapy; tyrosine kinase inhibitors
Special Issues, Collections and Topics in MDPI journals

Dr. Christina Messineo Annunziata (https://sciprofiles.com/profile/1095344)
Website (https://irp.nih.gov/pi/christina-annunziata)
Editorial Board Member
Women's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Interests: ovarian cancer; clinical trials; immunotherapy; NF-kappaB; cancer stem cells

Prof. Dr. Vasso Apostolopoulos (https://sciprofiles.com/profile/139297)
Website (https://www.vu.edu.au/research/vasso-apostolopoulos)
Editorial Board Member
Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia
Interests: immunology; drugs; vaccines; autoimmune disorders; cancer; infectious diseases; prevention of chronic diseases; healthy ageing; mental health; drug addiction; SARS-CoV-2
Special Issues, Collections and Topics in MDPI journals

Dr. Marcos Araúzo-Bravo (https://sciprofiles.com/profile/1132800)
Website (https://www.ikerbasque.net/en/marcos-j-arauzo-bravo)
Editorial Board Member
1. Computational Biology and Systems Biomedicine, Biodonostia Health Research Institute, Calle Doctor Begiristain s/n, 20014 San Sebastian, Spain
2. Basque Foundation for Science, IKERBASQUE, Calle María Díaz Harokoa 3, 48013 Bilbao, Spain
3. CIBER of Frailty and Healthy Aging (CIBERfes), 28029 Madrid, Spain
4. Max Planck Institute for Molecular Biomedicine, Computational Biology and Bioinformatics, Röntgenstr. 20, 48149 Münster, Germany
5. Department of Cell Biology and Histology, Faculty of Medicine and Nursing, University of Basque Country (UPV/EHU), 48940 Leioa, Spain
Interests: Computational Biology; Next Generation Sequencing; Single Cell Data Analysis; Artificial Intelligence; Machine Learning; Deep Learning; Image Processing; Data Mining; Biomedical Data Analysis; Systems Biology; Epigenomics; Epigenetic Regulation; Cancer Metabolism.

Prof. Dr. William Arcese (https://sciprofiles.com/profile/1117917)
Website (https://www.ptvonline.it/index.php/component/phocadownload/category/4-amministrazione-trasparente?download=462:cv-arcese)
Editorial Board Member
Department of Biomedicine and Prevention, Tor Vergata University of Rome, 00133 Rome, Italy
Interests: Allogeneic and Autologous Stem Cell Transplantation; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodisplastic Diseases; Myeloproliferative Diseases; Cellular Immunotherapy

Back to TopTop

Prof. Dr. Sandro Ardizzone (https://sciprofiles.com/profile/2433452)
Website (https://www.topdoctors.it/dottor/sandro-ardizzone)
Editorial Board Member
Division of Gastroenterology, ASST Fatebenefratelli-Sacco, via G.B. Grassi 74, 20157 Milano, Italy
Interests: gastroenterology; digestive endoscopy; inflammatory bowel disease (IBD)
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Alexander Arlt (https://sciprofiles.com/profile/434520)
Website (http://inflammation-at-interfaces.de/en/profile/members/members/alexander-arlt)
Editorial Board Member
Laboratory of Molecular Gastroenterology & Hepatology, Department of Internal Medicine I, UKSH-Campus Kiel, 24105 Kiel, Germany
Interests: NF-kappaB; cell death; pancreatic cancer; inflammation
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Eishi Ashihara (https://sciprofiles.com/profile/1081536)
Website (https://nrid.nii.ac.jp/nrid/1000070275197/)
Editorial Board Member
Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, 5 Nakauchi, Misasagi, Yamashina, Kyoto 607-8414, Japan
Interests: molecular targeting therapy; epigenetics; cancer; hematological malignancy; multiple myeloma; cancer stem cell; nucleic acid medicine; drug delivery system; exosome
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. David Ashley
Website (https://scholars.duke.edu/person/David.Ashley)
Editorial Board Member
Department of Neurosurgery, Duke University Medical School, Durham, NC 27701, USA
Interests: Brain tumors; Glioblastoma; Immunotherapy; Innate immunity; Epigenetics; Genomics

Prof. Dr. Chalid Assaf (https://sciprofiles.com/profile/1499224)
Website (https://www.helios-gesundheit.de/kliniken/krefeld/unser-angebot/mitarbeiter/profil/person/chalid-assaf/)
Editorial Board Member
1. Department of Dermatology and Allergy, Skin Cancer Center Charité, Charité—Universitätsmedizin Berlin, 10117 Berlin, Germany
2. Department of Dermatology and Venerolgy, HELIOS Klinikum Krefeld, 47805 Krefeld, Germany
Interests: dermatooncology; cutaneous lymphoma; malignant melanoma; dermatopathology; clinical trials; targeted therapies; autoimmune diseases
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Eric Assenat (https://sciprofiles.com/profile/1884687)
Website (https://www.orpha.net/consor/cgi-bin/Directory_Professionals.php?lng=EN&data_id=29043&MISSING%20CONTENT=Dr-Eric-ASSENAT&title=Dr-Eric-ASSENAT)
Editorial Board Member
Medical Oncology Department, CHU St. Eloi, 34000 Montpellier, France
Interests: Hepatocellular Carcinoma; Pancreatic Cancer; Endocrine tumor; Biliary tract cancer; Digestive Oncology; Translationnal Research; Liver physiopathology and carcinogenesis; Digestive Enndoscopy

Prof. Dr. Djordje Atanackovic (https://sciprofiles.com/profile/825760)
Website (https://www.medschool.umaryland.edu/profiles/Atanackovic-Djordje/)
Editorial Board Member

Back to TopTop

Blood and Marrow Transplantation Program, Department of Medicine, University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA

Interests: tumor immunology; cancer immunotherapy; CAR T cells; cancer vaccines; T cells; monoclonal antibodies; multiple myeloma; stem cell transplantation; adoptive immunotherapy

Special Issues, Collections and Topics in MDPI journals

Dr. Patrick Auberger (https://sciprofiles.com/profile/9267)

Website (http://www.unice.fr/c3m/EN/Equipe2.html)

Editorial Board Member

Team "Myeloid Malignancies and Multiple Myeloma", Université Côte d'Azur, Inserm U1065/C3M, 06204 Nice, France

Interests: Onco-Hematology; signaling; apoptosis; autophagy; resistance to Therapy; new therapeutic strategies

Special Issues, Collections and Topics in MDPI journals

Dr. Didier Auboeuf (https://sciprofiles.com/profile/896891)

Website (http://www.ens-lyon.fr/LBMC/laboratoire/annuaire/1-auboeuf-didier)

Editorial Board Member

Laboratory of Biology and Modelling of the Cell, Ecole Normale Supérieure de Lyon, 69342 Lyon, France

Interests: Splicing; Splicing Factors; RNA Binding Proteins; RNA Processing.

Dr. Antonio Avallone (https://sciprofiles.com/profile/2213073)

Website (https://moh-it.pure.elsevier.com/en/persons/antonio-avallone)

Editorial Board Member

National Cancer Institute, Fondazione G. Pascale, 80131 Napoli, Italy

Interests: colorectal; neoadjuvant rectal; PET-FDG in rectal cancer

Prof. Dr. Matias A. Avila (https://sciprofiles.com/profile/1070389)

Website (https://cima.cun.es/investigacion/personal-investigacion/matias-avila-zaragoza)

Editorial Board Member

1. Hepatology Program, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain
2. Hepatology Program, CIMA, University of Navarra, Pamplona, Spain

Interests: hepatocarcinogenesis; cell signaling; differentiation; epigenetics

Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Irit Avivi

Website (https://www.tasmc.org.il/sites/en/Personnel/pages/avivi-irit.aspx)

Editorial Board Member

1. Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center, 6 Weizmann St., Tel Aviv 6423906, Israel
2. Institute of Hematology, Tel-Aviv Sourasky Medical Center, 6 Weizmann St., Tel Aviv 6423906, Israel

Interests: multiple myeloma; non Hodgkin lymphoma; hematologic malignancy

Prof. Dr. Sanjay Awasthi (https://sciprofiles.com/profile/827786)

Website (https://www.ttuhsc.edu/medicine/internal/research/bios/awasthi.aspx)

Editorial Board Member

1. Department of Internal Medicine, Division of Hematology & Oncology, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA
2. Department of Surgery, Texas Tech University Health Sciences Center, Lubbock, TX 79415, USA

Interests: glutathione-mediated xenobiotic metabolism and transport of glutathionylated metabolites; oxidative stress; EGFR; Ral; Ras; Rac; Rho; MEK; ERK; MYC; p53; Rb; mTOR; AKT; PI3K; JAK/STAT; VHL; WNT and Ca pathway signaling; epigenetic regulation of gene expression; carcinogenesis; oncogenic and tumor suppressor pathways; transport mediated cancer drug resistance; radiation resistance; cancer therapy (all

Back to TopTop

sites and histologies)
Special Issues, Collections and Topics in MDPI journals

(/toggle_desktop_layout_cookie)

Prof. Dr. Cihan Ay (https://sciprofiles.com/profile/886273)
Website (https://innere-med-1.meduniwien.ac.at/haematology/allgemeine-informationen/mitarbeiterinnen/cihan-ay/)
Editorial Board Member
Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria
Interests: venous thromboembolism; cancer; cancer-associated thrombosis; anticoagulation; risk factors; haemostasis; bleeding

Prof. Dr. Francis A. Ayuk
Website (https://www.uke.de/allgemein/arztprofile-und-wissenschaftlerprofile/arztprofilseite_francis_ayuk.html)
Editorial Board Member
Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
Interests: stem cell transplantation; cell and gene therapy

Prof. Dr. David Azria (https://sciprofiles.com/profile/2214959)
Website (https://www.icm.unicancer.fr/fr/annuaire-professionnels/david-azria)
Editorial Board Member
Montpellier Cancer Institute (ICM), University of Montpellier, Montpellier, France
Interests: radiobiology; radiotherapy; prostate cancer; normal tissue; predictive assays
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Giuseppe Badalamenti (https://sciprofiles.com/profile/969309)
Website (https://pure.unipa.it/en/persons/giuseppe-badalamenti-4)
Editorial Board Member
Department of Surgical, Oncological, and Oral Sciences, Section of Medical Oncology, University of Palermo, Via Del Vespro 127, Palermo, Italy
Interests: soft tissue sarcomas; gastrointestinal stromal tumors; neuroendocrine tumors
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Cećile Badoual (https://sciprofiles.com/profile/848552)
Website (https://www.esmo.org/about-esmo/profiles/cecile-badoual)
Editorial Board Member
Department of Pathology, European Hospital Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, F-75015 Paris, France
Interests: Head and Neck Squamous Carcinoma; Human Papillomavirus; Pathology; Microenvironment; Immunotherapy
Special Issues, Collections and Topics in MDPI journals

Dr. Dominique Bagnard (https://sciprofiles.com/profile/821224)
Website (https://www.neurex.org/the-research-network/by-city/strasbourg/item/241)
Editorial Board Member
INSERM 1119, BMNST Laboratory, Université de Strasbourg, 67000 Strasbourg, France
Interests: cancer drug design; cancer drug development; cancer biomarkers; drug efficacy; molecular signature; therapeutic peptides; in vivo models; organoids

Prof. Dr. Armita Bahrami (https://sciprofiles.com/profile/2223784)
Website (https://winshipcancer.emory.edu/bios/faculty/bahrami-armita.html)

Back to TopTop

Editorial Board Member

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30307, USA

Interests: genetics of sarcoma; pathology of sarcoma; pathology of pediatric solid tumors; pathology of bone and soft tissue tumors; genetics of pediatric solid tumors; pathology and genetics of pediatric melanoma; telomerase and cancer

Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Simon Bailey

Website (https://www.ncl.ac.uk/medical-sciences/people/profile/simonbailey.html)

Editorial Board Member

Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle upon Tyne NE1 7RU, UK

Interests: paediatric oncology; cancer biomarkers

Dr. Martin J. Baker (https://sciprofiles.com/profile/987790)

Website (https://www.mankatomortuary.com/obituaries/martin-baker)

Editorial Board Member

Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, 1256 Biomedical Research Building II/III, 421 Curie Blvd., Philadelphia, PA 19104-6160, USA

Interests: GTPase; Rac1; Ras; signaling; prostate cancer; receptor signaling; g-protein

---

Dr. Leonora Balaj

Website (https://connects.catalyst.harvard.edu/Profiles/display/Person/115192)

Editorial Board Member

Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, USA

Interests: role of extracellular vesicles (EVs) and their potential as carriers of biomolecules relevant to disease detection; progression as well as potential therapeutics

Special Issues, Collections and Topics in MDPI journals

Dr. Alfonso Baldi (https://sciprofiles.com/profile/594572)

Website (http://www.alfonsobaldi.it/curriculum-vitae/)

Editorial Board Member

Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania "L. Vanvitelli", 81020 Caserta, Italy

Interests: electrochemotherapy; cancer; cell culture; gene expression; immunohistochemistry; cell signaling; apoptosis; cell proliferation; cancer biomarkers; regression analysis; phosphorylation; diagnosis; endometriosis; melanoma; osteoarthritis; articular cartilage; p53; chondrocytes; mesothelioma

Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Nicola Baldini (https://sciprofiles.com/profile/1356340)

Website (https://www.unibo.it/sitoweb/nicola.baldini5)

Editorial Board Member

1. Laboratory for Orthopaedic Pathophysiology and Regenerative Medicine, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy
2. Department of Biomedical and Neuromotor Sciences, University of Bologna, 40123 Bologna, Italy

Interests: sarcoma; bone metastases; tumor microenvironment

Prof. Dr. Reto J. Bale (https://sciprofiles.com/profile/766849)

Website (http://sip.i-med.ac.at/img/pdf/LebenslaufBale.pdf)

Editorial Board Member

Department of Radiology, Section of Interventional Oncology-Microinvasive Therapy, Medical University of Innsbruck, 6020 Innsbruck, Austria

Interests: minimal invasive; interventional oncology; thermal ablation; image fusion; stereotaxy; navigation; microwave ablation; radiofrequency ablation; stereotactic radiofrequency ablation (SRFA); liver tumor; percutaneous tumor treatment

Prof. Dr. Marija Balić (https://sciprofiles.com/profile/783482)
Website (https://forschung.medunigraz.at/fodok/suchen.person_uebersicht?sprache_in=en&menue_id_in=101&id_in=80089)
Editorial Board Member
Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria
Interests: breast cancer; systemic treatment; clinical trials; liquid biopsy; circulating tumor cells
Special Issues, Collections and Topics in MDPI journals

Dr. Gianpaolo Balzano (https://sciprofiles.com/profile/1559242)
Website (https://moh-it.pure.elsevier.com/en/persons/gianpaolo-balzano)
Editorial Board Member
Division of Pancreas Surgery, Clinical and Translational Pancreas Center, San Raffaele Hospital, 20132 Milan, Italy
Interests: pancreatic cancer,; pancreatic surgery; minimally invasive pancreas surgery; neoadjuvant treatments; neuroendocrine tumors; cystic pancreatic neoplasia,; ERAS

Prof. Dr. Hamid Band (https://sciprofiles.com/profile/1134793)
Website (https://www.unmc.edu/eppley/about/faculty/band.html)
Editorial Board Member
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA
Interests: cancer cell signaling; tyrosine kinases; ubiquitin pathways; receptor traffic; breast cancer; leukemogenesis; cancer immunology

Prof. Dr. Debabrata Banerjee (https://sciprofiles.com/profile/704254)
Website (https://burdwandoctors.com/listing/prof-dr-debabrata-banerjee-2/)
Editorial Board Member
Department of Pharmacology, Rutgers, Robert Wood Johnson Medical School (RWJMS), Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA
Interests: metabolic cooperation between tumor cells and stromal cells; role of carcinoma associated fibroblasts
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Aria Baniahmad (https://sciprofiles.com/profile/305160)
Website (https://www.uniklinikum-jena.de/humangenetik/Allgemeine+Informationen/Mitarbeiter/individuelle+Mitarbeiterseiten/Baniahmad+Aria+CV.html)
Editorial Board Member
Institute of Human Genetics, Jena University Hospital, Am Klinikum 1, Jena 07747, Germany
Interests: Androgen regulation of prostate cancer; Androgen receptor biology; Cellular senescence in cancer

Prof. Dr. João T. Barata (https://sciprofiles.com/profile/1065272)
Website (https://imm.medicina.ulisboa.pt/investigation/laboratories/joao-barata-lab/#intro)
Editorial Board Member
Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal
Interests: leukemia; cancer biology; signaling; signaling therapies; targeted therapies; Interleukin-7; lymphopoiesis; T cells

Prof. Dr. Wollenberg Barbara (https://sciprofiles.com/profile/407545)
Website (https://www.professoren.tum.de/en/wollenberg-barbara)
Editorial Board Member
Department of Otolaryngology Head and Neck Surgery, Technical University Munich, 80333 Munich, Germany
Interests: head and neck cancer (HNSCC); tumorimmunology; immunotherapy; clinical study HNSCC; platelets; platelet-driven cancer progression; toll like receptors and cancer
Special Issues, Collections and Topics in MDPI journals

Back to TopTop

Dr. Massimo Barberis (https://sciprofiles.com/profile/589082)
Website (https://www.ieo.it/it/PNA/Trova-Medico/Massimo-Barberis-BDADBDB2ACB2CBC6BACFC9B3CDCEC6BB/)
Editorial Board Member
Istituto Europeo di Oncologia, Milan, Italy
Interests: molecular pathology; thoracic oncology; laboratory management
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Raymond Barnhill (https://sciprofiles.com/profile/2383633)
Website (https://www.raymondbarnhillmd.com/)
Editorial Board Member
Department of Translational Research, Institut Curie, 75005 Paris, France
Interests: melanoma; pathology; biology of metastases; extravascular migratory metastasis/pericytic mimicry; angiotropism; vascular co-option; histopathologic growth patterns of metastasis

Dr. Rupert Bartsch (https://sciprofiles.com/profile/1323461)
Website (https://www.meduniwien.ac.at/hp/n790-clinical-oncology/research-groupssupervisors/supervisors-a-b/bartsch-rupert/)
Editorial Board Member
Department of Medicine 1, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria
Interests: Breast Cancer; HER2; Immunotherapy; Endocrine Treatment; Brain Metastases

Prof. Dr. David S. Baskin (https://sciprofiles.com/profile/87716)
Website (https://www.houstonmethodist.org/faculty/david-baskin/)
Editorial Board Member
Department of Neurosurgery, Houston Methodist Hospital, Houston, TX 77030, USA
Interests: stroke; neurological surgery; brain tumors
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Fulvio Basolo (https://sciprofiles.com/profile/462396)
Website (https://www.unipi.it/index.php/documenti-ateneo/item/9699-fulvio-basolo)
Editorial Board Member
Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, 56126 Pisa, Italy
Interests: surgical pathology; thyroid cancer; thyroid cytology; cytopathology; molecular pathology; molecular genetics

Prof. Dr. Alakananda Basu (https://sciprofiles.com/profile/6797)
Website (https://experts.unthsc.edu/en/persons/alakananda-basu)
Editorial Board Member
Department of Microbiology, Immunology & Genetics, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
Interests: Signal transduction, Akt, protein kinase C, mechanistic target of rapamycin/S6 kinase, apoptosis, autophagy, senescence, breast cancer
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Maxime Battistella (https://sciprofiles.com/profile/1416153)
Website (https://www.aphp.fr/offre-de-soin/medecin/3208652/076/23)
Editorial Board Member
1. Department of Pathology, Saint-Louis University Hospital, 75010 Paris, France
2. Pathology Department, Université de Paris, 75010 Paris, France
3. INSERM U976, 75010 Paris, France

Back to TopTop

Interests: skin sarcoma; cutaneous lymphoma; adnexal carcinomas; melanoma; translational research; immunotherapy; targeted treatment; molecular pathology

Dr. Brigitta G. Baumert (https://sciprofiles.com/profile/1085700)
Website (https://www.ksgr.ch/brigitta-baumert)
Editorial Board Member
Institute of Radiation Oncology, Cantonal Hospital Graubuenden, 7000 Chur, Switzerland
Interests: neuro-oncology; radiation-oncology; brain tumours; imaging for radiotherapy
Special Issues, Collections and Topics in MDPI journals

Dr. Brigitte Bauvois (https://sciprofiles.com/profile/63790)
Website (https://www.researchgate.net/profile/Brigitte-Bauvois)
Editorial Board Member
Centre de Recherche des Cordeliers, INSERM, Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Sorbonne Université, Université Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, F-75006 Paris, France
Interests: Onco-hematology; hemoregulators; cell death; metalloproteinase; signaling

Dr. Constantin N. Baxevanis (https://sciprofiles.com/profile/110777)
Website (https://cnbaxevanis.com/)
Editorial Board Member
Cancer Immunology and Immunotherapy Center, Cancer Research Center, Saint Savas Cancer Hospital, 171 Alexandras Av., 11522 Athens, Greece
Interests: cancer immunology; cancer immunotherapy; biomarkers; precision oncology; resistance; cancer vaccines; immune escape; immune checkpoint inhibitors
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Richard Bayliss (https://sciprofiles.com/profile/405763)
Website (https://biologicalsciences.leeds.ac.uk/molecular-and-cellular-biology/staff/23/prof-richard-bayliss)
Editorial Board Member
Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK
Interests: protein kinases; cell cycle; oncogenic gene fusions; structural biology; Myc
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Jean-Francois Beaulieu (https://sciprofiles.com/profile/288667)
Website (https://www.usherbrooke.ca/recherche/specialistes/details/jean-francois.beaulieu)
Editorial Board Member
Department of Immunology and Cell Biology, Université de Sherbrooke, Sherbrooke, QC J1E 4K8, Canada
Interests: colorectal cancer; integrins and cell-extracellular matrix interactions; oncogenes; transcription; biomarkers
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Cecilia Becattini
Website (https://www.unipg.it/personale/cecilia.becattini/en/)
Editorial Board Member
Department of Internal Medicine, Università degli Studi di Perugia, 06123 Perugia, Italy
Interests: tumors; thromboembolism

Prof. Dr. William T. Beck (https://sciprofiles.com/profile/504811)
Website (https://pharmacy.uic.edu/departments/biopharmaceutical-sciences/directory/wtbeck)
Editorial Board Member
Department of Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA
Interests: molecular pharmacology and genetics of anticancer drug action and tumor cell drug resistance; action of and tumor cell resistance to inhibitors of the DNA topoisomerases; molecular mechanisms of regulation of genes associated with multidrug resistance in cancer; role of splicing factors in tumorigenesis and anticancer drug action

Prof. Dr. Jürgen Becker (https://sciprofiles.com/profile/853695)
Website (https://dktk.dkfz.de/de/forschung/dktk-wissenschaftler/jurgen-becker)
Editorial Board Member

1. Translational Skin Cancer Research, German Cancer Consortium (DKTK), University of Duisburg-Essen, 45117 Essen, Germany
2. Deutsches Krebsforschungszentrum (DKFZ), 69120 Heidelberg, Germany

Interests: skin cancers; Merkel cell carcinoma; immunology; tumor cell evolution; tumor cell plasticity; epigenetics; immunotherapy; therapy resistance; biomarker

Special Issues, Collections and Topics in MDPI journals

Dr. Therese Becker (https://sciprofiles.com/profile/63724)

Website (https://www.unsw.edu.au/staff/therese-becker)

Editorial Board Member

1. Ingham Institute for Applied Medical Research, Liverpool, NSW 2170, Australia
2. School of Medicine, Western Sydney University, Campbelltown, NSW 2560, Australia
3. South Western Clinical School, University of New South Wales, Liverpool, NSW 2170, Australia

Interests: liquid biopsy; biomarker detection; circulating tumor cell

Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Stephen J. Beebe (https://sciprofiles.com/profile/40058)

Website (https://www.odu.edu/directory/people/s/sbeebe)

Editorial Board Member

Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, VA 23529, USA

Interests: cell signal transduction; cancer mechanisms; cancer therapies and resistances to therapy; programmed cell death; mitochondrial functions; bioenergetics and metabolism; regulated and immunogenic cell death; pulsed electric field effects on cells, tumors and immunity

Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Jürgen Behrens (https://sciprofiles.com/profile/1622050)

Website (https://www.chemistry.nat.fau.eu/steinrueck-group/group-members/univisid/40050085/)

Editorial Board Member

Nikolaus-Fiebiger Center, Friedrich-Alexander Universität Erlangen-Nuremberg, 91054 Erlangen, Germany

Interests: Wnt pathway; molecular biology of colorectal cancer; cell signaling

Dr. Ruud L. M. Bekkers (https://sciprofiles.com/profile/1713722)

Website (https://www.catharinaziekenhuis.nl/patient/specialismen/18-gynaecologie/wie-helpen-u/580-bekkers.html)

Editorial Board Member

1. Department Gynecology and Obstetrics, Catharina Hospital, 5602 ZA Eindhoven, The Netherlands
2. GROW School for Oncology and Developmental Biology, Maastricht University, 6200 Maastricht Nijmegen, The Netherlands

Interests: gynecologic oncology; gynecological cancers; HPV; screening; endometriosis; ovarian cancer; cervical cancer; endometrial cancer; database studies

Prof. Dr. Claus Belka

Website (http://www.klinikum.uni-muenchen.de/International-Patient-Office/en/departments/radiation-oncology/index.html)

Editorial Board Member

1. Clinical Cooperation Group Personalized Radiotherapy in Head and Neck Cancer, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, 85764 Neuherberg, Germany
2. Department of Radiation Oncology, University Hospital, LMU Munich, 81377 Munich, Germany
3. German Cancer Consortium (DKTK), Partner Site Munich, 81377 Munich, Germany

Interests: radiation oncology; prostate cancer; lung cancer; brain tumor; head neck cancer; image guidance; radiation physics; molecular radiation oncology; cell death research; synthetic lethality

Prof. Dr. Doris M. Benbrook

Website (https://medicine.ouhsc.edu/Academic-Departments/Obstetrics-and-Gynecology/Faculty/Gynecologic-Oncology/doris-m-

benbrook)

Editorial Board Member

1. Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
2. Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA

Interests: Development of novel therapeutics for gynecologic cancers

Special Issues, Collections and Topics in MDPI journals

Dr. Roberto Benelli (https://sciprofiles.com/profile/636633)

Website (https://orcid.org/0000-0002-9769-0954)

Editorial Board Member

SSD Molecular Oncology and e Angiogenesis, IRCCS Ospedale Policlinico San Martino, Viale Rosanna Benzi 10, 16132 Genoa, Italy

Interests: colorectal cancer; tumor microenvironment; immunohistochemistry; intracellular signaling; 3D primary cultures; organoids; EGFR; Akt; Erk; COX2

Special Issues, Collections and Topics in MDPI journals

Dr. Don Benjamin (https://sciprofiles.com/profile/11627)

Website (https://scg.ch/component/eventbooking/lectures/dr-don-benjamin-universitaet-basel-basel)

Editorial Board Member

Growth & Development Unit, Rm. 583 Biozentrum, University of Basel, Klingelbergstrasse 50/70, CH-4056 Basel, Switzerland

Interests: mTOR; cancer metabolism; glycolysis; signal transduction; mRNA stability

Special Issues, Collections and Topics in MDPI journals

Prof. Dr. René-Jean Bensadoun

Website (https://medifrancesolution.com/our-specialiasts/rene-jean-bensadoun/)

Editorial Board Member

Department of Radiology Oncology, Centre De Haute Energie, 10 Boulevard Pasteur, 06000 Nice, France

Interests: radiation oncology; head & neck cancer; supportive care in cancer; low level laser therapy (photobiomodulation), new techniques in radiation oncology (IMRT, VMAT), cancer-treatment toxicity

Dr. Armand Bensussan (https://sciprofiles.com/profile/531845)

Website (http://cvscience.aviesan.fr/cv/658/armand-bensussan)

Editorial Board Member

Institut de Recherche Saint-Louis, Paris, France

Interests: tumor immunology; immunotherapy; cutaneous T cell lymphoma; breast cancer microenvironment; innate immunity

Special Issues, Collections and Topics in MDPI journals

Dr. Toru Beppu (https://sciprofiles.com/profile/2409788)

Website (https://orcid.org/0000-0001-9046-0454)

Editorial Board Member

1. Department of Surgery, Yamaga City Medical Center, Kumamoto 860-8555, Japan
2. Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto 860-8555, Japan

Interests: hepatocellular carcinoma; laparoscopic surgery; liver cancer; liver metastases; conversion surgery

Prof. Dr. Maxim V. Berezovski (https://sciprofiles.com/profile/589415)

Website (https://science.uottawa.ca/chemistry/people/berezovski-maxim-v)

Editorial Board Member

Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada

Interests: glioblastoma; lung cancer; circulating tumor cells; tumor-derived exosomes; aptamers; proteomics; biomarkers

Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Adam C. Berger (https://sciprofiles.com/profile/2064181)
Website (https://cinj.org/adam-c-berger-md-facs)
Editorial Board Member
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
Interests: melanoma; soft tissue sarcoma; merkel cell carcinoma; skin cancer; clinical trials; outcomes research; immunotherapy

Prof. Dr. Nathan A. Berger (https://sciprofiles.com/profile/1174635)
Website (https://case.edu/cancer/research/gispore)
Editorial Board Member
Department of Medicine, Biochemistry, Oncology, Genetics & Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
Interests: energy balance; obesity cancer
Special Issues, Collections and Topics in MDPI journals

Prof. Dr. Lothar Bergmann (https://sciprofiles.com/profile/1369563)
Website (https://www.esmo.org/Profiles/Lothar-Bergmann)
Editorial Board Member
Medical Clinic II, University Hospital, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany; Ambulantes Krebszentrum Schaubstrasse, D-60590 Frankfurt, Germany
Interests: lymphomas; hronic lymphatic leukaemias; suppressor genes and oncogene regulation; apoptosis in cancer cells; immune regulation

Cancers (/journal/cancers), EISSN 2072-6694, Published by MDPI

RSS (/rss/journal/cancers) **Content Alert (/journal/cancers/toc-alert)**

Cancers, Volume 14, Issue 21 (November-1 2022) – 301 articles



Cover Story (view full-size image (/files/uploaded/covers/cancers/big_cover-cancers-v14-i21.png)): Complementary and alternative medicine (CAM) therapies include a wide range of procedures and products that are often used by cancer patients to directly combat cancer and protect normal cells from the toxic effects of conventional therapies. Most often, their use is self-prescribed, based on a collection of scattered information from websites and advice from relatives or friends, possibly leading to unexpected toxicities and a reduction in the efficacy of cancer therapy. Despite claims of promising and potential benefits made by prescribers, many CAMs lack clear scientific evidence of their safety and efficacy. Given the widespread use of CAM, in this review we focused on the most important known data on the interaction risk between anticancer drugs and CAMs in accordance with the meaning of integrative medicine, providing a practical guide for caregivers and patients. View this paper (https://www.mdpi.com/2072-6694/14/21/5203)

(https://www.mdpi.com/2072-6694/14/21/5203)

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list (/journal/cancers/toc-alert).

- You may sign up for e-mail alerts (/journal/cancers/toc-alert) to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader (http://www.adobe.com/) to open them.

Order results

Publication Date

Result details

Compact

Section

All Sections

Show export options

Open Access Review (/2072-6694/14/21/5473/pdf?version=1668070944)

Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies (/2072-6694/14/21/5473)

Cancers **2022**, *14*(21), 5473; https://doi.org/10.3390/cancers14215473 (https://doi.org/10.3390/cancers14215473) - 07 Nov 2022

Open Access Review (/2072-6694/14/21/5472/pdf?version=1667894666)

Histone Deacetylase Functions in Gastric Cancer: Therapeutic Target? (/2072-6694/14/21/5472)

Cancers **2022**, *14*(21), 5472; https://doi.org/10.3390/cancers14215472 (https://doi.org/10.3390/cancers14215472) - 07 Nov 2022

Open Access Review (/2072-6694/14/21/5471/pdf?version=1667896961)

Aptamers, a New Therapeutic Opportunity for the Treatment of Multiple Myeloma (/2072-6694/14/21/5471)

Cancers **2022**, *14*(21), 5471; https://doi.org/10.3390/cancers14215471 (https://doi.org/10.3390/cancers14215471) - 07 Nov 2022

Open Access Systematic Review (/2072-6694/14/21/5470/pdf?version=1667893714)

The Effects of Patient-Reported Outcome Screening on the Survival of People with Cancer: A Systematic Review and Meta-Analysis (/2072-6694/14/21/5470)

Cancers **2022**, *14*(21), 5470; https://doi.org/10.3390/cancers14215470 (https://doi.org/10.3390/cancers14215470) - 07 Nov 2022

Open Access Article (/2072-6694/14/21/5469/pdf?version=1667895955)

Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients (/2072-6694/14/21/5469)

Cancers **2022**, *14*(21), 5469; https://doi.org/10.3390/cancers14215469 (https://doi.org/10.3390/cancers14215469) - 07 Nov 2022

Open Access Review (/2072-6694/14/21/5468/pdf?version=1667898589)

Wnt/β-Catenin Signaling as a Driver of Stemness and Metabolic Reprogramming in Hepatocellular Carcinoma (/2072-6694/14/21/5468)

Cancers **2022**, *14*(21), 5468; https://doi.org/10.3390/cancers14215468 (https://doi.org/10.3390/cancers14215468) - 07 Nov 2022

Open Access Review (/2072-6694/14/21/5467/pdf?version=1667895490)

Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer (/2072-6694/14/21/5467)

Cancers **2022**, *14*(21), 5467; https://doi.org/10.3390/cancers14215467 (https://doi.org/10.3390/cancers14215467) - 07 Nov 2022

Open Access Systematic Review (/2072-6694/14/21/5466/pdf?version=1668047527)

Speech and Language Errors during Awake Brain Surgery and Postoperative Language Outcome in Glioma Patients: A Systematic Review (/2072-6694/14/21/5466)

Cancers **2022**, *14*(21), 5466; https://doi.org/10.3390/cancers14215466 (https://doi.org/10.3390/cancers14215466) - 07 Nov 2022

Open Access Article (/2072-6694/14/21/5465/pdf?version=1667817331)

The Glasgow Prognostic Score Predicts Survival Outcomes in Neuroendocrine Neoplasms of the Gastro–Entero–Pancreatic (GEP-NEN) System (/2072-6694/14/21/5465)

Back to TopTop

Cancers **2022**, *14*(21), 5465; **https://doi.org/10.3390/cancers14215465 (https://doi.org/10.3390/cancers14215465)** - 07 Nov 2022

Open Access Systematic Review (/2072-6694/14/21/5464/pdf?version=1667898963)

Anastomotic Leak in Ovarian Cancer Cytoreduction Surgery: A Systematic Review and Meta-Analysis (/2072-6694/14/21/5464)

Cancers **2022**, *14*(21), 5464; **https://doi.org/10.3390/cancers14215464 (https://doi.org/10.3390/cancers14215464)** - 07 Nov 2022

Open Access Article (/2072-6694/14/21/5463/pdf?version=1667899141)

Enhanced Recovery after Uterine Corpus Cancer Surgery: A 10 Year Retrospective Cohort Study of Robotic Surgery in an NHS Cancer Centre (/2072-6694/14/21/5463)

Cancers **2022**, *14*(21), 5463; **https://doi.org/10.3390/cancers14215463 (https://doi.org/10.3390/cancers14215463)** - 07 Nov 2022

Open Access Article (/2072-6694/14/21/5462/pdf?version=1667816086)

Impact of Lymph Node Dissection on Postoperative Complications of Total Thyroidectomy in Patients with Thyroid Carcinoma (/2072-6694/14/21/5462)

Cancers **2022**, *14*(21), 5462; **https://doi.org/10.3390/cancers14215462 (https://doi.org/10.3390/cancers14215462)** - 07 Nov 2022

Open Access Article (/2072-6694/14/21/5461/pdf?version=1675751026)

A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis (/2072-6694/14/21/5461)

Cancers **2022**, *14*(21), 5461; **https://doi.org/10.3390/cancers14215461 (https://doi.org/10.3390/cancers14215461)** - 07 Nov 2022
Correction (/2072-6694/15/4/1035)

Open Access Feature Paper Review (/2072-6694/14/21/5460/pdf?version=1667814600)

The Monocyte, a Maestro in the Tumor Microenvironment (TME) of Breast Cancer (/2072-6694/14/21/5460)

Cancers **2022**, *14*(21), 5460; **https://doi.org/10.3390/cancers14215460 (https://doi.org/10.3390/cancers14215460)** - 07 Nov 2022

Open Access Article (/2072-6694/14/21/5459/pdf?version=1667806553)

Preoperative Serum Markers and Risk Classification in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Study (/2072-6694/14/21/5459)

Cancers **2022**, *14*(21), 5459; **https://doi.org/10.3390/cancers14215459 (https://doi.org/10.3390/cancers14215459)** - 07 Nov 2022

Open Access Review (/2072-6694/14/21/5458/pdf?version=1667891264)

Intravascular NK/T-Cell Lymphoma: What We Know about This Diagnostically Challenging, Aggressive Disease (/2072-6694/14/21/5458)

Cancers **2022**, *14*(21), 5458; **https://doi.org/10.3390/cancers14215458 (https://doi.org/10.3390/cancers14215458)** - 06 Nov 2022

Open Access Article (/2072-6694/14/21/5457/pdf?version=1667886069)

An Effective Method for Lung Cancer Diagnosis from CT Scan Using Deep Learning-Based Support Vector Network (/2072-6694/14/21/5457)

Cancers **2022**, *14*(21), 5457; **https://doi.org/10.3390/cancers14215457 (https://doi.org/10.3390/cancers14215457)** - 06 Nov 2022

Open Access Review (/2072-6694/14/21/5456/pdf?version=1667896098)

Targeted Therapy and Immunotherapy for Heterogeneous Breast Cancer (/2072-6694/14/21/5456)

Cancers **2022**, *14*(21), 5456; **https://doi.org/10.3390/cancers14215456 (https://doi.org/10.3390/cancers14215456)** - 06 Nov 2022

Open Access Article (/2072-6694/14/21/5455/pdf?version=1667986968)

Recurrence of Oral Leukoplakia after CO_2 Laser Resection: A Prospective Longitudinal Study (/2072-6694/14/21/5455)

Cancers **2022**, *14*(21), 5455; **https://doi.org/10.3390/cancers14215455 (https://doi.org/10.3390/cancers14215455)** - 06 Nov 2022

Open Access Article (/2072-6694/14/21/5454/pdf?version=1668045458)

Discovery of Mitochondrial Complex I Inhibitors as Anticancer and Radiosensitizer Drugs Based on Compensatory Stimulation of Lactate Release (/2072-6694/14/21/5454)

Cancers **2022**, *14*(21), 5454; **https://doi.org/10.3390/cancers14215454 (https://doi.org/10.3390/cancers14215454)** - 06 Nov 2022

Open Access Article (/2072-6694/14/21/5453/pdf?version=1667956156)

CAXII Is a Surrogate Marker for Luminal Breast Tumors Regulated by ER and GATA3 (/2072-6694/14/21/5453)

Cancers **2022**, *14*(21), 5453; **https://doi.org/10.3390/cancers14215453 (https://doi.org/10.3390/cancers14215453)** - 06 Nov 2022

Open Access Article (/2072-6694/14/21/5452/pdf?version=1667782342)

Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer Committee (/2072-6694/14/21/5452)

Cancers **2022**, *14*(21), 5452; **https://doi.org/10.3390/cancers14215452 (https://doi.org/10.3390/cancers14215452)** - 06 Nov 2022

Open Access Article (/2072-6694/14/21/5451/pdf?version=1667898038)

A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors (/2072-6694/14/21/5451)

Cancers **2022**, *14*(21), 5451; **https://doi.org/10.3390/cancers14215451 (https://doi.org/10.3390/cancers14215451)** - 05 Nov 2022

Open Access Review (/2072-6694/14/21/5450/pdf?version=1667645581)

Long Non-Coding RNA and microRNA Interplay in Colorectal Cancer and Their Effect on the Tumor Microenvironment (/2072-6694/14/21/5450)

Cancers **2022**, *14*(21), 5450; **https://doi.org/10.3390/cancers14215450 (https://doi.org/10.3390/cancers14215450)** - 05 Nov 2022

Open Access Article (/2072-6694/14/21/5449/pdf?version=1667879573)

CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy (/2072-6694/14/21/5449)

Cancers **2022**, *14*(21), 5449; **https://doi.org/10.3390/cancers14215449 (https://doi.org/10.3390/cancers14215449)** - 05 Nov 2022

Back to TopTop

Open Access Review (/2072-6694/14/21/5448/pdf?version=1667638703)

Prostate Cancer Stem Cells: The Role of CD133 (/2072-6694/14/21/5448)

Cancers **2022**, *14*(21), 5448; **https://doi.org/10.3390/cancers14215448 (https://doi.org/10.3390/cancers14215448)** - 05 Nov 2022

(/toggle_desktop_layout_cookie)

Open Access Article (/2072-6694/14/21/5447/pdf?version=1667905528)

Testicular Neoplasms: Primary Tumour Size Is Closely Interrelated with Histology, Clinical Staging, and Tumour Marker Expression Rates—A Comprehensive Statistical Analysis (/2072-6694/14/21/5447)

Cancers **2022**, *14*(21), 5447; **https://doi.org/10.3390/cancers14215447 (https://doi.org/10.3390/cancers14215447)** - 05 Nov 2022

Open Access Article (/2072-6694/14/21/5446/pdf?version=1667892317)

Water-Soluble Truncated Fatty Acid–Porphyrin Conjugates Provide Photo-Sensitizer Activity for Photodynamic Therapy in Malignant Mesothelioma (/2072-6694/14/21/5446)

Cancers **2022**, *14*(21), 5446; **https://doi.org/10.3390/cancers14215446 (https://doi.org/10.3390/cancers14215446)** - 05 Nov 2022

Open Access Article (/2072-6694/14/21/5445/pdf?version=1667635483)

Reliable Flow-Cytometric Approach for Minimal Residual Disease Monitoring in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia after CD19-Targeted Therapy (/2072-6694/14/21/5445)

Cancers **2022**, *14*(21), 5445; **https://doi.org/10.3390/cancers14215445 (https://doi.org/10.3390/cancers14215445)** - 05 Nov 2022

Open Access Review (/2072-6694/14/21/5444/pdf?version=1668101416)

Classic and New Markers in Diagnostics and Classification of Breast Cancer (/2072-6694/14/21/5444)

Cancers **2022**, *14*(21), 5444; **https://doi.org/10.3390/cancers14215444 (https://doi.org/10.3390/cancers14215444)** - 05 Nov 2022

Open Access Review (/2072-6694/14/21/5443/pdf?version=1667629117)

Protein Arginine Methyltransferases as Therapeutic Targets in Hematological Malignancies (/2072-6694/14/21/5443)

Cancers **2022**, *14*(21), 5443; **https://doi.org/10.3390/cancers14215443 (https://doi.org/10.3390/cancers14215443)** - 05 Nov 2022

Open Access Review (/2072-6694/14/21/5442/pdf?version=1667905581)

Role of CAR T Cell Metabolism for Therapeutic Efficacy (/2072-6694/14/21/5442)

Cancers **2022**, *14*(21), 5442; **https://doi.org/10.3390/cancers14215442 (https://doi.org/10.3390/cancers14215442)** - 04 Nov 2022

Open Access Systematic Review (/2072-6694/14/21/5441/pdf?version=1667895505)

Salivary Microbiota Composition in Patients with Oral Squamous Cell Carcinoma: A Systematic Review (/2072-6694/14/21/5441)

Cancers **2022**, *14*(21), 5441; **https://doi.org/10.3390/cancers14215441 (https://doi.org/10.3390/cancers14215441)** - 04 Nov 2022

Open Access Article (/2072-6694/14/21/5440/pdf?version=1667890833)

Accurate Characterization of Bladder Cancer Cells with Intraoperative Flow Cytometry (/2072-6694/14/21/5440)

Cancers **2022**, *14*(21), 5440; **https://doi.org/10.3390/cancers14215440 (https://doi.org/10.3390/cancers14215440)** - 04 Nov 2022

Open Access Article (/2072-6694/14/21/5439/pdf?version=1667981450)

Identification of MYEOV-Associated Gene Network as a Potential Therapeutic Target in Pancreatic Cancer (/2072-6694/14/21/5439)

Cancers **2022**, *14*(21), 5439; **https://doi.org/10.3390/cancers14215439 (https://doi.org/10.3390/cancers14215439)** - 04 Nov 2022

Open Access Review (/2072-6694/14/21/5438/pdf?version=1667569022)

Nanoparticle Enhancement of Natural Killer (NK) Cell-Based Immunotherapy (/2072-6694/14/21/5438)

Cancers **2022**, *14*(21), 5438; **https://doi.org/10.3390/cancers14215438 (https://doi.org/10.3390/cancers14215438)** - 04 Nov 2022

Open Access Review (/2072-6694/14/21/5437/pdf?version=1667559098)

Autotaxin in Breast Cancer: Role, Epigenetic Regulation and Clinical Implications (/2072-6694/14/21/5437)

Cancers **2022**, *14*(21), 5437; **https://doi.org/10.3390/cancers14215437 (https://doi.org/10.3390/cancers14215437)** - 04 Nov 2022

Open Access Review (/2072-6694/14/21/5436/pdf?version=1667554861)

Pharmacogenetics of Drug Metabolism: The Role of Gene Polymorphism in the Regulation of Doxorubicin Safety and Efficacy (/2072-6694/14/21/5436)

Cancers **2022**, *14*(21), 5436; **https://doi.org/10.3390/cancers14215436 (https://doi.org/10.3390/cancers14215436)** - 04 Nov 2022

Open Access Review (/2072-6694/14/21/5435/pdf?version=1667553160)

Targeting Heat Shock Proteins in Malignant Brain Tumors: From Basic Research to Clinical Trials (/2072-6694/14/21/5435)

Cancers **2022**, *14*(21), 5435; **https://doi.org/10.3390/cancers14215435 (https://doi.org/10.3390/cancers14215435)** - 04 Nov 2022

Open Access Article (/2072-6694/14/21/5434/pdf?version=1667552885)

CDCA8/SNAI2 Complex Activates CD44 to Promote Proliferation and Invasion of Pancreatic Ductal Adenocarcinoma (/2072-6694/14/21/5434)

Cancers **2022**, *14*(21), 5434; **https://doi.org/10.3390/cancers14215434 (https://doi.org/10.3390/cancers14215434)** - 04 Nov 2022

Open Access Perspective (/2072-6694/14/21/5433/pdf?version=1667550281)

Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors (/2072-6694/14/21/5433)

Cancers **2022**, *14*(21), 5433; **https://doi.org/10.3390/cancers14215433 (https://doi.org/10.3390/cancers14215433)** - 04 Nov 2022

Open Access Communication (/2072-6694/14/21/5432/pdf?version=1667548899)

Feasibility and Safety of Single-Probe Cryoablation with Liquid Nitrogen: An Initial Experience in 24 Various Tumor Lesions (/2072-6694/14/21/5432)

Back to TopTop

Cancers **2022**, *14*(21), 5432; **https://doi.org/10.3390/cancers14215432 (https://doi.org/10.3390/cancers14215432)** - 04 Nov 2022

Open Access Review (/2072-6694/14/21/5431/pdf?version=1667544377)

Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma (/2072-6694/14/21/5431)

(/toggle_desktop_layout_cookie)

Cancers **2022**, *14*(21), 5431; **https://doi.org/10.3390/cancers14215431 (https://doi.org/10.3390/cancers14215431)** - 04 Nov 2022

Open Access Review (/2072-6694/14/21/5430/pdf?version=1667541236)

KRAS in NSCLC: State of the Art and Future Perspectives (/2072-6694/14/21/5430)

Cancers **2022**, *14*(21), 5430; **https://doi.org/10.3390/cancers14215430 (https://doi.org/10.3390/cancers14215430)** - 04 Nov 2022

Open Access Article (/2072-6694/14/21/5429/pdf?version=1667980497)

Integrated Biomarker Analysis Reveals L1CAM as a Potential Stratification Marker for No Specific Molecular Profile High-Risk Endometrial Carcinoma (/2072-6694/14/21/5429)

Cancers **2022**, *14*(21), 5429; **https://doi.org/10.3390/cancers14215429 (https://doi.org/10.3390/cancers14215429)** - 03 Nov 2022

Open Access Article (/2072-6694/14/21/5428/pdf?version=1667897842)

The Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Poor Prognosis Factor in Patients with Hepatocellular Carcinoma: An Analysis of Microvessel Density (/2072-6694/14/21/5428)

Cancers **2022**, *14*(21), 5428; **https://doi.org/10.3390/cancers14215428 (https://doi.org/10.3390/cancers14215428)** - 03 Nov 2022

Open Access Article (/2072-6694/14/21/5427/pdf?version=1667888068)

An Indeterminate for Malignancy FNA Report Does Not Increase the Surgical Risk of Incidental Thyroid Carcinoma (/2072-6694/14/21/5427)

Cancers **2022**, *14*(21), 5427; **https://doi.org/10.3390/cancers14215427 (https://doi.org/10.3390/cancers14215427)** - 03 Nov 2022

Open Access Article (/2072-6694/14/21/5426/pdf?version=1667890438)

Application of Electronic Health Record Text Mining: Real-World Tolerability, Safety, and Efficacy of Adjuvant Melanoma Treatments (/2072-6694/14/21/5426)

Cancers **2022**, *14*(21), 5426; **https://doi.org/10.3390/cancers14215426 (https://doi.org/10.3390/cancers14215426)** - 03 Nov 2022

Open Access Review (/2072-6694/14/21/5425/pdf?version=1667480245)

Protein Kinase C (PKC) Isozymes as Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer (/2072-6694/14/21/5425)

Cancers **2022**, *14*(21), 5425; **https://doi.org/10.3390/cancers14215425 (https://doi.org/10.3390/cancers14215425)** - 03 Nov 2022

Open Access Article (/2072-6694/14/21/5424/pdf?version=1667879195)

Generalization of Deep Learning in Digital Pathology: Experience in Breast Cancer Metastasis Detection (/2072-6694/14/21/5424)

Cancers **2022**, *14*(21), 5424; **https://doi.org/10.3390/cancers14215424 (https://doi.org/10.3390/cancers14215424)** - 03 Nov 2022

Open Access Review (/2072-6694/14/21/5423/pdf?version=1667475088)

UroVysion™ Fluorescence In Situ Hybridization in Urological Cancers: A Narrative Review and Future Perspectives (/2072-6694/14/21/5423)

Cancers **2022**, *14*(21), 5423; **https://doi.org/10.3390/cancers14215423 (https://doi.org/10.3390/cancers14215423)** - 03 Nov 2022

Open Access Editorial (/2072-6694/14/21/5422/pdf?version=1667887180)

Role of the PP2A Pathway in Cholangiocarcinoma: State of the Art and Future Perspectives (/2072-6694/14/21/5422)

Cancers **2022**, *14*(21), 5422; **https://doi.org/10.3390/cancers14215422 (https://doi.org/10.3390/cancers14215422)** - 03 Nov 2022

Open Access Article (/2072-6694/14/21/5421/pdf?version=1667469548)

Glucose Enhances Pro-Tumorigenic Functions of Mammary Adipose-Derived Mesenchymal Stromal/Stem Cells on Breast Cancer Cell Lines (/2072-6694/14/21/5421)

Cancers **2022**, *14*(21), 5421; **https://doi.org/10.3390/cancers14215421 (https://doi.org/10.3390/cancers14215421)** - 03 Nov 2022

Open Access Systematic Review (/2072-6694/14/21/5420/pdf?version=1667467193)

Tumors Involving the Infratemporal Fossa: A Systematic Review of Clinical Characteristics and Treatment Outcomes (/2072-6694/14/21/5420)

Cancers **2022**, *14*(21), 5420; **https://doi.org/10.3390/cancers14215420 (https://doi.org/10.3390/cancers14215420)** - 03 Nov 2022

Open Access Article (/2072-6694/14/21/5419/pdf?version=1667877439)

Clinical and Molecular Features in Medulloblastomas Subtypes in Children in a Cohort in Taiwan (/2072-6694/14/21/5419)

Cancers **2022**, *14*(21), 5419; **https://doi.org/10.3390/cancers14215419 (https://doi.org/10.3390/cancers14215419)** - 03 Nov 2022

Open Access Article (/2072-6694/14/21/5418/pdf?version=1667869122)

The Potential of MicroRNAs as Non-Invasive Prostate Cancer Biomarkers: A Systematic Literature Review Based on a Machine Learning Approach (/2072-6694/14/21/5418)

Cancers **2022**, *14*(21), 5418; **https://doi.org/10.3390/cancers14215418 (https://doi.org/10.3390/cancers14215418)** - 03 Nov 2022

Open Access Article (/2072-6694/14/21/5417/pdf?version=1667464227)

Global, Regional, and National Burdens with Temporal Trends of Early-, Intermediate-, and Later-Onset Gastric Cancer from 1990 to 2019 and Predictions up to 2035 (/2072-6694/14/21/5417)

Cancers **2022**, *14*(21), 5417; **https://doi.org/10.3390/cancers14215417 (https://doi.org/10.3390/cancers14215417)** - 03 Nov 2022

Open Access Review (/2072-6694/14/21/5416/pdf?version=1667462338)

Organoids for Modeling (Colorectal) Cancer in a Dish (/2072-6694/14/21/5416)

Cancers **2022**, *14*(21), 5416; **https://doi.org/10.3390/cancers14215416 (https://doi.org/10.3390/cancers14215416)** - 03 Nov 2022

Back to TopTop

Open Access Review (/2072-6694/14/21/5415/pdf?version=1667461240)

Glycocalyx Acts as a Central Player in the Development of Tumor Microenvironment by Extracellular Vesicles for Angiogenesis and Metastasis (/2072-6694/14/21/5415)

Cancers **2022**, *14*(21), 5415; **https://doi.org/10.3390/cancers14215415 (https://doi.org/10.3390/cancers14215415)** - 03 Nov 2022

(/toggle_desktop_layout_cookie)

Open Access Review (/2072-6694/14/21/5414/pdf?version=1667456782)

The Role of miR-155 in Antitumor Immunity (/2072-6694/14/21/5414)

Cancers **2022**, *14*(21), 5414; **https://doi.org/10.3390/cancers14215414 (https://doi.org/10.3390/cancers14215414)** - 03 Nov 2022

Open Access Article (/2072-6694/14/21/5413/pdf?version=1667450993)

Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA Cohort (/2072-6694/14/21/5413)

Cancers **2022**, *14*(21), 5413; **https://doi.org/10.3390/cancers14215413 (https://doi.org/10.3390/cancers14215413)** - 03 Nov 2022

Open Access Article (/2072-6694/14/21/5412/pdf?version=1667890102)

Optimization of Transpedicular Electrode Insertion for Electroporation-Based Treatments of Vertebral Tumors (/2072-6694/14/21/5412)

Cancers **2022**, *14*(21), 5412; **https://doi.org/10.3390/cancers14215412 (https://doi.org/10.3390/cancers14215412)** - 02 Nov 2022

Open Access Review (/2072-6694/14/21/5411/pdf?version=1667904470)

CIC-Rearranged Sarcomas: An Intriguing Entity That May Lead the Way to the Comprehension of More Common Cancers (/2072-6694/14/21/5411)

Cancers **2022**, *14*(21), 5411; **https://doi.org/10.3390/cancers14215411 (https://doi.org/10.3390/cancers14215411)** - 02 Nov 2022

Open Access Article (/2072-6694/14/21/5410/pdf?version=1667895376)

Resilience in Lower Grade Glioma Patients (/2072-6694/14/21/5410)

Cancers **2022**, *14*(21), 5410; **https://doi.org/10.3390/cancers14215410 (https://doi.org/10.3390/cancers14215410)** - 02 Nov 2022

Open Access Article (/2072-6694/14/21/5409/pdf?version=1667899889)

Genetic Inactivation of *Notch1* Synergizes with Loss of *Trp53* to Induce Tumor Formation in the Adult Mouse Forebrain (/2072-6694/14/21/5409)

Cancers **2022**, *14*(21), 5409; **https://doi.org/10.3390/cancers14215409 (https://doi.org/10.3390/cancers14215409)** - 02 Nov 2022

Open Access Review (/2072-6694/14/21/5408/pdf?version=1667886669)

Real-World Study: A Powerful Tool for Malignant Tumor Research in General Surgery (/2072-6694/14/21/5408)

Cancers **2022**, *14*(21), 5408; **https://doi.org/10.3390/cancers14215408 (https://doi.org/10.3390/cancers14215408)** - 02 Nov 2022

Open Access Article (/2072-6694/14/21/5407/pdf?version=1667974664)

A Novel Potential Role for Monocytes Revealed by Single Cell Analysis of Immunotherapy Induced Immune Related Adverse Events (/2072-6694/14/21/5407)

Cancers **2022**, *14*(21), 5407; **https://doi.org/10.3390/cancers14215407 (https://doi.org/10.3390/cancers14215407)** - 02 Nov 2022

Open Access Review (/2072-6694/14/21/5406/pdf?version=1667798625)

Implications and Emerging Therapeutic Avenues of Inflammatory Response in HPV+ Head and Neck Squamous Cell Carcinoma (/2072-6694/14/21/5406)

Cancers **2022**, *14*(21), 5406; **https://doi.org/10.3390/cancers14215406 (https://doi.org/10.3390/cancers14215406)** - 02 Nov 2022

Open Access Article (/2072-6694/14/21/5405/pdf?version=1667391942)

Cancer Cachexia among Patients with Advanced Non-Small-Cell Lung Cancer on Immunotherapy: An Observational Study with Exploratory Gut Microbiota Analysis (/2072-6694/14/21/5405)

Cancers **2022**, *14*(21), 5405; **https://doi.org/10.3390/cancers14215405 (https://doi.org/10.3390/cancers14215405)** - 02 Nov 2022

Open Access Review (/2072-6694/14/21/5404/pdf?version=1667396766)

Factors and Mechanisms That Influence Chromatin-Mediated Enhancer–Promoter Interactions and Transcriptional Regulation (/2072-6694/14/21/5404)

Cancers **2022**, *14*(21), 5404; **https://doi.org/10.3390/cancers14215404 (https://doi.org/10.3390/cancers14215404)** - 02 Nov 2022

Open Access Review (/2072-6694/14/21/5403/pdf?version=1667528321)

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do (/2072-6694/14/21/5403)

Cancers **2022**, *14*(21), 5403; **https://doi.org/10.3390/cancers14215403 (https://doi.org/10.3390/cancers14215403)** - 02 Nov 2022

Open Access Review (/2072-6694/14/21/5402/pdf?version=1667436229)

Physical Activity as the Best Supportive Care in Cancer: The Clinician's and the Researcher's Perspectives (/2072-6694/14/21/5402)

Cancers **2022**, *14*(21), 5402; **https://doi.org/10.3390/cancers14215402 (https://doi.org/10.3390/cancers14215402)** - 02 Nov 2022

Open Access Article (/2072-6694/14/21/5401/pdf?version=1667545634)

Exploring Gut Microbiome in Predicting the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer (/2072-6694/14/21/5401)

Cancers **2022**, *14*(21), 5401; **https://doi.org/10.3390/cancers14215401 (https://doi.org/10.3390/cancers14215401)** - 02 Nov 2022

Open Access Article (/2072-6694/14/21/5400/pdf?version=1667381465)

Inhibition of LIFR Blocks Adiposity-Driven Endometrioid Endometrial Cancer Growth (/2072-6694/14/21/5400)

Cancers **2022**, *14*(21), 5400; **https://doi.org/10.3390/cancers14215400 (https://doi.org/10.3390/cancers14215400)** - 02 Nov 2022

Open Access Article (/2072-6694/14/21/5399/pdf?version=1667381300)

***BRCA1/2* Mutation Testing in Patients with HER2-Negative Advanced Breast Cancer: Real-World Data from the United States, Europe, and Israel (/2072-6694/14/21/5399)**

Back to TopTop

Cancers **2022**, *14*(21), 5399; **https://doi.org/10.3390/cancers14215399 (https://doi.org/10.3390/cancers14215399)** - 02 Nov 2022

Open Access Review (/2072-6694/14/21/5398/pdf?version=1667381312)

Meta-Analysis of Repeat Hepatectomy versus Radiofrequency Ablation for Recurrence of Hepatocellular Carcinoma (/2072-6694/14/21/5398)

Cancers **2022**, *14*(21), 5398; **https://doi.org/10.3390/cancers14215398 (https://doi.org/10.3390/cancers14215398)** - 02 Nov 2022

Open Access Systematic Review (/2072-6694/14/21/5397/pdf?version=1667378756)

Current Applications of Artificial Intelligence to Classify Cervical Lymph Nodes in Patients with Head and Neck Squamous Cell Carcinoma—A Systematic Review (/2072-6694/14/21/5397)

Cancers **2022**, *14*(21), 5397; **https://doi.org/10.3390/cancers14215397 (https://doi.org/10.3390/cancers14215397)** - 02 Nov 2022

Open Access Article (/2072-6694/14/21/5396/pdf?version=1667527441)

Epigenetic Reprogramming of Kaposi's Sarcoma-Associated Herpesvirus during Hypoxic Reactivation (/2072-6694/14/21/5396)

Cancers **2022**, *14*(21), 5396; **https://doi.org/10.3390/cancers14215396 (https://doi.org/10.3390/cancers14215396)** - 02 Nov 2022

Open Access Review (/2072-6694/14/21/5395/pdf?version=1667377622)

Recreational Drugs and the Risk of Hepatocellular Carcinoma (/2072-6694/14/21/5395)

Cancers **2022**, *14*(21), 5395; **https://doi.org/10.3390/cancers14215395 (https://doi.org/10.3390/cancers14215395)** - 02 Nov 2022

Open Access Review (/2072-6694/14/21/5394/pdf?version=1667373661)

The Function and Molecular Mechanism of Commensal Microbiome in Promoting Malignant Progression of Lung Cancer (/2072-6694/14/21/5394)

Cancers **2022**, *14*(21), 5394; **https://doi.org/10.3390/cancers14215394 (https://doi.org/10.3390/cancers14215394)** - 02 Nov 2022

Open Access Article (/2072-6694/14/21/5393/pdf?version=1667376707)

Hypoxia-Inducible Factor-1 Alpha Expression Is Predictive of Pathological Complete Response in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy (/2072-6694/14/21/5393)

Cancers **2022**, *14*(21), 5393; **https://doi.org/10.3390/cancers14215393 (https://doi.org/10.3390/cancers14215393)** - 02 Nov 2022

Open Access Article (/2072-6694/14/21/5392/pdf?version=1667902553)

Thermography as a Method for Bedside Monitoring of Infantile Hemangiomas (/2072-6694/14/21/5392)

Cancers **2022**, *14*(21), 5392; **https://doi.org/10.3390/cancers14215392 (https://doi.org/10.3390/cancers14215392)** - 01 Nov 2022

Open Access Article (/2072-6694/14/21/5391/pdf?version=1667372001)

The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status (/2072-6694/14/21/5391)

Cancers **2022**, *14*(21), 5391; **https://doi.org/10.3390/cancers14215391 (https://doi.org/10.3390/cancers14215391)** - 01 Nov 2022

Open Access Review (/2072-6694/14/21/5390/pdf?version=1667893485)

Minimising the Toxicities of First Line Hodgkin Lymphoma Treatment in the Modern Era (/2072-6694/14/21/5390)

Cancers **2022**, *14*(21), 5390; **https://doi.org/10.3390/cancers14215390 (https://doi.org/10.3390/cancers14215390)** - 01 Nov 2022

Open Access Review (/2072-6694/14/21/5389/pdf?version=1667785566)

Smart Nanoformulations for Brain Cancer Theranostics: Challenges and Promises (/2072-6694/14/21/5389)

Cancers **2022**, *14*(21), 5389; **https://doi.org/10.3390/cancers14215389 (https://doi.org/10.3390/cancers14215389)** - 01 Nov 2022

Open Access Review (/2072-6694/14/21/5388/pdf?version=1667885421)

The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance (/2072-6694/14/21/5388)

Cancers **2022**, *14*(21), 5388; **https://doi.org/10.3390/cancers14215388 (https://doi.org/10.3390/cancers14215388)** - 01 Nov 2022

Open Access Article (/2072-6694/14/21/5387/pdf?version=1667295457)

Use of High-Plex Data Reveals Novel Insights into the Tumour Microenvironment of Clear Cell Renal Cell Carcinoma (/2072-6694/14/21/5387)

Cancers **2022**, *14*(21), 5387; **https://doi.org/10.3390/cancers14215387 (https://doi.org/10.3390/cancers14215387)** - 01 Nov 2022

Open Access Review (/2072-6694/14/21/5386/pdf?version=1667290432)

Tau Protein as Therapeutic Target for Cancer? Focus on Glioblastoma (/2072-6694/14/21/5386)

Cancers **2022**, *14*(21), 5386; **https://doi.org/10.3390/cancers14215386 (https://doi.org/10.3390/cancers14215386)** - 01 Nov 2022

Open Access Review (/2072-6694/14/21/5385/pdf?version=1667288386)

Human Papillomavirus-Related Non-Metastatic Oropharyngeal Carcinoma: Current Local Treatment Options and Future Perspectives (/2072-6694/14/21/5385)

Cancers **2022**, *14*(21), 5385; **https://doi.org/10.3390/cancers14215385 (https://doi.org/10.3390/cancers14215385)** - 01 Nov 2022

Open Access Review (/2072-6694/14/21/5384/pdf?version=1667288583)

A Comprehensive Overview of Recent Advances in Epigenetics in Pediatric Acute Lymphoblastic Leukemia (/2072-6694/14/21/5384)

Cancers **2022**, *14*(21), 5384; **https://doi.org/10.3390/cancers14215384 (https://doi.org/10.3390/cancers14215384)** - 01 Nov 2022

Open Access Article (/2072-6694/14/21/5383/pdf?version=1667290572)

***Tillandsia usneoides* Extract Decreases the Primary Tumor in a Murine Breast Cancer Model but Not in Melanoma (/2072-6694/14/21/5383)**

Cancers **2022**, *14*(21), 5383; **https://doi.org/10.3390/cancers14215383 (https://doi.org/10.3390/cancers14215383)** - 01 Nov 2022

Open Access Review (/2072-6694/14/21/5382/pdf?version=1667986319)

Artificial Intelligence-Driven Diagnosis of Pancreatic Cancer (/2072-6694/14/21/5382)

Back to TopTop

Cancers **2022**, *14*(21), 5382; **https://doi.org/10.3390/cancers14215382 (https://doi.org/10.3390/cancers14215382)** - 31 Oct 2022

Open Access Article (/2072-6694/14/21/5381/pdf?version=1667894577)

IGF2BP2 Promotes Epithelial to Mesenchymal Transition and Metastasis through Stabilizing HMGA1 mRNA in Gastric Cancer (/2072-6694/14/21/5381)

Cancers **2022**, *14*(21), 5381; **https://doi.org/10.3390/cancers14215381 (https://doi.org/10.3390/cancers14215381)** - 31 Oct 2022

Open Access Article (/2072-6694/14/21/5380/pdf?version=1667793172)

Clinical Features, Phenotypic Markers and Outcomes of Diffuse Large B-Cell Lymphoma between HIV-Infected and HIV-Uninfected Chinese Patients (/2072-6694/14/21/5380)

Cancers **2022**, *14*(21), 5380; **https://doi.org/10.3390/cancers14215380 (https://doi.org/10.3390/cancers14215380)** - 31 Oct 2022

Open Access Article (/2072-6694/14/21/5379/pdf?version=1667895312)

Dysbiosis of the Fecal and Biliary Microbiota in Biliary Tract Cancer (/2072-6694/14/21/5379)

Cancers **2022**, *14*(21), 5379; **https://doi.org/10.3390/cancers14215379 (https://doi.org/10.3390/cancers14215379)** - 31 Oct 2022

Open Access Review (/2072-6694/14/21/5378/pdf?version=1667886192)

Liquid Biopsy in Cancer: Focus on Lymphoproliferative Disorders (/2072-6694/14/21/5378)

Cancers **2022**, *14*(21), 5378; **https://doi.org/10.3390/cancers14215378 (https://doi.org/10.3390/cancers14215378)** - 31 Oct 2022

Open Access Review (/2072-6694/14/21/5377/pdf?version=1667889298)

New Directions in the Therapy of Glioblastoma (/2072-6694/14/21/5377)

Cancers **2022**, *14*(21), 5377; **https://doi.org/10.3390/cancers14215377 (https://doi.org/10.3390/cancers14215377)** - 31 Oct 2022

Open Access Review (/2072-6694/14/21/5376/pdf?version=1667982010)

Perioperative Nursing as the Guiding Thread of a Prehabilitation Program (/2072-6694/14/21/5376)

Cancers **2022**, *14*(21), 5376; **https://doi.org/10.3390/cancers14215376 (https://doi.org/10.3390/cancers14215376)** - 31 Oct 2022

Open Access Article (/2072-6694/14/21/5375/pdf?version=1667284666)

Methylome Profiling of PD-L1-Expressing Glioblastomas Shows Enrichment of Post-Transcriptional and RNA-Associated Gene Regulation (/2072-6694/14/21/5375)

Cancers **2022**, *14*(21), 5375; **https://doi.org/10.3390/cancers14215375 (https://doi.org/10.3390/cancers14215375)** - 31 Oct 2022

Open Access Review (/2072-6694/14/21/5374/pdf?version=1667888520)

The Proliferative Role of Immune Checkpoints in Tumors: Double Regulation (/2072-6694/14/21/5374)

Cancers **2022**, *14*(21), 5374; **https://doi.org/10.3390/cancers14215374 (https://doi.org/10.3390/cancers14215374)** - 31 Oct 2022

Open Access Review (/2072-6694/14/21/5373/pdf?version=1667475192)

Luteolin, a Potent Anticancer Compound: From Chemistry to Cellular Interactions and Synergetic Perspectives (/2072-6694/14/21/5373)

Cancers **2022**, *14*(21), 5373; **https://doi.org/10.3390/cancers14215373 (https://doi.org/10.3390/cancers14215373)** - 31 Oct 2022

Open Access Article (/2072-6694/14/21/5372/pdf?version=1667896644)

Impact of Microscopic Confirmation on Therapeutic Management of Pancreatic Cancer Patients: Lessons from an Italian Regional Tumor Registry (/2072-6694/14/21/5372)

Cancers **2022**, *14*(21), 5372; **https://doi.org/10.3390/cancers14215372 (https://doi.org/10.3390/cancers14215372)** - 31 Oct 2022

Open Access Correction (/2072-6694/14/21/5371/pdf?version=1667218107)

Correction: Godugu et al. Anti-Cancer Activities of Thyrointegrin $\alpha_V\beta_3$ Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in Glioblastoma. *Cancers* 2021, *13*, 2780 (/2072-6694/14/21/5371)

Cancers **2022**, *14*(21), 5371; **https://doi.org/10.3390/cancers14215371 (https://doi.org/10.3390/cancers14215371)** - 31 Oct 2022

Open Access Review (/2072-6694/14/21/5370/pdf?version=1667214375)

Cell-Free DNA Analysis within the Challenges of Thyroid Cancer Management (/2072-6694/14/21/5370)

Cancers **2022**, *14*(21), 5370; **https://doi.org/10.3390/cancers14215370 (https://doi.org/10.3390/cancers14215370)** - 31 Oct 2022

Open Access Article (/2072-6694/14/21/5369/pdf?version=1667215635)

A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition (/2072-6694/14/21/5369)

Cancers **2022**, *14*(21), 5369; **https://doi.org/10.3390/cancers14215369 (https://doi.org/10.3390/cancers14215369)** - 31 Oct 2022

Open Access Article (/2072-6694/14/21/5368/pdf?version=1667377200)

Nuclear Membrane Protein SUN5 Is Highly Expressed and Promotes Proliferation and Migration in Colorectal Cancer by Regulating the ERK Pathway (/2072-6694/14/21/5368)

Cancers **2022**, *14*(21), 5368; **https://doi.org/10.3390/cancers14215368 (https://doi.org/10.3390/cancers14215368)** - 31 Oct 2022

Open Access Article (/2072-6694/14/21/5367/pdf?version=1667213082)

The Histone Methyltransferase SETD8 Regulates the Expression of Tumor Suppressor Genes via H4K20 Methylation and the p53 Signaling Pathway in Endometrial Cancer Cells (/2072-6694/14/21/5367)

Cancers **2022**, *14*(21), 5367; **https://doi.org/10.3390/cancers14215367 (https://doi.org/10.3390/cancers14215367)** - 31 Oct 2022

Open Access Review (/2072-6694/14/21/5366/pdf?version=1667265181)

Gold Nanoparticle-Mediated Gene Therapy (/2072-6694/14/21/5366)

Back to TopTop

Cancers **2022**, *14*(21), 5366; **https://doi.org/10.3390/cancers14215366 (https://doi.org/10.3390/cancers14215366)** - 31 Oct 2022

Open Access Article (/2072-6694/14/21/5365/pdf?version=1667295057)

Recurrence Score® Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial (/2072-6694/14/21/5365)

Cancers **2022**, *14*(21), 5365; **https://doi.org/10.3390/cancers14215365 (https://doi.org/10.3390/cancers14215365)** - 31 Oct 2022

Open Access Article (/2072-6694/14/21/5364/pdf?version=1667207531)

Transcriptomic Profiling of Breast Cancer Cells Induced by Tumor-Associated Macrophages Generates a Robust Prognostic Gene Signature (/2072-6694/14/21/5364)

Cancers **2022**, *14*(21), 5364; **https://doi.org/10.3390/cancers14215364 (https://doi.org/10.3390/cancers14215364)** - 31 Oct 2022

Open Access Review (/2072-6694/14/21/5363/pdf?version=1667202709)

Electroporation in Head-and-Neck Cancer: An Innovative Approach with Immunotherapy and Nanotechnology Combination (/2072-6694/14/21/5363)

Cancers **2022**, *14*(21), 5363; **https://doi.org/10.3390/cancers14215363 (https://doi.org/10.3390/cancers14215363)** - 31 Oct 2022

Open Access Article (/2072-6694/14/21/5362/pdf?version=1667200883)

Adherens Junction Integrity Is a Critical Determinant of Sodium Iodide Symporter Residency at the Plasma Membrane of Thyroid Cells (/2072-6694/14/21/5362)

Cancers **2022**, *14*(21), 5362; **https://doi.org/10.3390/cancers14215362 (https://doi.org/10.3390/cancers14215362)** - 31 Oct 2022

Open Access Article (/2072-6694/14/21/5361/pdf?version=1667194262)

Diagnosis of Depth of Submucosal Invasion in Colorectal Cancer with AI Using Deep Learning (/2072-6694/14/21/5361)

Cancers **2022**, *14*(21), 5361; **https://doi.org/10.3390/cancers14215361 (https://doi.org/10.3390/cancers14215361)** - 31 Oct 2022

Open Access Review (/2072-6694/14/21/5360/pdf?version=1667190464)

Breast Cancer and COVID-19: Challenges in Surgical Management (/2072-6694/14/21/5360)

Cancers **2022**, *14*(21), 5360; **https://doi.org/10.3390/cancers14215360 (https://doi.org/10.3390/cancers14215360)** - 31 Oct 2022

Open Access Article (/2072-6694/14/21/5359/pdf?version=1667131887)

Go with the Flow—Early Assessment of Measurable Residual Disease in Children with Acute Lymphoblastic Leukemia Treated According to ALL IC-BFM2009 (/2072-6694/14/21/5359)

Cancers **2022**, *14*(21), 5359; **https://doi.org/10.3390/cancers14215359 (https://doi.org/10.3390/cancers14215359)** - 30 Oct 2022

Open Access Review (/2072-6694/14/21/5358/pdf?version=1667886883)

Pathologies of Precursor Lesions of Biliary Tract Carcinoma (/2072-6694/14/21/5358)

Cancers **2022**, *14*(21), 5358; **https://doi.org/10.3390/cancers14215358 (https://doi.org/10.3390/cancers14215358)** - 30 Oct 2022

Open Access Article (/2072-6694/14/21/5357/pdf?version=1667124480)

Proton Pump Inhibitors Use and the Risk of Pancreatic Cancer: Evidence from Eleven Epidemiological Studies, Comprising 1.5 Million Individuals (/2072-6694/14/21/5357)

Cancers **2022**, *14*(21), 5357; **https://doi.org/10.3390/cancers14215357 (https://doi.org/10.3390/cancers14215357)** - 30 Oct 2022

Open Access Article (/2072-6694/14/21/5356/pdf?version=1667569198)

Patients Regret Their Choice of Therapy Significantly Less Frequently after Robot-Assisted Radical Prostatectomy as Opposed to Open Radical Prostatectomy: Patient-Reported Results of the Multicenter Cross-Sectional IMPROVE Study (/2072-6694/14/21/5356)

Cancers **2022**, *14*(21), 5356; **https://doi.org/10.3390/cancers14215356 (https://doi.org/10.3390/cancers14215356)** - 30 Oct 2022

Open Access Article (/2072-6694/14/21/5355/pdf?version=1667181767)

Predicting Malignant Lymph Nodes Using a Novel Scoring System Based on Multi-Endobronchial Ultrasound Features (/2072-6694/14/21/5355)

Cancers **2022**, *14*(21), 5355; **https://doi.org/10.3390/cancers14215355 (https://doi.org/10.3390/cancers14215355)** - 30 Oct 2022

Open Access Review (/2072-6694/14/21/5354/pdf?version=1667119141)

The E3 Ligases in Cervical Cancer and Endometrial Cancer (/2072-6694/14/21/5354)

Cancers **2022**, *14*(21), 5354; **https://doi.org/10.3390/cancers14215354 (https://doi.org/10.3390/cancers14215354)** - 30 Oct 2022

Open Access Article (/2072-6694/14/21/5353/pdf?version=1667461949)

The Impact of the COVID Pandemic on the Incidence of Presentations with Cancer-Related Symptoms in Primary Care (/2072-6694/14/21/5353)

Cancers **2022**, *14*(21), 5353; **https://doi.org/10.3390/cancers14215353 (https://doi.org/10.3390/cancers14215353)** - 30 Oct 2022

Open Access Review (/2072-6694/14/21/5352/pdf?version=1667281564)

The Clinical and Molecular Features in the VHL Renal Cancers; Close or Distant Relatives with Sporadic Clear Cell Renal Cell Carcinoma? (/2072-6694/14/21/5352)

Cancers **2022**, *14*(21), 5352; **https://doi.org/10.3390/cancers14215352 (https://doi.org/10.3390/cancers14215352)** - 30 Oct 2022

Open Access Review (/2072-6694/14/21/5351/pdf?version=1667114371)

Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe (/2072-6694/14/21/5351)

Cancers **2022**, *14*(21), 5351; **https://doi.org/10.3390/cancers14215351 (https://doi.org/10.3390/cancers14215351)** - 30 Oct 2022

Open Access Review (/2072-6694/14/21/5350/pdf?version=1667886553)

The Role of *Fusobacterium nucleatum* in Colorectal Cancer Cell Proliferation and Migration (/2072-6694/14/21/5350)

Cancers **2022**, *14*(21), 5350; **https://doi.org/10.3390/cancers14215350 (https://doi.org/10.3390/cancers14215350)** - 30 Oct 2022

Back to TopTop

Open Access Article (/2072-6694/14/21/5349/pdf?version=1667110396)

Radiofrequency Electromagnetic Fields Cause Non-Temperature-Induced Physical and Biological Effects in Cancer Cells (/2072-6694/14/21/5349)

Cancers **2022**, *14*(21), 5349; **https://doi.org/10.3390/cancers14215349 (https://doi.org/10.3390/cancers14215349)** - 30 Oct 2022

(/toggle_desktop_layout_cookie)

Open Access Article (/2072-6694/14/21/5348/pdf?version=1667109594)

Refusal of Surgery in Pituitary Adenoma Patients: A Population-Based Analysis (/2072-6694/14/21/5348)

Cancers **2022**, *14*(21), 5348; **https://doi.org/10.3390/cancers14215348 (https://doi.org/10.3390/cancers14215348)** - 30 Oct 2022

Open Access Article (/2072-6694/14/21/5347/pdf?version=1667270720)

Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors (/2072-6694/14/21/5347)

Cancers **2022**, *14*(21), 5347; **https://doi.org/10.3390/cancers14215347 (https://doi.org/10.3390/cancers14215347)** - 30 Oct 2022

Open Access Article (/2072-6694/14/21/5346/pdf?version=1667887877)

A Novel m7G-Related Genes-Based Signature with Prognostic Value and Predictive Ability to Select Patients Responsive to Personalized Treatment Strategies in Bladder Cancer (/2072-6694/14/21/5346)

Cancers **2022**, *14*(21), 5346; **https://doi.org/10.3390/cancers14215346 (https://doi.org/10.3390/cancers14215346)** - 29 Oct 2022

Open Access Review (/2072-6694/14/21/5345/pdf?version=1667878541)

Metabolic Plasticity of Cancer Stem Cells in Response to Microenvironmental Cues (/2072-6694/14/21/5345)

Cancers **2022**, *14*(21), 5345; **https://doi.org/10.3390/cancers14215345 (https://doi.org/10.3390/cancers14215345)** - 29 Oct 2022

Open Access Article (/2072-6694/14/21/5344/pdf?version=1674034187)

Glycolysis-Related SLC2A1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy (/2072-6694/14/21/5344)

Cancers **2022**, *14*(21), 5344; **https://doi.org/10.3390/cancers14215344 (https://doi.org/10.3390/cancers14215344)** - 29 Oct 2022

Correction (/2072-6694/15/3/586)

Open Access Article (/2072-6694/14/21/5343/pdf?version=1667885921)

UM-164, a Dual Inhibitor of c-Src and p38 MAPK, Suppresses Proliferation of Glioma by Reducing YAP Activity (/2072-6694/14/21/5343)

Cancers **2022**, *14*(21), 5343; **https://doi.org/10.3390/cancers14215343 (https://doi.org/10.3390/cancers14215343)** - 29 Oct 2022

Open Access Article (/2072-6694/14/21/5342/pdf?version=1667887888)

Latent Microsporidia Infection Prevalence as a Risk Factor in Colon Cancer Patients (/2072-6694/14/21/5342)

Cancers **2022**, *14*(21), 5342; **https://doi.org/10.3390/cancers14215342 (https://doi.org/10.3390/cancers14215342)** - 29 Oct 2022

Open Access Review (/2072-6694/14/21/5341/pdf?version=1667887568)

Medical Device Advances in the Treatment of Glioblastoma (/2072-6694/14/21/5341)

Cancers **2022**, *14*(21), 5341; **https://doi.org/10.3390/cancers14215341 (https://doi.org/10.3390/cancers14215341)** - 29 Oct 2022

Open Access Review (/2072-6694/14/21/5340/pdf?version=1667877815)

Looking into Endoplasmic Reticulum Stress: The Key to Drug-Resistance of Multiple Myeloma? (/2072-6694/14/21/5340)

Cancers **2022**, *14*(21), 5340; **https://doi.org/10.3390/cancers14215340 (https://doi.org/10.3390/cancers14215340)** - 29 Oct 2022

Open Access Feature Paper Review (/2072-6694/14/21/5339/pdf?version=1667573059)

Oligometastatic Non-Small Cell Lung Cancer: A Practical Review of Prospective Trials (/2072-6694/14/21/5339)

Cancers **2022**, *14*(21), 5339; **https://doi.org/10.3390/cancers14215339 (https://doi.org/10.3390/cancers14215339)** - 29 Oct 2022

Open Access Article (/2072-6694/14/21/5338/pdf?version=1668049969)

Risk Prediction Models for Patients with Head and Neck Cancer among the Taiwanese Population (/2072-6694/14/21/5338)

Cancers **2022**, *14*(21), 5338; **https://doi.org/10.3390/cancers14215338 (https://doi.org/10.3390/cancers14215338)** - 29 Oct 2022

Open Access Article (/2072-6694/14/21/5337/pdf?version=1667812794)

Distinct B-Cell Specific Transcriptional Contexts of the BCL2 Oncogene Impact Pre-Malignant Development in Mouse Models (/2072-6694/14/21/5337)

Cancers **2022**, *14*(21), 5337; **https://doi.org/10.3390/cancers14215337 (https://doi.org/10.3390/cancers14215337)** - 29 Oct 2022

Open Access Article (/2072-6694/14/21/5336/pdf?version=1667041333)

Sabizabulin, a Potent Orally Bioavailable Colchicine Binding Site Agent, Suppresses HER2+ Breast Cancer and Metastasis (/2072-6694/14/21/5336)

Cancers **2022**, *14*(21), 5336; **https://doi.org/10.3390/cancers14215336 (https://doi.org/10.3390/cancers14215336)** - 29 Oct 2022

Open Access Article (/2072-6694/14/21/5335/pdf?version=1667296363)

Intraoperative Evaluation of Brain-Tumor Microvascularization through MicroV IOUS: A Protocol for Image Acquisition and Analysis of Radiomic Features (/2072-6694/14/21/5335)

Cancers **2022**, *14*(21), 5335; **https://doi.org/10.3390/cancers14215335 (https://doi.org/10.3390/cancers14215335)** - 29 Oct 2022

Open Access Review (/2072-6694/14/21/5334/pdf?version=1667898742)

The Role of Deep Learning in Advancing Breast Cancer Detection Using Different Imaging Modalities: A Systematic Review (/2072-6694/14/21/5334)

Cancers **2022**, *14*(21), 5334; **https://doi.org/10.3390/cancers14215334 (https://doi.org/10.3390/cancers14215334)** - 29 Oct 2022

Open Access Article (/2072-6694/14/21/5333/pdf?version=1667038355)

Human Papillomavirus Oncoproteins Confer Sensitivity to Cisplatin by Interfering with Epidermal Growth Factor Receptor Nuclear Trafficking Related to More Favorable Clinical Survival Outcomes in Non-Small Cell Lung Cancer (/2072-6694/14/21/5333)

Back to TopTop

Cancers **2022**, *14*(21), 5333; **https://doi.org/10.3390/cancers14215333 (https://doi.org/10.3390/cancers14215333)** - 29 Oct 2022

Open Access Review (/2072-6694/14/21/5332/pdf?version=1667179257)

Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints (/2072-6694/14/21/5332)

Cancers **2022**, *14*(21), 5332; **https://doi.org/10.3390/cancers14215332 (https://doi.org/10.3390/cancers14215332)** - 29 Oct 2022

Open Access Article (/2072-6694/14/21/5331/pdf?version=1667035159)

Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma (/2072-6694/14/21/5331)

Cancers **2022**, *14*(21), 5331; **https://doi.org/10.3390/cancers14215331 (https://doi.org/10.3390/cancers14215331)** - 29 Oct 2022

Open Access Review (/2072-6694/14/21/5330/pdf?version=1667037148)

Current Molecular Profile of Gastrointestinal Stromal Tumors and Systemic Therapeutic Implications (/2072-6694/14/21/5330)

Cancers **2022**, *14*(21), 5330; **https://doi.org/10.3390/cancers14215330 (https://doi.org/10.3390/cancers14215330)** - 29 Oct 2022

Open Access Article (/2072-6694/14/21/5329/pdf?version=1667353476)

Antiplatelet Drugs on the Recurrence of Hepatocellular Carcinoma after Liver Transplantation (/2072-6694/14/21/5329)

Cancers **2022**, *14*(21), 5329; **https://doi.org/10.3390/cancers14215329 (https://doi.org/10.3390/cancers14215329)** - 29 Oct 2022

Open Access Review (/2072-6694/14/21/5328/pdf?version=1667881020)

Proteoglycans Determine the Dynamic Landscape of EMT and Cancer Cell Stemness (/2072-6694/14/21/5328)

Cancers **2022**, *14*(21), 5328; **https://doi.org/10.3390/cancers14215328 (https://doi.org/10.3390/cancers14215328)** - 29 Oct 2022

Open Access Article (/2072-6694/14/21/5327/pdf?version=1667802406)

A Robust Personalized Classification Method for Breast Cancer Metastasis Prediction (/2072-6694/14/21/5327)

Cancers **2022**, *14*(21), 5327; **https://doi.org/10.3390/cancers14215327 (https://doi.org/10.3390/cancers14215327)** - 29 Oct 2022

Open Access Review (/2072-6694/14/21/5326/pdf?version=1667033301)

The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective (/2072-6694/14/21/5326)

Cancers **2022**, *14*(21), 5326; **https://doi.org/10.3390/cancers14215326 (https://doi.org/10.3390/cancers14215326)** - 29 Oct 2022

Open Access Review (/2072-6694/14/21/5325/pdf?version=1667027452)

Recent Advances in Immunotherapy for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma (/2072-6694/14/21/5325)

Cancers **2022**, *14*(21), 5325; **https://doi.org/10.3390/cancers14215325 (https://doi.org/10.3390/cancers14215325)** - 29 Oct 2022

Open Access Article (/2072-6694/14/21/5324/pdf?version=1667177354)

Transarterial Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma Patients: Outcome Assessment Applying a Prognostic Score (/2072-6694/14/21/5324)

Cancers **2022**, *14*(21), 5324; **https://doi.org/10.3390/cancers14215324 (https://doi.org/10.3390/cancers14215324)** - 29 Oct 2022

Open Access Article (/2072-6694/14/21/5323/pdf?version=1667898917)

The Liver Maximum Capacity Test (LiMAx) Is Associated with Short-Term Survival in Patients with Early Stage HCC Undergoing Transarterial Treatment (/2072-6694/14/21/5323)

Cancers **2022**, *14*(21), 5323; **https://doi.org/10.3390/cancers14215323 (https://doi.org/10.3390/cancers14215323)** - 28 Oct 2022

Open Access Article (/2072-6694/14/21/5322/pdf?version=1667996222)

K-RAS Associated Gene-Mutation-Based Algorithm for Prediction of Treatment Response of Patients with Subtypes of Breast Cancer and Especially Triple-Negative Cancer (/2072-6694/14/21/5322)

Cancers **2022**, *14*(21), 5322; **https://doi.org/10.3390/cancers14215322 (https://doi.org/10.3390/cancers14215322)** - 28 Oct 2022

Open Access Review (/2072-6694/14/21/5321/pdf?version=1667881056)

In Vivo Models for Prostate Cancer Research (/2072-6694/14/21/5321)

Cancers **2022**, *14*(21), 5321; **https://doi.org/10.3390/cancers14215321 (https://doi.org/10.3390/cancers14215321)** - 28 Oct 2022

Open Access Article (/2072-6694/14/21/5320/pdf?version=1667897127)

Neoadjuvant Chemotherapy Followed by Radiofrequency Ablation May Be a New Treatment Modality for Colorectal Liver Metastasis: A Propensity Score Matching Comparative Study (/2072-6694/14/21/5320)

Cancers **2022**, *14*(21), 5320; **https://doi.org/10.3390/cancers14215320 (https://doi.org/10.3390/cancers14215320)** - 28 Oct 2022

Open Access Article (/2072-6694/14/21/5319/pdf?version=1667893084)

Range-Bounded Adaptive Therapy in Metastatic Prostate Cancer (/2072-6694/14/21/5319)

Cancers **2022**, *14*(21), 5319; **https://doi.org/10.3390/cancers14215319 (https://doi.org/10.3390/cancers14215319)** - 28 Oct 2022

Open Access Article (/2072-6694/14/21/5318/pdf?version=1667316347)

Artificial Intelligence Predicted Overall Survival and Classified Mature B-Cell Neoplasms Based on Immuno-Oncology and Immune Checkpoint Panels (/2072-6694/14/21/5318)

Cancers **2022**, *14*(21), 5318; **https://doi.org/10.3390/cancers14215318 (https://doi.org/10.3390/cancers14215318)** - 28 Oct 2022

Open Access Review (/2072-6694/14/21/5317/pdf?version=1667887107)

Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy (/2072-6694/14/21/5317)

Cancers **2022**, *14*(21), 5317; **https://doi.org/10.3390/cancers14215317 (https://doi.org/10.3390/cancers14215317)** - 28 Oct 2022

Back to TopTop

Open Access Article (/2072-6694/14/21/5316/pdf?version=1668053646)

Urinary Zinc Loss Identifies Prostate Cancer Patients (/2072-6694/14/21/5316)

Cancers **2022**, *14*(21), 5316; **https://doi.org/10.3390/cancers14215316 (https://doi.org/10.3390/cancers14215316)** - 28 Oct 2022

(/toggle_desktop_layout_cookie)

Open Access Systematic Review (/2072-6694/14/21/5315/pdf?version=1667879748)

Safety of Anti-Angiogenic Drugs in Pediatric Patients with Solid Tumors: A Systematic Review and Meta-Analysis (/2072-6694/14/21/5315)

Cancers **2022**, *14*(21), 5315; **https://doi.org/10.3390/cancers14215315 (https://doi.org/10.3390/cancers14215315)** - 28 Oct 2022

Open Access Article (/2072-6694/14/21/5314/pdf?version=1667875743)

Prognostic Value of [18F]-FDG PET/CT Radiomics Combined with Sarcopenia Status among Patients with Advanced Gastroesophageal Cancer (/2072-6694/14/21/5314)

Cancers **2022**, *14*(21), 5314; **https://doi.org/10.3390/cancers14215314 (https://doi.org/10.3390/cancers14215314)** - 28 Oct 2022

Open Access Review (/2072-6694/14/21/5313/pdf?version=1667879731)

Systemic Therapy Development in Von Hippel–Lindau Disease: An Outsized Contribution from an Orphan Disease (/2072-6694/14/21/5313)

Cancers **2022**, *14*(21), 5313; **https://doi.org/10.3390/cancers14215313 (https://doi.org/10.3390/cancers14215313)** - 28 Oct 2022

Open Access Article (/2072-6694/14/21/5312/pdf?version=1667880021)

A Soft Label Deep Learning to Assist Breast Cancer Target Therapy and Thyroid Cancer Diagnosis (/2072-6694/14/21/5312)

Cancers **2022**, *14*(21), 5312; **https://doi.org/10.3390/cancers14215312 (https://doi.org/10.3390/cancers14215312)** - 28 Oct 2022

Open Access Article (/2072-6694/14/21/5311/pdf?version=1667895586)

Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe (/2072-6694/14/21/5311)

Cancers **2022**, *14*(21), 5311; **https://doi.org/10.3390/cancers14215311 (https://doi.org/10.3390/cancers14215311)** - 28 Oct 2022

Open Access Article (/2072-6694/14/21/5310/pdf?version=1667896476)

Quality of Life (QoL) of Children and Adolescents Participating in a Precision Medicine Trial for High-Risk Childhood Cancer (/2072-6694/14/21/5310)

Cancers **2022**, *14*(21), 5310; **https://doi.org/10.3390/cancers14215310 (https://doi.org/10.3390/cancers14215310)** - 28 Oct 2022

Open Access Article (/2072-6694/14/21/5309/pdf?version=1668049310)

A Novel apaQTL-SNP for the Modification of Non-Small-Cell Lung Cancer Susceptibility across Histological Subtypes (/2072-6694/14/21/5309)

Cancers **2022**, *14*(21), 5309; **https://doi.org/10.3390/cancers14215309 (https://doi.org/10.3390/cancers14215309)** - 28 Oct 2022

Open Access Article (/2072-6694/14/21/5308/pdf?version=1667876840)

The Riddle of Cetuximab-Related Skin Toxicity: ^{1}H-NMR Sebum Analysis Revealed Dynamic Lipid Alterations Associated with Skin Toxicity Development in Metastatic Colorectal Cancer Patients (/2072-6694/14/21/5308)

Cancers **2022**, *14*(21), 5308; **https://doi.org/10.3390/cancers14215308 (https://doi.org/10.3390/cancers14215308)** - 28 Oct 2022

Open Access Article (/2072-6694/14/21/5307/pdf?version=1667887353)

Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon *EGFR* Mutations: A Comparative Cohort Study in China (AFANDA Study) (/2072-6694/14/21/5307)

Cancers **2022**, *14*(21), 5307; **https://doi.org/10.3390/cancers14215307 (https://doi.org/10.3390/cancers14215307)** - 28 Oct 2022

Open Access Review (/2072-6694/14/21/5306/pdf?version=1667900556)

The Predictive and Prognostic Role of RAS–RAF–MEK–ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets (/2072-6694/14/21/5306)

Cancers **2022**, *14*(21), 5306; **https://doi.org/10.3390/cancers14215306 (https://doi.org/10.3390/cancers14215306)** - 28 Oct 2022

Open Access Review (/2072-6694/14/21/5305/pdf?version=1666954934)

The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer (/2072-6694/14/21/5305)

Cancers **2022**, *14*(21), 5305; **https://doi.org/10.3390/cancers14215305 (https://doi.org/10.3390/cancers14215305)** - 28 Oct 2022

Open Access Review (/2072-6694/14/21/5304/pdf?version=1666951544)

MicroRNAs' Crucial Role in Salivary Gland Cancers' Onset and Prognosis (/2072-6694/14/21/5304)

Cancers **2022**, *14*(21), 5304; **https://doi.org/10.3390/cancers14215304 (https://doi.org/10.3390/cancers14215304)** - 28 Oct 2022

Open Access Article (/2072-6694/14/21/5303/pdf?version=1667879975)

Interplay between Immune Cell Infiltration and Tumor Histological Subtype: A Case of Adrenocortical Cancer (/2072-6694/14/21/5303)

Cancers **2022**, *14*(21), 5303; **https://doi.org/10.3390/cancers14215303 (https://doi.org/10.3390/cancers14215303)** - 28 Oct 2022

Open Access Review (/2072-6694/14/21/5302/pdf?version=1666949778)

Exploring the Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer (/2072-6694/14/21/5302)

Cancers **2022**, *14*(21), 5302; **https://doi.org/10.3390/cancers14215302 (https://doi.org/10.3390/cancers14215302)** - 28 Oct 2022

Open Access Article (/2072-6694/14/21/5301/pdf?version=1666948297)

Subclass Analysis of Malignant, Inflammatory and Degenerative Pathologies Based on Multiple Timepoint FAPI-PET Acquisitions Using FAPI-02, FAPI-46 and FAPI-74 (/2072-6694/14/21/5301)

Cancers **2022**, *14*(21), 5301; **https://doi.org/10.3390/cancers14215301 (https://doi.org/10.3390/cancers14215301)** - 28 Oct 2022

Open Access Article (/2072-6694/14/21/5300/pdf?version=1667201278) Top

CXCL8 Up-Regulated LSECtin through AKT Signal and Correlates with the Immune Microenvironment Modulation in Colon Cancer (/2072-6694/14/21/5300)

Cancers **2022**, *14*(21), 5300; **https://doi.org/10.3390/cancers14215300 (https://doi.org/10.3390/cancers14215300)** - 28 Oct 2022

Open Access Article (/2072-6694/14/21/5300/pdf?version=1667875402)

Immunomodulatory Effects of Stereotactic Body Radiotherapy and Vaccination with Heat-Killed Mycobacterium Obuense (IMM-101) in Patients with Locally Advanced Pancreatic Cancer (/2072-6694/14/21/5299)

Cancers **2022**, *14*(21), 5299; **https://doi.org/10.3390/cancers14215299 (https://doi.org/10.3390/cancers14215299)** - 27 Oct 2022

Open Access Review (/2072-6694/14/21/5298/pdf?version=1667875152)

RET Proto-Oncogene—Not Such an Obvious Starting Point in Cancer Therapy (/2072-6694/14/21/5298)

Cancers **2022**, *14*(21), 5298; **https://doi.org/10.3390/cancers14215298 (https://doi.org/10.3390/cancers14215298)** - 27 Oct 2022

Open Access Systematic Review (/2072-6694/14/21/5297/pdf?version=1667876018)

Focus on the Dynamics of Neutrophil-to-Lymphocyte Ratio in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis and Systematic Review (/2072-6694/14/21/5297)

Cancers **2022**, *14*(21), 5297; **https://doi.org/10.3390/cancers14215297 (https://doi.org/10.3390/cancers14215297)** - 27 Oct 2022

Open Access Article (/2072-6694/14/21/5296/pdf?version=1667874170)

Microwave Catheter Navigation System for the Radiofrequency Liver Ablation (/2072-6694/14/21/5296)

Cancers **2022**, *14*(21), 5296; **https://doi.org/10.3390/cancers14215296 (https://doi.org/10.3390/cancers14215296)** - 27 Oct 2022

Open Access Article (/2072-6694/14/21/5295/pdf?version=1667879778)

The Urothelial Transcriptomic Response to Interferon Gamma: Implications for Bladder Cancer Prognosis and Immunotherapy (/2072-6694/14/21/5295)

Cancers **2022**, *14*(21), 5295; **https://doi.org/10.3390/cancers14215295 (https://doi.org/10.3390/cancers14215295)** - 27 Oct 2022

Open Access Article (/2072-6694/14/21/5294/pdf?version=1667874058)

Hepcidin Upregulation in Colorectal Cancer Associates with Accumulation of Regulatory Macrophages and Epithelial–Mesenchymal Transition and Correlates with Progression of the Disease (/2072-6694/14/21/5294)

Cancers **2022**, *14*(21), 5294; **https://doi.org/10.3390/cancers14215294 (https://doi.org/10.3390/cancers14215294)** - 27 Oct 2022

Open Access Review (/2072-6694/14/21/5293/pdf?version=1675166583)

Re-Whole Brain Radiotherapy May Be One of the Treatment Choices for Symptomatic Brain Metastases Patients (/2072-6694/14/21/5293)

Cancers **2022**, *14*(21), 5293; **https://doi.org/10.3390/cancers14215293 (https://doi.org/10.3390/cancers14215293)** - 27 Oct 2022

Open Access Article (/2072-6694/14/21/5292/pdf?version=1667270487)

Modified Albumin-Bilirubin Grade and Alpha-Fetoprotein Score (mALF Score) for Predicting the Prognosis of Hepatocellular Carcinoma after Hepatectomy (/2072-6694/14/21/5292)

Cancers **2022**, *14*(21), 5292; **https://doi.org/10.3390/cancers14215292 (https://doi.org/10.3390/cancers14215292)** - 27 Oct 2022

Open Access Article (/2072-6694/14/21/5291/pdf?version=1667889494)

A Deep Learning Model System for Diagnosis and Management of Adnexal Masses (/2072-6694/14/21/5291)

Cancers **2022**, *14*(21), 5291; **https://doi.org/10.3390/cancers14215291 (https://doi.org/10.3390/cancers14215291)** - 27 Oct 2022

Open Access Review (/2072-6694/14/21/5290/pdf?version=1666875582)

What Is the Role of Body Composition Assessment in HCC Management? (/2072-6694/14/21/5290)

Cancers **2022**, *14*(21), 5290; **https://doi.org/10.3390/cancers14215290 (https://doi.org/10.3390/cancers14215290)** - 27 Oct 2022

Open Access Article (/2072-6694/14/21/5289/pdf?version=1667879318)

New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC (/2072-6694/14/21/5289)

Cancers **2022**, *14*(21), 5289; **https://doi.org/10.3390/cancers14215289 (https://doi.org/10.3390/cancers14215289)** - 27 Oct 2022

Open Access Article (/2072-6694/14/21/5288/pdf?version=1666874389)

Impact of Patient, Surgical, and Perioperative Factors on Discharge Disposition after Radical Cystectomy (/2072-6694/14/21/5288)

Cancers **2022**, *14*(21), 5288; **https://doi.org/10.3390/cancers14215288 (https://doi.org/10.3390/cancers14215288)** - 27 Oct 2022

Open Access Article (/2072-6694/14/21/5287/pdf?version=1666873919)

Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy (/2072-6694/14/21/5287)

Cancers **2022**, *14*(21), 5287; **https://doi.org/10.3390/cancers14215287 (https://doi.org/10.3390/cancers14215287)** - 27 Oct 2022

Open Access Review (/2072-6694/14/21/5286/pdf?version=1667357371)

Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+) (/2072-6694/14/21/5286)

Cancers **2022**, *14*(21), 5286; **https://doi.org/10.3390/cancers14215286 (https://doi.org/10.3390/cancers14215286)** - 27 Oct 2022

Open Access Perspective (/2072-6694/14/21/5285/pdf?version=1666933165)

Immunotherapy and Modern Radiotherapy Technique for Older Patients with Locally Advanced Head and Neck Cancer: A Proposed Paradigm by the International Geriatric Radiotherapy Group (/2072-6694/14/21/5285)

Cancers **2022**, *14*(21), 5285; **https://doi.org/10.3390/cancers14215285 (https://doi.org/10.3390/cancers14215285)** - 27 Oct 2022

Open Access Article (/2072-6694/14/21/5284/pdf?version=1667872762)

Penile Squamous Cell Carcinomas in Sub-Saharan Africa and Europe: Differential Etiopathogenesis (/2072-6694/14/21/5284)

Cancers **2022**, *14*(21), 5284; **https://doi.org/10.3390/cancers14215284 (https://doi.org/10.3390/cancers14215284)** - 27 Oct 2022

Back to TopTop

Open Access Article (/2072-6694/14/21/5283/pdf?version=1666869487)

Palliative Treatment of Esophageal Cancer Using Calcium Electroporation (/2072-6694/14/21/5283)

Cancers **2022**, *14*(21), 5283; **https://doi.org/10.3390/cancers14215283 (https://doi.org/10.3390/cancers14215283)** - 27 Oct 2022

(/toggle_desktop_layout_cookie)

Open Access Article (/2072-6694/14/21/5282/pdf?version=1667877222)

A Novel Plasma-Based Methylation Panel for Upper Gastrointestinal Cancer Early Detection (/2072-6694/14/21/5282)

Cancers **2022**, *14*(21), 5282; **https://doi.org/10.3390/cancers14215282 (https://doi.org/10.3390/cancers14215282)** - 27 Oct 2022

Open Access Article (/2072-6694/14/21/5281/pdf?version=1666868046)

Acoustic Radiation Force Impulse Elastography Assessment of Lymphoedema Tissue: An Insight into Tissue Stiffness (/2072-6694/14/21/5281)

Cancers **2022**, *14*(21), 5281; **https://doi.org/10.3390/cancers14215281 (https://doi.org/10.3390/cancers14215281)** - 27 Oct 2022

Open Access Article (/2072-6694/14/21/5280/pdf?version=1666865284)

Association between Immunologic Markers and Cirrhosis in Individuals from a Prospective Chronic Hepatitis C Cohort (/2072-6694/14/21/5280)

Cancers **2022**, *14*(21), 5280; **https://doi.org/10.3390/cancers14215280 (https://doi.org/10.3390/cancers14215280)** - 27 Oct 2022

Open Access Article (/2072-6694/14/21/5279/pdf?version=1666866309)

Comprehensive Characterization of the Regulatory Landscape of Adrenocortical Carcinoma: Novel Transcription Factors and Targets Associated with Prognosis (/2072-6694/14/21/5279)

Cancers **2022**, *14*(21), 5279; **https://doi.org/10.3390/cancers14215279 (https://doi.org/10.3390/cancers14215279)** - 27 Oct 2022

Open Access Review (/2072-6694/14/21/5278/pdf?version=1666868298)

DNA Repair Mechanisms, Protein Interactions and Therapeutic Targeting of the MRN Complex (/2072-6694/14/21/5278)

Cancers **2022**, *14*(21), 5278; **https://doi.org/10.3390/cancers14215278 (https://doi.org/10.3390/cancers14215278)** - 27 Oct 2022

Open Access Review (/2072-6694/14/21/5277/pdf?version=1666864097)

Integration between Novel Imaging Technologies and Modern Radiotherapy Techniques: How the Eye Drove the Chisel (/2072-6694/14/21/5277)

Cancers **2022**, *14*(21), 5277; **https://doi.org/10.3390/cancers14215277 (https://doi.org/10.3390/cancers14215277)** - 27 Oct 2022

Open Access Article (/2072-6694/14/21/5276/pdf?version=1667190640)

Timely Leukapheresis May Interfere with the "Fitness" of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients (/2072-6694/14/21/5276)

Cancers **2022**, *14*(21), 5276; **https://doi.org/10.3390/cancers14215276 (https://doi.org/10.3390/cancers14215276)** - 27 Oct 2022

Open Access Article (/2072-6694/14/21/5275/pdf?version=1666862630)

CFR-PEEK Pedicle Screw Instrumentation for Spinal Neoplasms: A Single Center Experience on Safety and Efficacy (/2072-6694/14/21/5275)

Cancers **2022**, *14*(21), 5275; **https://doi.org/10.3390/cancers14215275 (https://doi.org/10.3390/cancers14215275)** - 27 Oct 2022

Open Access Article (/2072-6694/14/21/5274/pdf?version=1666862109)

Panel Sequencing of Primary Cutaneous B-Cell Lymphoma (/2072-6694/14/21/5274)

Cancers **2022**, *14*(21), 5274; **https://doi.org/10.3390/cancers14215274 (https://doi.org/10.3390/cancers14215274)** - 27 Oct 2022

Open Access Article (/2072-6694/14/21/5273/pdf?version=1666921372)

miR766-3p and miR124-3p Dictate Drug Resistance and Clinical Outcome in HNSCC (/2072-6694/14/21/5273)

Cancers **2022**, *14*(21), 5273; **https://doi.org/10.3390/cancers14215273 (https://doi.org/10.3390/cancers14215273)** - 27 Oct 2022

Open Access Article (/2072-6694/14/21/5272/pdf?version=1666864582)

Mechanistic Studies and a Retrospective Cohort Study: The Interaction between PPAR Agonists and Immunomodulatory Agents in Multiple Myeloma (/2072-6694/14/21/5272)

Cancers **2022**, *14*(21), 5272; **https://doi.org/10.3390/cancers14215272 (https://doi.org/10.3390/cancers14215272)** - 27 Oct 2022

Open Access Review (/2072-6694/14/21/5271/pdf?version=1666860313)

Rosai–Dorfman Disease between Proliferation and Neoplasia (/2072-6694/14/21/5271)

Cancers **2022**, *14*(21), 5271; **https://doi.org/10.3390/cancers14215271 (https://doi.org/10.3390/cancers14215271)** - 27 Oct 2022

Open Access Review (/2072-6694/14/21/5270/pdf?version=1666859129)

Tumor Necrosis Factor: What Is in a Name? (/2072-6694/14/21/5270)

Cancers **2022**, *14*(21), 5270; **https://doi.org/10.3390/cancers14215270 (https://doi.org/10.3390/cancers14215270)** - 27 Oct 2022

Open Access Article (/2072-6694/14/21/5269/pdf?version=1666859745)

Quantifying Liver Heterogeneity via R2*-MRI with Super-Paramagnetic Iron Oxide Nanoparticles (SPION) to Characterize Liver Function and Tumor (/2072-6694/14/21/5269)

Cancers **2022**, *14*(21), 5269; **https://doi.org/10.3390/cancers14215269 (https://doi.org/10.3390/cancers14215269)** - 27 Oct 2022

Open Access Review (/2072-6694/14/21/5268/pdf?version=1667876377)

Metabolic Pathways, Enzymes, and Metabolites: Opportunities in Cancer Therapy (/2072-6694/14/21/5268)

Cancers **2022**, *14*(21), 5268; **https://doi.org/10.3390/cancers14215268 (https://doi.org/10.3390/cancers14215268)** - 27 Oct 2022

Open Access Article (/2072-6694/14/21/5267/pdf?version=1666856642)

Pathologic Predictors of Response to Treatment of Immune Checkpoint Inhibitor–Induced Kidney Injury (/2072-6694/14/21/5267)

Cancers **2022**, *14*(21), 5267; **https://doi.org/10.3390/cancers14215267 (https://doi.org/10.3390/cancers14215267)** - 27 Oct 2022

Back to TopTop

Open Access Article (/2072-6694/14/21/5266/pdf?version=1668062341)

Evaluation of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma Using Clinical-Ultrasound Radiomic Machine Learning-Based Model (/2072-6694/14/21/5266)

Cancers **2022**, *14*(21), 5266; **https://doi.org/10.3390/cancers14215266 (https://doi.org/10.3390/cancers14215266)** - 26 Oct 2022

(/toggle_desktop_layout_cookie)

Open Access Perspective (/2072-6694/14/21/5265/pdf?version=1667873000)

A New Source of Heterogeneity in Comparative and Translational Clinical Trials: The "Border-Time" Bias (/2072-6694/14/21/5265)

Cancers **2022**, *14*(21), 5265; **https://doi.org/10.3390/cancers14215265 (https://doi.org/10.3390/cancers14215265)** - 26 Oct 2022

Open Access Review (/2072-6694/14/21/5264/pdf?version=1667878340)

Deep Learning Approaches in Histopathology (/2072-6694/14/21/5264)

Cancers **2022**, *14*(21), 5264; **https://doi.org/10.3390/cancers14215264 (https://doi.org/10.3390/cancers14215264)** - 26 Oct 2022

Open Access Article (/2072-6694/14/21/5263/pdf?version=1667876957)

Overall Survival for Esophageal Squamous Cell Carcinoma with Multiple Primary Cancers after Curative Esophagectomy—A Retrospective Single-Institution Study (/2072-6694/14/21/5263)

Cancers **2022**, *14*(21), 5263; **https://doi.org/10.3390/cancers14215263 (https://doi.org/10.3390/cancers14215263)** - 26 Oct 2022

Open Access Review (/2072-6694/14/21/5262/pdf?version=1667872165)

Inflammation as a Therapeutic Target in Cancer Cachexia (/2072-6694/14/21/5262)

Cancers **2022**, *14*(21), 5262; **https://doi.org/10.3390/cancers14215262 (https://doi.org/10.3390/cancers14215262)** - 26 Oct 2022

Open Access Article (/2072-6694/14/21/5261/pdf?version=1667807307)

Development and Implementation of an Advanced Program for Robotic Treatment of Prostate Cancer—Is Surgical Quality Transferable? (/2072-6694/14/21/5261)

Cancers **2022**, *14*(21), 5261; **https://doi.org/10.3390/cancers14215261 (https://doi.org/10.3390/cancers14215261)** - 26 Oct 2022

Open Access Article (/2072-6694/14/21/5260/pdf?version=1667887933)

Polygodial, a Sesquiterpene Dialdehyde, Activates Apoptotic Signaling in Castration-Resistant Prostate Cancer Cell Lines by Inducing Oxidative Stress (/2072-6694/14/21/5260)

Cancers **2022**, *14*(21), 5260; **https://doi.org/10.3390/cancers14215260 (https://doi.org/10.3390/cancers14215260)** - 26 Oct 2022

Open Access Review (/2072-6694/14/21/5259/pdf?version=1667877673)

DGKα, Bridging Membrane Shape Changes with Specific Molecular Species of DAG/PA: Implications in Cancer and Immunosurveillance (/2072-6694/14/21/5259)

Cancers **2022**, *14*(21), 5259; **https://doi.org/10.3390/cancers14215259 (https://doi.org/10.3390/cancers14215259)** - 26 Oct 2022

Open Access Article (/2072-6694/14/21/5258/pdf?version=1667874596)

The Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis (/2072-6694/14/21/5258)

Cancers **2022**, *14*(21), 5258; **https://doi.org/10.3390/cancers14215258 (https://doi.org/10.3390/cancers14215258)** - 26 Oct 2022

Open Access Review (/2072-6694/14/21/5257/pdf?version=1667877788)

The Molecular Interplay between Human Oncoviruses and Telomerase in Cancer Development (/2072-6694/14/21/5257)

Cancers **2022**, *14*(21), 5257; **https://doi.org/10.3390/cancers14215257 (https://doi.org/10.3390/cancers14215257)** - 26 Oct 2022

Open Access Article (/2072-6694/14/21/5256/pdf?version=1667807448)

Visceral Obesity Is a More Important Factor for Colorectal Adenomas than Skeletal Muscle or Body Fat (/2072-6694/14/21/5256)

Cancers **2022**, *14*(21), 5256; **https://doi.org/10.3390/cancers14215256 (https://doi.org/10.3390/cancers14215256)** - 26 Oct 2022

Open Access Communication (/2072-6694/14/21/5255/pdf?version=1666789160)

Colorectal Cancer and the Obese Patient: A Call for Guidelines (/2072-6694/14/21/5255)

Cancers **2022**, *14*(21), 5255; **https://doi.org/10.3390/cancers14215255 (https://doi.org/10.3390/cancers14215255)** - 26 Oct 2022

Open Access Review (/2072-6694/14/21/5254/pdf?version=1667877322)

Quantitative Framework for Bench-to-Bedside Cancer Research (/2072-6694/14/21/5254)

Cancers **2022**, *14*(21), 5254; **https://doi.org/10.3390/cancers14215254 (https://doi.org/10.3390/cancers14215254)** - 26 Oct 2022

Open Access Article (/2072-6694/14/21/5253/pdf?version=1666787151)

Tyrosine Kinase Inhibitor Independent Gene Expression Signature in CML Offers New Targets for LSPC Eradication Therapy (/2072-6694/14/21/5253)

Cancers **2022**, *14*(21), 5253; **https://doi.org/10.3390/cancers14215253 (https://doi.org/10.3390/cancers14215253)** - 26 Oct 2022

Open Access Review (/2072-6694/14/21/5252/pdf?version=1666794322)

The Potential Role of 3D In Vitro Acute Myeloid Leukemia Culture Models in Understanding Drug Resistance in Leukemia Stem Cells (/2072-6694/14/21/5252)

Cancers **2022**, *14*(21), 5252; **https://doi.org/10.3390/cancers14215252 (https://doi.org/10.3390/cancers14215252)** - 26 Oct 2022

Open Access Review (/2072-6694/14/21/5251/pdf?version=1667874173)

HDACi: The Columbus' Egg in Improving Cancer Treatment and Reducing Neurotoxicity? (/2072-6694/14/21/5251)

Cancers **2022**, *14*(21), 5251; **https://doi.org/10.3390/cancers14215251 (https://doi.org/10.3390/cancers14215251)** - 26 Oct 2022

Open Access Article (/2072-6694/14/21/5250/pdf?version=1666784135)

Evaluation of the Heat Shock Protein 90 Inhibitor Ganetespib as a Sensitizer to Hyperthermia-Based Cancer Treatments (/2072-6694/14/21/5250)

Back to TopTop

Cancers **2022**, *14*(21), 5250; **https://doi.org/10.3390/cancers14215250 (https://doi.org/10.3390/cancers14215250)** - 26 Oct 2022

Open Access Article (/2072-6694/14/21/5249/pdf?version=1666782966)

Perioperative and Oncological Outcomes of Robotic-Assisted, Video-Assisted Thoracoscopic and Open Lobectomy for Patients with N1 Metastatic Non-Small Cell Lung Cancer: A Propensity Score-Matched Study (/2072-6694/14/21/5249)

Cancers **2022**, *14*(21), 5249; **https://doi.org/10.3390/cancers14215249 (https://doi.org/10.3390/cancers14215249)** - 26 Oct 2022

Open Access Review (/2072-6694/14/21/5248/pdf?version=1666788234)

Treatment Sequencing Strategies in Advanced Neuroendocrine Tumors: A Review (/2072-6694/14/21/5248)

Cancers **2022**, *14*(21), 5248; **https://doi.org/10.3390/cancers14215248 (https://doi.org/10.3390/cancers14215248)** - 26 Oct 2022

Open Access Review (/2072-6694/14/21/5247/pdf?version=1666777956)

Monoclonal Gammopathies of Clinical Significance: A Critical Appraisal (/2072-6694/14/21/5247)

Cancers **2022**, *14*(21), 5247; **https://doi.org/10.3390/cancers14215247 (https://doi.org/10.3390/cancers14215247)** - 26 Oct 2022

Open Access Review (/2072-6694/14/21/5246/pdf?version=1666777275)

Neural Component of the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma (/2072-6694/14/21/5246)

Cancers **2022**, *14*(21), 5246; **https://doi.org/10.3390/cancers14215246 (https://doi.org/10.3390/cancers14215246)** - 26 Oct 2022

Open Access Review (/2072-6694/14/21/5245/pdf?version=1666777300)

Bridging the Scientific Gaps to Identify Effective Treatments in Adrenocortical Cancer (/2072-6694/14/21/5245)

Cancers **2022**, *14*(21), 5245; **https://doi.org/10.3390/cancers14215245 (https://doi.org/10.3390/cancers14215245)** - 26 Oct 2022

Open Access Review (/2072-6694/14/21/5244/pdf?version=1666941559)

Molecular Engines, Therapeutic Targets, and Challenges in Pediatric Brain Tumors: A Special Emphasis on Hydrogen Sulfide and RNA-Based Nano-Delivery (/2072-6694/14/21/5244)

Cancers **2022**, *14*(21), 5244; **https://doi.org/10.3390/cancers14215244 (https://doi.org/10.3390/cancers14215244)** - 26 Oct 2022

Open Access Article (/2072-6694/14/21/5243/pdf?version=1666850663)

A Negative Body Image among Adolescent and Young Adult (AYA) Cancer Survivors: Results from the Population-Based SURVAYA Study (/2072-6694/14/21/5243)

Cancers **2022**, *14*(21), 5243; **https://doi.org/10.3390/cancers14215243 (https://doi.org/10.3390/cancers14215243)** - 26 Oct 2022

Open Access Review (/2072-6694/14/21/5242/pdf?version=1667958187)

Zinc Finger Proteins: Functions and Mechanisms in Colon Cancer (/2072-6694/14/21/5242)

Cancers **2022**, *14*(21), 5242; **https://doi.org/10.3390/cancers14215242 (https://doi.org/10.3390/cancers14215242)** - 26 Oct 2022

Open Access Article (/2072-6694/14/21/5241/pdf?version=1667872595)

Novel BH4-BCL-2 Domain Antagonists Induce BCL-2-Mediated Apoptosis in Triple-Negative Breast Cancer (/2072-6694/14/21/5241)

Cancers **2022**, *14*(21), 5241; **https://doi.org/10.3390/cancers14215241 (https://doi.org/10.3390/cancers14215241)** - 26 Oct 2022

Open Access Article (/2072-6694/14/21/5240/pdf?version=1667795818)

TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of *BRCA2* Mutation Status (/2072-6694/14/21/5240)

Cancers **2022**, *14*(21), 5240; **https://doi.org/10.3390/cancers14215240 (https://doi.org/10.3390/cancers14215240)** - 26 Oct 2022

Open Access Article (/2072-6694/14/21/5239/pdf?version=1666769703)

Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis (/2072-6694/14/21/5239)

Cancers **2022**, *14*(21), 5239; **https://doi.org/10.3390/cancers14215239 (https://doi.org/10.3390/cancers14215239)** - 26 Oct 2022

Open Access Article (/2072-6694/14/21/5238/pdf?version=1667273882)

A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix® PC1 System (/2072-6694/14/21/5238)

Cancers **2022**, *14*(21), 5238; **https://doi.org/10.3390/cancers14215238 (https://doi.org/10.3390/cancers14215238)** - 26 Oct 2022

Open Access Article (/2072-6694/14/21/5237/pdf?version=1667531320)

LncRNA LINC01537 Promotes Gastric Cancer Metastasis and Tumorigenesis by Stabilizing RIPK4 to Activate NF-κB Signaling (/2072-6694/14/21/5237)

Cancers **2022**, *14*(21), 5237; **https://doi.org/10.3390/cancers14215237 (https://doi.org/10.3390/cancers14215237)** - 25 Oct 2022

Open Access Perspective (/2072-6694/14/21/5236/pdf?version=1667791722)

LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence (/2072-6694/14/21/5236)

Cancers **2022**, *14*(21), 5236; **https://doi.org/10.3390/cancers14215236 (https://doi.org/10.3390/cancers14215236)** - 25 Oct 2022

Open Access Article (/2072-6694/14/21/5235/pdf?version=1667559008)

Geostatistical Modeling and Heterogeneity Analysis of Tumor Molecular Landscape (/2072-6694/14/21/5235)

Cancers **2022**, *14*(21), 5235; **https://doi.org/10.3390/cancers14215235 (https://doi.org/10.3390/cancers14215235)** - 25 Oct 2022

Open Access Article (/2072-6694/14/21/5234/pdf?version=1667555104)

Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV Trial (/2072-6694/14/21/5234)

Cancers **2022**, *14*(21), 5234; **https://doi.org/10.3390/cancers14215234 (https://doi.org/10.3390/cancers14215234)** - 25 Oct 2022

Open Access Article (/2072-6694/14/21/5233/pdf?version=1667806326)

The RSL3 Induction of *KLK* Lung Adenocarcinoma Cell Ferroptosis by Inhibition of USP11 Activity and the NRF2-GSH Axis (/2072-6694/14/21/5233)

Cancers **2022**, *14*(21), 5233; **https://doi.org/10.3390/cancers14215233 (https://doi.org/10.3390/cancers14215233)** - 25 Oct 2022

Open Access Review (/2072-6694/14/21/5233/pdf?version=1666552052)

Diagnosis and Management of Porocarcinoma (/2072-6694/14/21/5232)

Cancers **2022**, *14*(21), 5232; **https://doi.org/10.3390/cancers14215232 (https://doi.org/10.3390/cancers14215232)** - 25 Oct 2022

Open Access Article (/2072-6694/14/21/5231/pdf?version=1666854193)

The Clinical Characteristics and Treatments for Large Cell Carcinoma Patients Older than 65 Years Old: A Population-Based Study (/2072-6694/14/21/5231)

Cancers **2022**, *14*(21), 5231; **https://doi.org/10.3390/cancers14215231 (https://doi.org/10.3390/cancers14215231)** - 25 Oct 2022

Open Access Article (/2072-6694/14/21/5230/pdf?version=1667532895)

Individualized Decision Making in Transperineal Prostate Biopsy: Should All Men Undergo an Additional Systematic Biopsy? (/2072-6694/14/21/5230)

Cancers **2022**, *14*(21), 5230; **https://doi.org/10.3390/cancers14215230 (https://doi.org/10.3390/cancers14215230)** - 25 Oct 2022

Open Access Review (/2072-6694/14/21/5229/pdf?version=1667801903)

Oligometastatic Disease: When Stage IV Breast Cancer Could Be "Cured" (/2072-6694/14/21/5229)

Cancers **2022**, *14*(21), 5229; **https://doi.org/10.3390/cancers14215229 (https://doi.org/10.3390/cancers14215229)** - 25 Oct 2022

Open Access Article (/2072-6694/14/21/5228/pdf?version=1667802496)

Prognosis and Immunological Characteristics of PGK1 in Lung Adenocarcinoma: A Systematic Analysis (/2072-6694/14/21/5228)

Cancers **2022**, *14*(21), 5228; **https://doi.org/10.3390/cancers14215228 (https://doi.org/10.3390/cancers14215228)** - 25 Oct 2022

Open Access Review (/2072-6694/14/21/5227/pdf?version=1667556000)

Pleiotropy of PP2A Phosphatases in Cancer with a Focus on Glioblastoma *IDH* Wildtype (/2072-6694/14/21/5227)

Cancers **2022**, *14*(21), 5227; **https://doi.org/10.3390/cancers14215227 (https://doi.org/10.3390/cancers14215227)** - 25 Oct 2022

Open Access Article (/2072-6694/14/21/5226/pdf?version=1666692749)

ZFP14 Regulates Cancer Cell Growth and Migration by Modulating p53 Protein Stability as Part of the MDM2 E3 Ubiquitin Ligase Complex (/2072-6694/14/21/5226)

Cancers **2022**, *14*(21), 5226; **https://doi.org/10.3390/cancers14215226 (https://doi.org/10.3390/cancers14215226)** - 25 Oct 2022

Open Access Article (/2072-6694/14/21/5225/pdf?version=1666691117)

A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer (/2072-6694/14/21/5225)

Cancers **2022**, *14*(21), 5225; **https://doi.org/10.3390/cancers14215225 (https://doi.org/10.3390/cancers14215225)** - 25 Oct 2022

Open Access Review (/2072-6694/14/21/5224/pdf?version=1667798893)

Metabolic Reprogramming in Tumor-Associated Macrophages in the Ovarian Tumor Microenvironment (/2072-6694/14/21/5224)

Cancers **2022**, *14*(21), 5224; **https://doi.org/10.3390/cancers14215224 (https://doi.org/10.3390/cancers14215224)** - 25 Oct 2022

Open Access Article (/2072-6694/14/21/5223/pdf?version=1666689917)

Securing Resection Margin Using Indocyanine Green Diffusion Range on Gastric Wall during NIR Fluorescence-Guided Surgery in Early Gastric Cancer Patients (/2072-6694/14/21/5223)

Cancers **2022**, *14*(21), 5223; **https://doi.org/10.3390/cancers14215223 (https://doi.org/10.3390/cancers14215223)** - 25 Oct 2022

Open Access Article (/2072-6694/14/21/5222/pdf?version=1667442841)

Aptamer-Based Sandwich Assay Formats for Detection and Discrimination of Human High- and Low-Molecular-Weight uPA for Cancer Prognosis and Diagnosis (/2072-6694/14/21/5222)

Cancers **2022**, *14*(21), 5222; **https://doi.org/10.3390/cancers14215222 (https://doi.org/10.3390/cancers14215222)** - 25 Oct 2022

Open Access Article (/2072-6694/14/21/5221/pdf?version=1667535636)

A Deep Learning-Aided Automated Method for Calculating Metabolic Tumor Volume in Diffuse Large B-Cell Lymphoma (/2072-6694/14/21/5221)

Cancers **2022**, *14*(21), 5221; **https://doi.org/10.3390/cancers14215221 (https://doi.org/10.3390/cancers14215221)** - 25 Oct 2022

Open Access Article (/2072-6694/14/21/5220/pdf?version=1667791093)

Next-Generation Antisense Oligonucleotide of TGF-β2 Enhances T Cell-Mediated Anticancer Efficacy of Anti-PD-1 Therapy in a Humanized Mouse Model of Immune-Excluded Melanoma (/2072-6694/14/21/5220)

Cancers **2022**, *14*(21), 5220; **https://doi.org/10.3390/cancers14215220 (https://doi.org/10.3390/cancers14215220)** - 25 Oct 2022

Open Access Article (/2072-6694/14/21/5219/pdf?version=1666777701)

Respiratory Tract Cancer Incidences across Industry Groups: A Nationwide Cohort Study with More Than 70 Million Person-Years of Follow-Up (/2072-6694/14/21/5219)

Cancers **2022**, *14*(21), 5219; **https://doi.org/10.3390/cancers14215219 (https://doi.org/10.3390/cancers14215219)** - 25 Oct 2022

Open Access Article (/2072-6694/14/21/5218/pdf?version=1667804349)

FTO Inhibits Epithelial Ovarian Cancer Progression by Destabilising SNAI1 mRNA through IGF2BP2 (/2072-6694/14/21/5218)

Cancers **2022**, *14*(21), 5218; **https://doi.org/10.3390/cancers14215218 (https://doi.org/10.3390/cancers14215218)** - 25 Oct 2022

Open Access Review (/2072-6694/14/21/5217/pdf?version=1667556834)

Vulvar Malignant Melanoma: A Narrative Review (/2072-6694/14/21/5217)

Cancers **2022**, *14*(21), 5217; **https://doi.org/10.3390/cancers14215217 (https://doi.org/10.3390/cancers14215217)** - 25 Oct 2022

Back to TopTop

Open Access Article (/2072-6694/14/21/5216/pdf?version=1667539483)

Analysis of Primary Cilium Expression and Hedgehog Pathway Activation in Mesothelioma Throws Back Its Complex Biology (/2072-6694/14/21/5216)

Cancers **2022**, *14*(21), 5216; **https://doi.org/10.3390/cancers14215216 (https://doi.org/10.3390/cancers14215216)** - 25 Oct 2022

(/toggle_desktop_layout_cookie)

Open Access Article (/2072-6694/14/21/5215/pdf?version=1667296529)

Inhibition of IκB Kinase Is a Potential Therapeutic Strategy to Circumvent Resistance to Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer Cells (/2072-6694/14/21/5215)

Cancers **2022**, *14*(21), 5215; **https://doi.org/10.3390/cancers14215215 (https://doi.org/10.3390/cancers14215215)** - 24 Oct 2022

Open Access Article (/2072-6694/14/21/5214/pdf?version=1667295451)

Is Lymphocyte C-Reactive Protein Ratio Useful for Predicting Survival in Patients with Non-Metastatic Soft Tissue Sarcoma? (/2072-6694/14/21/5214)

Cancers **2022**, *14*(21), 5214; **https://doi.org/10.3390/cancers14215214 (https://doi.org/10.3390/cancers14215214)** - 24 Oct 2022

Open Access Article (/2072-6694/14/21/5213/pdf?version=1667545305)

Viral Integration Plays a Minor Role in the Development and Prognostication of Oral Squamous Cell Carcinoma (/2072-6694/14/21/5213)

Cancers **2022**, *14*(21), 5213; **https://doi.org/10.3390/cancers14215213 (https://doi.org/10.3390/cancers14215213)** - 24 Oct 2022

Open Access Article (/2072-6694/14/21/5212/pdf?version=1667441120)

Amino Acid Solutions for ^{177}Lu-Oxodotreotide Premedication: A Tolerance Study (/2072-6694/14/21/5212)

Cancers **2022**, *14*(21), 5212; **https://doi.org/10.3390/cancers14215212 (https://doi.org/10.3390/cancers14215212)** - 24 Oct 2022

Open Access Article (/2072-6694/14/21/5211/pdf?version=1667179319)

Sinonasal Inverted Papilloma–Associated and De Novo Squamous Cell Carcinoma: A Tale of Two Cities or Not (/2072-6694/14/21/5211)

Cancers **2022**, *14*(21), 5211; **https://doi.org/10.3390/cancers14215211 (https://doi.org/10.3390/cancers14215211)** - 24 Oct 2022

Open Access Article (/2072-6694/14/21/5210/pdf?version=1667374337)

PARP10 Mediates Mono-ADP-Ribosylation of Aurora-A Regulating G2/M Transition of the Cell Cycle (/2072-6694/14/21/5210)

Cancers **2022**, *14*(21), 5210; **https://doi.org/10.3390/cancers14215210 (https://doi.org/10.3390/cancers14215210)** - 24 Oct 2022

Open Access Review (/2072-6694/14/21/5209/pdf?version=1666769029)

Cellular Plasticity and Heterotypic Interactions during Breast Morphogenesis and Cancer Initiation (/2072-6694/14/21/5209)

Cancers **2022**, *14*(21), 5209; **https://doi.org/10.3390/cancers14215209 (https://doi.org/10.3390/cancers14215209)** - 24 Oct 2022

Open Access Article (/2072-6694/14/21/5208/pdf?version=1666615830)

Predictors of Survival in Elderly Patients with Metastatic Colon Cancer: A Population-Based Cohort Study (/2072-6694/14/21/5208)

Cancers **2022**, *14*(21), 5208; **https://doi.org/10.3390/cancers14215208 (https://doi.org/10.3390/cancers14215208)** - 24 Oct 2022

Open Access Article (/2072-6694/14/21/5207/pdf?version=1666604979)

Luminal and Tumor-Associated Gut Microbiome Features Linked to Precancerous Lesions Malignancy Risk: A Compositional Approach (/2072-6694/14/21/5207)

Cancers **2022**, *14*(21), 5207; **https://doi.org/10.3390/cancers14215207 (https://doi.org/10.3390/cancers14215207)** - 24 Oct 2022

Open Access Review (/2072-6694/14/21/5206/pdf?version=1667360981)

Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies (/2072-6694/14/21/5206)

Cancers **2022**, *14*(21), 5206; **https://doi.org/10.3390/cancers14215206 (https://doi.org/10.3390/cancers14215206)** - 24 Oct 2022

Open Access Systematic Review (/2072-6694/14/21/5205/pdf?version=1667373985)

Role of Immunotherapy in the Treatment of Cancer: A Systematic Review (/2072-6694/14/21/5205)

Cancers **2022**, *14*(21), 5205; **https://doi.org/10.3390/cancers14215205 (https://doi.org/10.3390/cancers14215205)** - 24 Oct 2022

Open Access Article (/2072-6694/14/21/5204/pdf?version=1666599577)

Second Primary Cancers following Colorectal Cancer in Sicily, Italy (/2072-6694/14/21/5204)

Cancers **2022**, *14*(21), 5204; **https://doi.org/10.3390/cancers14215204 (https://doi.org/10.3390/cancers14215204)** - 24 Oct 2022

Open Access Opinion (/2072-6694/14/21/5203/pdf?version=1667349811)

Evaluation of Concomitant Use of Anticancer Drugs and Herbal Products: From Interactions to Synergic Activity (/2072-6694/14/21/5203)

Cancers **2022**, *14*(21), 5203; **https://doi.org/10.3390/cancers14215203 (https://doi.org/10.3390/cancers14215203)** - 23 Oct 2022

Open Access Editorial (/2072-6694/14/21/5202/pdf?version=1667375813)

The Juggernaut of Adaptive Metabolism in Cancers: Implications and Therapeutic Targets (/2072-6694/14/21/5202)

Cancers **2022**, *14*(21), 5202; **https://doi.org/10.3390/cancers14215202 (https://doi.org/10.3390/cancers14215202)** - 23 Oct 2022

Open Access Article (/2072-6694/14/21/5201/pdf?version=1666533693)

Prognostic Value and Quantitative CT Analysis in RANKL Expression of Spinal GCTB in the Denosumab Era: A Machine Learning Approach (/2072-6694/14/21/5201)

Cancers **2022**, *14*(21), 5201; **https://doi.org/10.3390/cancers14215201 (https://doi.org/10.3390/cancers14215201)** - 23 Oct 2022

Open Access Review (/2072-6694/14/21/5200/pdf?version=1666521373)

Perspectives on the Management of Oligometastatic Disease in Esophago-Gastric Cancer (/2072-6694/14/21/5200)

Cancers **2022**, *14*(21), 5200; **https://doi.org/10.3390/cancers14215200 (https://doi.org/10.3390/cancers14215200)** - 23 Oct 2022

Back to TopTop

Open Access Article (/2072-6694/14/21/5199/pdf?version=1666671404)

Occupational Exposure to Pesticides Affects Pivotal Immunologic Anti-Tumor Responses in Breast Cancer Women from the Intermediate Risk of Recurrence and Death (/2072-6694/14/21/5199)

Cancers **2022**, *14*(21), 5199; **https://doi.org/10.3390/cancers14215199 (https://doi.org/10.3390/cancers14215199)** - 23 Oct 2022

(/toggle_desktop_layout_cookie)

Open Access Article (/2072-6694/14/21/5198/pdf?version=1666519036)

Analysis of Infectious Complications after Thermal Ablation of Hepatocellular Carcinoma and the Impact on Long-Term Survival (/2072-6694/14/21/5198)

Cancers **2022**, *14*(21), 5198; **https://doi.org/10.3390/cancers14215198 (https://doi.org/10.3390/cancers14215198)** - 23 Oct 2022

Open Access Article (/2072-6694/14/21/5197/pdf?version=1666671590)

Interaction of HPV16 and Cutaneous HPV in Head and Neck Cancer (/2072-6694/14/21/5197)

Cancers **2022**, *14*(21), 5197; **https://doi.org/10.3390/cancers14215197 (https://doi.org/10.3390/cancers14215197)** - 23 Oct 2022

Open Access Review (/2072-6694/14/21/5196/pdf?version=1667360987)

A Whole New Comprehension about ncRNA-Encoded Peptides/Proteins in Cancers (/2072-6694/14/21/5196)

Cancers **2022**, *14*(21), 5196; **https://doi.org/10.3390/cancers14215196 (https://doi.org/10.3390/cancers14215196)** - 23 Oct 2022

Open Access Article (/2072-6694/14/21/5195/pdf?version=1667381950)

Epithelial and Stromal Characteristics of Primary Tumors Predict the Bone Metastatic Subtype of Prostate Cancer and Patient Survival after Androgen-Deprivation Therapy (/2072-6694/14/21/5195)

Cancers **2022**, *14*(21), 5195; **https://doi.org/10.3390/cancers14215195 (https://doi.org/10.3390/cancers14215195)** - 23 Oct 2022

Open Access Editorial (/2072-6694/14/21/5194/pdf?version=1666510689)

CD26 and Cancer (/2072-6694/14/21/5194)

Cancers **2022**, *14*(21), 5194; **https://doi.org/10.3390/cancers14215194 (https://doi.org/10.3390/cancers14215194)** - 23 Oct 2022

Open Access Article (/2072-6694/14/21/5193/pdf?version=1666508415)

Effectiveness of Cervical Testing in and outside a Screening Program—A Case-Control Study (/2072-6694/14/21/5193)

Cancers **2022**, *14*(21), 5193; **https://doi.org/10.3390/cancers14215193 (https://doi.org/10.3390/cancers14215193)** - 23 Oct 2022

Open Access Article (/2072-6694/14/21/5192/pdf?version=1666446253)

Symptoms of Depression and Anxiety in Adults with High-Grade Glioma: A Literature Review and Findings in a Group of Patients before Chemoradiotherapy and One Year Later (/2072-6694/14/21/5192)

Cancers **2022**, *14*(21), 5192; **https://doi.org/10.3390/cancers14215192 (https://doi.org/10.3390/cancers14215192)** - 22 Oct 2022

Open Access Communication (/2072-6694/14/21/5191/pdf?version=1667269338)

Both In Situ and Circulating SLC3A2 Could Be Used as Prognostic Markers for Human Lung Squamous Cell Carcinoma and Lung Adenocarcinoma (/2072-6694/14/21/5191)

Cancers **2022**, *14*(21), 5191; **https://doi.org/10.3390/cancers14215191 (https://doi.org/10.3390/cancers14215191)** - 22 Oct 2022

Open Access Systematic Review (/2072-6694/14/21/5190/pdf?version=1666436324)

A Systematic Review on the Impact of Hypofractionated and Stereotactic Radiotherapy on Immune Cell Subpopulations in Cancer Patients (/2072-6694/14/21/5190)

Cancers **2022**, *14*(21), 5190; **https://doi.org/10.3390/cancers14215190 (https://doi.org/10.3390/cancers14215190)** - 22 Oct 2022

Open Access Article (/2072-6694/14/21/5189/pdf?version=1667893393)

Impact of Change in Body Composition during Follow-Up on the Survival of GEP-NET (/2072-6694/14/21/5189)

Cancers **2022**, *14*(21), 5189; **https://doi.org/10.3390/cancers14215189 (https://doi.org/10.3390/cancers14215189)** - 22 Oct 2022

Open Access Article (/2072-6694/14/21/5188/pdf?version=1666432332)

STING Contributes to Cancer-Induced Bone Pain by Promoting M1 Polarization of Microglia in the Medial Prefrontal Cortex (/2072-6694/14/21/5188)

Cancers **2022**, *14*(21), 5188; **https://doi.org/10.3390/cancers14215188 (https://doi.org/10.3390/cancers14215188)** - 22 Oct 2022

Open Access Review (/2072-6694/14/21/5187/pdf?version=1666431289)

Endometrial Cancer in Reproductive Age: Fertility-Sparing Approach and Reproductive Outcomes (/2072-6694/14/21/5187)

Cancers **2022**, *14*(21), 5187; **https://doi.org/10.3390/cancers14215187 (https://doi.org/10.3390/cancers14215187)** - 22 Oct 2022

Open Access Article (/2072-6694/14/21/5186/pdf?version=1666433488)

Prognostic Model for Intracranial Progression after Stereotactic Radiosurgery: A Multicenter Validation Study (/2072-6694/14/21/5186)

Cancers **2022**, *14*(21), 5186; **https://doi.org/10.3390/cancers14215186 (https://doi.org/10.3390/cancers14215186)** - 22 Oct 2022

Open Access Perspective (/2072-6694/14/21/5185/pdf?version=1666429972)

A Novel Strategy to Model Age-Related Cancer for Elucidation of the Role of Th17 Inflammaging in Cancer Progression (/2072-6694/14/21/5185)

Cancers **2022**, *14*(21), 5185; **https://doi.org/10.3390/cancers14215185 (https://doi.org/10.3390/cancers14215185)** - 22 Oct 2022

Open Access Review (/2072-6694/14/21/5184/pdf?version=1666853850)

Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms? (/2072-6694/14/21/5184)

Cancers **2022**, *14*(21), 5184; **https://doi.org/10.3390/cancers14215184 (https://doi.org/10.3390/cancers14215184)** - 22 Oct 2022

Open Access Article (/2072-6694/14/21/5183/pdf?version=1666429275)

Heterogeneity and Differentiation Trajectories of Infiltrating CD8+ T Cells in Lung Adenocarcinoma (/2072-6694/14/21/5183)

Cancers **2022**, *14*(21), 5183; **https://doi.org/10.3390/cancers14215183 (https://doi.org/10.3390/cancers14215183)** - 22 Oct 2022

Open Access Article (/2072-6694/14/21/5183/pdf?version=1666393665)

Regulatory Role of Sphingosine-1-Phosphate and C16:0 Ceramide, in Immunogenic Cell Death of Colon Cancer Cells Induced by Bak/Bax-Activation (/2072-6694/14/21/5182)

Cancers **2022**, *14*(21), 5182; **https://doi.org/10.3390/cancers14215182 (https://doi.org/10.3390/cancers14215182)** - 22 Oct 2022

Open Access Article (/2072-6694/14/21/5181/pdf?version=1666427224)

CroReLU: Cross-Crossing Space-Based Visual Activation Function for Lung Cancer Pathology Image Recognition (/2072-6694/14/21/5181)

Cancers **2022**, *14*(21), 5181; **https://doi.org/10.3390/cancers14215181 (https://doi.org/10.3390/cancers14215181)** - 22 Oct 2022

Open Access Article (/2072-6694/14/21/5180/pdf?version=1667292716)

The Prognostic and Therapeutic Implications of the Chemoresistance Gene BIRC5 in Triple-Negative Breast Cancer (/2072-6694/14/21/5180)

Cancers **2022**, *14*(21), 5180; **https://doi.org/10.3390/cancers14215180 (https://doi.org/10.3390/cancers14215180)** - 22 Oct 2022

Open Access Article (/2072-6694/14/21/5179/pdf?version=1667922827)

Spermidine/Spermine N1-Acetyltransferase 1 (*SAT1*)—A Potential Gene Target for Selective Sensitization of Glioblastoma Cells Using an Ionizable Lipid Nanoparticle to Deliver siRNA (/2072-6694/14/21/5179)

Cancers **2022**, *14*(21), 5179; **https://doi.org/10.3390/cancers14215179 (https://doi.org/10.3390/cancers14215179)** - 22 Oct 2022

Open Access Article (/2072-6694/14/21/5178/pdf?version=1666847582)

Endogenous Propionibacterium acnes Promotes Ovarian Cancer Progression via Regulating Hedgehog Signalling Pathway (/2072-6694/14/21/5178)

Cancers **2022**, *14*(21), 5178; **https://doi.org/10.3390/cancers14215178 (https://doi.org/10.3390/cancers14215178)** - 22 Oct 2022

Open Access Article (/2072-6694/14/21/5177/pdf?version=1666423704)

Glioblastoma-Derived Three-Dimensional Ex Vivo Models to Evaluate Effects and Efficacy of Tumor Treating Fields (TTFields) (/2072-6694/14/21/5177)

Cancers **2022**, *14*(21), 5177; **https://doi.org/10.3390/cancers14215177 (https://doi.org/10.3390/cancers14215177)** - 22 Oct 2022

Open Access Review (/2072-6694/14/21/5176/pdf?version=1666857200)

Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53 (/2072-6694/14/21/5176)

Cancers **2022**, *14*(21), 5176; **https://doi.org/10.3390/cancers14215176 (https://doi.org/10.3390/cancers14215176)** - 22 Oct 2022

Open Access Article (/2072-6694/14/21/5175/pdf?version=1666693916)

Molecular Classification of Colorectal Cancer by microRNA Profiling: Correlation with the Consensus Molecular Subtypes (CMS) and Validation of miR-30b Targets (/2072-6694/14/21/5175)

Cancers **2022**, *14*(21), 5175; **https://doi.org/10.3390/cancers14215175 (https://doi.org/10.3390/cancers14215175)** - 22 Oct 2022

Open Access Article (/2072-6694/14/21/5174/pdf?version=1666873753)

Discovery of Highly Functionalized 5-hydroxy-2*H*-pyrrol-2-ones That Exhibit Antiestrogenic Effects in Breast and Endometrial Cancer Cells and Potentiate the Antitumoral Effect of Tamoxifen (/2072-6694/14/21/5174)

Cancers **2022**, *14*(21), 5174; **https://doi.org/10.3390/cancers14215174 (https://doi.org/10.3390/cancers14215174)** - 22 Oct 2022

Open Access Article (/2072-6694/14/21/5173/pdf?version=1666418535)

Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma (/2072-6694/14/21/5173)

Cancers **2022**, *14*(21), 5173; **https://doi.org/10.3390/cancers14215173 (https://doi.org/10.3390/cancers14215173)** - 22 Oct 2022

Show export options

Displaying articles 1-301

Previous Issue
Volume 14, October-2 (/2072-6694/14/20)

Next Issue
Volume 14, November-2 (/2072-6694/14/22)

***Cancers* (/journal/cancers)**, EISSN 2072-6694, Published by MDPI

RSS (/rss/journal/cancers) **Content Alert (/journal/cancers/toc-alert)**

Further Information

Article Processing Charges (/apc)
Pay an Invoice (/about/payment)
Open Access Policy (/openaccess)
Contact MDPI (/about/contact)
Jobs at MDPI (https://careers.mdpi.com)

Guidelines

For Authors (/authors)
For Reviewers (/reviewers)
For Editors (/editors)

Back to TopTop

cancers

MDPI

Systematic Review

Role of Immunotherapy in the Treatment of Cancer: A Systematic Review

Sia Pei Ling [1], Long Chiau Ming [1,2], Jagjit Singh Dhaliwal [1], Madhu Gupta [3], Chrismawan Ardianto [2,*], Khang Wen Goh [4], Zahid Hussain [5] and Naeem Shafqat [1,*]

1 PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong BE1410, Brunei
2 Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60115, Indonesia
3 School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi 110017, India
4 Faculty of Data Science and Information Technology, INTI International University, Nilai 71800, Malaysia
5 Faculty of Health, University of Canberra, Bruce, ACT 2617, Australia
* Correspondence: chrismawan-a@ff.unair.ac.id (C.A.); sheikh.shafqat@ubd.edu.bn (N.S.)

Simple Summary: The main purpose of this article is to review the efficacy of immunotherapy either as a stand-alone treatment or in combination with the available conventional cancer treatment in stopping the reoccurrence of cancer. The article will assess and determine the efficacy of immunotherapy in the treatment of cancer via the overall survival and progression-free survival rate.

Abstract: Tremendous progress has been made in cancer research over the years, and, as a result, immunotherapy has emerged as an important therapy for the treatment of cancer, either as a stand-alone treatment or in conjunction with other cancer therapies. Immunotherapy has demonstrated encouraging outcomes and offers a viable strategy for not only enhancing the quality of life but also dramatically boosting the overall survival rate of cancer patients. The objective of this systematic review was to assess the efficacy of immunotherapy in the treatment of cancer. Databases such as PubMed and Science Direct were searched from their inception until September 2021, using the following keywords: cancer immunotherapy, cancer recurrence, cancer treatment options, and cancer therapies. The systematic review was conducted in accordance with the PRISMA protocol. There were a total of 599 articles; however, after applying the inclusion and exclusion criteria, the final review ended up with 34 publications. In conclusion, the studies have demonstrated that immunotherapy is a viable alternative treatment option for patients with recurrent or metastatic cancer, since the overall survival rate and progression-free survival rate were shown to be successful.

Keywords: cancer cell; breast cancer; neoplasm; non-small cell lung cancer; glioblastoma; antineoplastic agent; preventable death; medicine; biological therapy; immunomodulation

check for updates

Citation: Ling, S.P.; Ming, L.C.; Dhaliwal, J.S.; Gupta, M.; Ardianto, C.; Goh, K.W.; Hussain, Z.; Shafqat, N. Role of Immunotherapy in the Treatment of Cancer: A Systematic Review. *Cancers* **2022**, *14*, 5205. https://doi.org/10.3390/cancers14215205

Academic Editor: Lisardo Bosca

Received: 26 August 2022
Accepted: 15 October 2022
Published: 24 October 2022

1. Introduction

Cancer is considered as the second-leading cause of mortality in global map after cardiovascular disease. According to recent data from GLOBOCAN 2020, there were an estimated 10 million deaths worldwide caused by cancer in the year 2020 alone [1]. Among the different types of cancer, breast cancer is the most commonly diagnosed cancer worldwide (2 million cases), followed by lung, colorectum, prostate, skin (non-melanoma), and stomach cancer, respectively. In addition, it has been anticipated that there will be a tremendous increase in the elderly population around the world, leading to a cohort of elderly people with a higher risk of getting cancer due to age-related health deterioration [2].

Nevertheless, there have been major technological advances in cancer treatment during the last century, despite its inevitable side effects and the inadequacy it may bring upon treatment [3]. In fact, prior to the start of suitable cancer treatment, the patients who are diagnosed in an early stage of the disease showed a significant trend toward the overall

survival rate and were offered a cost-effective means of cancer treatment, as compared to those diagnosed at a later stage [4]. The main purpose of a treatment regimen is to cure cancer and to prolong the patient's life span by slowing down or blocking the growth of cancer cells. However, the treatment of cancer may vary depending on an early or late diagnosis, which will determine whether it has metastasized or not.

Over the years, surgery, radiotherapy, and chemotherapy have been considered as the three main pillars in cancer treatment, but, with the success in using immune treatment either alone or in combination with other cancer therapies, immunotherapy has emerged as the fourth crucial pillar in combating the disease [4]. Unlike other cancer treatments, immunotherapy utilizes the body's own immune system to recognize and attack cancer cells and, hence, offers a natural approach in controlling the progression of the disease. Most cancer therapies involving either surgery, radiotherapy, or chemotherapy have shown to be effective in the treatment of primary tumors, but relapse of the disease is still a typical recurring issue due to the presence of remaining malignant cells or tumor metastases [5]. Therefore, immunotherapy serves as one of the alternative or additional approaches, which utilizes the immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and cancer vaccines for the treatment of cancer [6,7].

Overall, the main purpose of this article is to review the efficacy of immunotherapy either as a stand-alone treatment or in combination with the available conventional cancer treatment in stopping the reoccurrence of cancer.

2. Methods

2.1. Search Strategy

The appropriate keywords, such as cancer immunotherapy, cancer recurrence, cancer treatment options, and cancer therapies were used to search in the PubMed and ScienceDirect databases for research articles published from their inception to September 2021. The language used to search for the research articles was limited to English only.

2.2. Eligibility Criteria

Study designs such as randomized controlled trials, non-randomized clinical trials, and prospective studies were included to further assess the efficacy of immunotherapy either as a stand-alone treatment or in combination with any of the typical cancer treatments used. However, research articles must mention the use of immunotherapy in patients with ongoing cancer treatment or cancer recurrence, to evaluate the treatment's efficacy in prolonging the overall cancer survival rate. Apart from that, any articles that include preclinical study, case reports or series, retrospective study, systematic review, or meta-analysis were also excluded.

2.3. Selection and Data Collection Process

The articles were thoroughly reviewed in order to select those articles that had fulfilled all the requirements established for the synthesis of this systematic review. The acquired data were then subsequently assessed and compiled by the authors.

2.4. Risk of Bias Assessment

The Cochrane assessment tool was used to assess the risk of bias and methodological quality in the included studies. The ROBINS-I tool was used to assess risk of bias in the results of the non-randomized studies included [8]. As for the randomized studies, the Cochrane risk-of-bias (RoB 2) tool was used instead [9]. Both of these tools require judgment, on the risk of bias arising from each domain, by answering the signaling questions. The overall judgment will result in the overall risk of bias.

2.5. Data Analysis

The following information from each of the eligible studies were extracted, which were according to the name of the study, first author and year of publication, study design, study

phase, type of cancer, number of patients, mean age, treatment groups, and the patients' overall survival and progression-free survival rates.

3. Results

3.1. Study Selection

A total of 599 articles were found prior to the database search, but only 111 potentially relevant articles were selected after the full-text screening. After a comprehensive review of the selected articles, 34 articles of both non-randomized trial and randomized controlled trials, fulfilling the inclusion criteria, were selected. The PRISMA flow chart is presented in Figure 1. Any articles that did not meet the inclusion criteria were excluded from this study, because they did not provide any information regarding the main objective of this review. Studies with human subjects were particularly chosen as part of the criteria, instead of animal studies, as the data from the patients would give an overall outcome of the interventions used. There were 22 non-randomized trials and 12 randomized controlled trials, which include the use of PD-1 inhibitors, vaccines, anti-EpCAM and anti-CD3 monoclonal antibodies, CTLA-4 antagonist, adoptive cell therapy, CD22-specific conjugated antibody, and antineoplastics. The 34 selected studies include 5 phase 1 trials, 9 phase 1–2 trials, 11 phase 2 trials, 1 phase 2–3 trials, and 8 phase 3 trials. These trial studies were grouped accordingly to the type of cancers, as shown in Table 1. Median overall survival and progression-free survival were assessed for each study, as they were the primary results used for this review.



Figure 1. PRISMA flow chart.

Table 1. The main characteristics and results of the studies are included in the systematic review.

Type of Cancer		Study Phase	Treatment Groups	Number of Patients	Mean Age, Years	Median Overall Survival, Months (95% CI); *p*-Value	Median Progression-Free Survival (95% CI); *p*-Value
Gastric Cancer	Wang et al. (2019) [10]	1b/2	A: Toripalimab B: Toripalimab plus XELOX (oxaliplatin, capecitabine)	A: 58 B: 18	A: 59.5 (52.0–66.0) B: 58.5 (48.0–69.0)	A: 4.8 months (N/A); p = N/A B: N/A	A: 1.9 months (N/A); p = N/A B: 5.8 months (N/A); p = N/A
Bladder Cancer	Shore et al. (2017) [11]	2	Low dose (LD) intravesical rAd-IFNα/Syn3 vs. high dose (HD) rAd-IFNα/Syn3	LD: 22 HD: 21	70.5 (64.5–77.5)	6.5 months (3.52–12.78)	LD: 3.52 months (3.02–12.78) HD: 11.73 months (5.88–N/A)
Non-Small Cell Lung Cancer	Ding et al. (2016) [12]	1b/2	Cytokine-induced killer (CIT group) vs. no treatment (control group)	49	CIT group: 63 (54–79) Control group: 57 (36–74)	CIT group: 13.3 months Control group: 8.2 months (N/A); p = 0.044	CIT group: 5 months Control group: 3.1 months (N/A); p = 0.020
	Cho et al. (2021) [13]	1	Quavonlimab plus pembrolizumab	40	66 (40–80)	11.0 months (5.9, 15.5); p = N/A	2.0 months (1.9, 3.9); p = N/A
	Planchard et al. (2020) [14]	3	A: Durvalumab vs. SoC B: Durvalumab plus tremelimumab (D + T) vs. SoC	A: 126 B: 469	A: Durvalumab 63.5 (35–79), SoC 62.0 (41–81) B: D + T 62.5 (26–81), SoC 65.0 (42–83)	A: Durvalumab 11.7 months (8.2, 17.4); p = 0, SoC 6.8 months (4.9, 10.2); p = 0 B: D + T 11.5 months (8.7, 14.1); p = 0, SoC 8.7 months (6.5, 11.7); p = 0	A: Durvalumab 3.8 months (1.9, 5.6); p = 0, SoC 2.2 months (1.9, 3.7); p = 0 B: D + T 9.1 months (6.6, 12.3); p = 0, SoC 3.5 months (1.9, 3.9); p = 0
	Hui et al. (2017) [15]	1	Pembrolizumab monotherapy	101	68.0 (N/A)	22.1 months (17.1–27.2); p = N/A	6.2 months (4.1, 8.6); p = N/A
	Spigel et al. (2018) [16]	2	Atezolizumab use in: Cohort 1: no previous treatment Cohort 2: prior platinum-based chemotherapy Cohort 3: prior platinum-based chemotherapy in brain metastases	Cohort 1: 31 Cohort 2: 93 Cohort 3: 13	1: 68 (42–85) 2: 65 (44–85) 3: 65 (52–74)	Cohort 1: 14.4 months (12.8, 22.1); p = N/A Cohort 2: 9.3 months (5.8, 17.6); p = N/A Cohort 3: 6.8 months (3.2, 19.4); p = N/A	Cohort 1: 4.5 months (3.3–8.3); p = N/A Cohort 2: 2.7 months (1.5–3.4); p = N/A Cohort 3: 2.5 months (1.2–4.2); p = N/A

Table 1. *Cont.*

Type of Cancer		Study Phase	Treatment Groups	Number of Patients	Mean Age, Years	Median Overall Survival, Months (95% CI); *p*-Value	Median Progression-Free Survival (95% CI); *p*-Value
Breast Cancer	Mittendorf et al. (2014) [17]	1/2	Vaccinated group (VC) E75 plus granulocyte-macrophage colony-stimulating factor (GM-CSF) vs. control group (CG) no treatment	187	VC: 57 (28–78) CG: 53 (32–83)	N/A	VC: 89.7% CG: 80.2% (N/A); p = 0.8
	Schmid et al. (2020) [18]	1b	Pembrolizumab plus chemotherapy	60	48.5 (26–71)	98% (90–100%); p = N/A	98% (90–100%); p = N/A
	Chumsri et al. (2019) [19]	3	Adjuvant chemotherapy plus trastuzumab vs. chemotherapy	3177	49.0 (23.0–80.0)	N/A	81.39% (78.54%–84.34%); p = N/A
Ovarian and Breast Cancer	Antonilli et al. (2016) [20]	1/2	Triple peptide vaccination	14	53.0 (42–70)	N/A	N/A
Glioblastoma	Liau et al. (2018) [21]	3	Temozolomide plus autologous tumor lysate-pulsed dendritic cell vaccine or Temozolomide plus placebo	331	56.0 (19–73)	23.1 (21.2-25.4)	N/A
Mesothelioma	Janssen et al. (2018) [22]	2	Nivolumab monotherapy	34	67.0 (50–81)	11.8 months (9.7–15.7); p = N/A	2.6 months (2.23–5.49); p = N/A
Cervical Cancer	Rischin et al. (2020) [23]	1	A: Cemiplimab monotherapy B: Cemiplimab plus hypofractionated radiation therapy (hfRT).	A: 10 B: 10	A: 55.0 (31.0–76.0) B: 51.5 (29.0–65.0)	A: 10.3 months (2.1–N/A); p = N/A B: 8.0 months (1.7–N/A); p = N/A	A: 1.9 months (1.0–9.0); p = N/A B: 3.6 months (0.6–5.7); p = N/A
	Harper et al. (2019) [24]	2b	A: Tipapkinogen Sovacivec vaccine B: placebo	206	A: 30.1 (18–60) B: 29.8 (19–50)	N/A	N/A
	Santin et al. (2020) [25]	2	Nivolumab monotherapy	26	45.0 (20–79)	14.5 months (8.3–26.8); p = N/A	3.5 months (1.9–5.1); p = N/A
Sarcoma	Ahmed et al. (2015) [26]	1/2	Human Epidermal Growth Factor Receptor 2 (HER2)—Specific Chimeric Antigen Receptor-Modified T Cells	19	17.0 (7.7–29.6)	10.3 months (5.1, 29.1); p = N/A	N/A
	Miwa et al. (2017) [27]	1/2	Dendritic cells pulsed with autologous tumor lysate	37	37.8 (8–65)	2.9% (N/A); p = N/A	42.3% (N/A); p = N/A

Table 1. *Cont.*

Type of Cancer		Study Phase	Treatment Groups	Number of Patients	Mean Age, Years	Median Overall Survival, Months (95% CI); *p*-Value	Median Progression-Free Survival (95% CI); *p*-Value
Head and Neck Squamous Cell Carcinoma	Ferris et al. (2020) [28]	3	A: Durvalumab vs. Soc B: Durvalumab plus tremelimumab vs. SoC	736	60.0 (N/A)	A: 7.6 months (6.1–9.8); p = 0.20 B: 6.5 months (5.5–8.2); p = 0.76	A: 2.1 months (1.9–3.0); p = N/A B: 2.0 months (1.9–2.3); p = N/A
	Saba et al. (2019) [29]	3	A: Nivolumab vs. SoC in < 65 years old patients. B: Nivolumab vs. SoC in ≥ 65-year-old patients	361	48.5 (26–71)	A: 8.2 months vs. 4.9 months (0.47–0.84); p = N/A B: 6.9 months vs. 6.0 months (0.51–1.12); p = N/A	A: 2.0 months vs. 2.7 months (0.71–1.30); p = N/A B: 2.1 months vs. 2.0 months (0.49–1.11); p = N/A
	Zandberg et al. (2019) [30]	2	Durvalumab monotherapy	112	60.0 (24.0–84.0)	7.1 months (1.9–5.6); p = N/A	2.1 months (1.9–3.7); p = N/A
Esophageal Squamous Cell Carcinoma	Zhang et al. (2020) [31]	2	Camrelizumab plus apatinib and chemotherapy	30	61.5 (43–70)	19.43 months (9.93–N/A); p = N/A	6.85 months (4.46–14.20); p = N/A
Prostate Cancer	Hansen et al. (2018) [32]	1b	Pembrolizumab monotherapy	245	65.0 (46–83)	7.9 months (6.5–N/A); p = N/A	3.5 months (1.7–6.5); p = N/A
	Schuhmacher et al. (2020) [33]	1/2	Ras homolog gene family member C vaccination	22	66.0 (54–77)	N/A	N/A
Melanoma	Garbe et al. (2008) [34]	3	Adjuvant interferon α2a with or without dacarbazine vs. surgery	444	N/A	59.0% vs. 42.0% (N/A); p = 0.0045	39.0% vs. 27.0% (N/A); p = 0.018
	Namikawa et al. (2018) [35]	2	Nivolumab plus ipilimumab	30	58.5 (31–81)	N/A	N/A
	Hemstock et al. (2020) [36]	3	Nivolumab vs. placebo	928	N/A	N/A	N/A
Leukemia	Anguille et al. (2017) [37]	2	Adjuvant dendritic cell vaccination	30	60.0 (30–79)	41.8 months (N/A); p = N/A	N/A
	Kreitman et al. (2021) [38]	3	Moxetummomab pasudotox	80	60	N/A	41.5 months (29.5, N/A); p = N/A

Table 1. *Cont.*

Type of Cancer		Study Phase	Treatment Groups	Number of Patients	Mean Age, Years	Median Overall Survival, Months (95% CI); *p*-Value	Median Progression-Free Survival (95% CI); *p*-Value
Lymphoma	Wang et al. (2020) [39]	2	KTE-X19 CAR T-Cell therapy	60	65.0 (38–79)	N/A	N/A
	Maruyama et al. (2017) [40]	2	Nivolumab	17	63.0 (29–83)	N/A	N/A
	Fan et al. (2014) [41]	1/2	A: Decitabine B: Decitabine plus chemotherapy C: Decitabine plus cytokine induced killer cells	32	58.8 (28–84)	N/A	A: 2.5 months (1–12); p = N/A B: 4 months (1–7); p = N/A C: 8 months (4–10); p = N/A
Malignant Ascites	Heiss et al. (2010) [42]	2/3	A: Paracentesis plus catumaxomab B: Paracentesis alone	258	N/A	A: 72 days (61–96); p = N/A B: 68 days (49–81); p = N/A	A: 46 days (35–53); p = N/A B: 11 days (9–16); p = N/A
	Burges et al. (2007) [43]	1/2	Catumaxomab	23	61.7 (42–80)	N/A	N/A

N/A = not available, SoC = standard of care.

3.2. Reporting Biases

There were a few confounding factors identified for the risk of bias for the non-randomized controlled trials in Table 2(A). One of the factors is hormonal therapy, which was seen in prostate cancer patients receiving luteinizing hormone-releasing hormone (LHRH) analogs during the treatment [32] Patients receiving this additional treatment along with immunotherapy may have had an influence on the overall effect of the results, as LHRH analogs aid in the inhibition of prostate cancer growth [44]. The other confounding factor were in patients with non-small cell lung cancer who are current smokers [16]. The results of the immunotherapy used in this case may be affected, as patients who are current smokers may reduce the efficacy of the treatment [45]. Hence, the confounding factors mentioned above may lead to distortion of the actual results in the efficacy of immunotherapy in cancer treatment.

All of the non-randomized trial studies included had a 'moderate' bias in the measurement of the outcome, due to the fact that the majority of the trials were open-label, which meant that the assessors were aware of the intervention received by the study participants.

As for the risk of bias in the randomized controlled trials in Table 2(B), most of the studies included had 'some concerns' in the bias arising from the randomization process and due to deviations from the intended interventions. Three studies, including Schmid et al. [18], Shore et al. [11], and Liau et al. [21], did not have any information on the type of randomization methods used or the interventions used on the participants, which raises concerns regarding the randomization process. In addition, most of the included studies were open-label studies even though they were randomized, except for Harper et al. [24] and Hemstock et al. [36].

Table 2. (**A**) Risk of bias for non-randomized controlled trials. (**B**) Risk of bias for randomized controlled trials.

(A)									
Study		**Pre-Intervention**		**At Intervention**		**Post Intervention**			**Overall Risk of Bias**
First Author	**Year**	**Bias Due to Confounding**	**Bias in Selection of Participants into the Study**	**Bias in Classification of Interventions**	**Bias Due to Deviations from Intended Interventions**	**Bias Due to Missing Data**	**Bias in Measurement of Outcomes**	**Bias in Selection of the Reported Result**	**Low, Moderate, Serious, Critical**
Wang et al. [10]	2019	Low	Low	Low	Low	Low	Moderate	Low	Moderate
Ding et al. [12]	2016	Low	Low	Low	Low	Low	Moderate	Low	Moderate
Rischin et al. [23]	2020	Low	Low	Low	Low	Low	Moderate	Low	Moderate
Mittendorf et al. [17]	2014	Low	Low	Low	Moderate	Low	Moderate	Low	Moderate
Cho et al. [13]	2021	Low	Low	Low	Low	Low	Moderate	Low	Moderate
Janssen et al. [22]	2018	Low	Low	Low	Low	Low	Moderate	Low	Moderate
Hansen et al. [32]	2018	Moderate	Low	Low	Low	Low	Moderate	Low	Moderate
Spigel et al. [16]	2018	Moderate	Low	Low	Low	Low	Moderate	Low	Moderate
Zandberg et al. [30]	2019	Low	Low	Low	Low	Low	Moderate	Low	Moderate
Anguille et al. [37]	2017	Low	Low	Low	Low	Low	Moderate	Low	Moderate
Namikawa et al. [35]	2018	Low	Low	Low	Low	Low	Moderate	Low	Moderate
Wang et al. [39]	2020	Low	Low	Low	Low	Low	Moderate	Low	Moderate
Santin et al. [25]	2020	Low	Low	Low	Low	Low	Moderate	Low	Moderate
Zhang et al. [31]	2020	Low	Low	Low	Low	Low	Moderate	Low	Moderate
Ahmed et al. [26]	2015	Low	Low	Low	Low	Low	Moderate	Low	Moderate
Schuhmacher et al. [33]	2020	Low	Low	Low	Low	Low	Moderate	Low	Moderate
Antonilli et al. [20]	2016	Low	Low	Low	Low	Low	Moderate	Low	Moderate
Maruyama et al. [40]	2017	Low	Low	Low	Low	Low	Moderate	Low	Moderate
Fan et al. [41]	2014	Low	Low	Low	Low	Low	Moderate	Low	Moderate
Burges et al. [43]	2007	Low	Low	Low	Low	Low	Moderate	Low	Low
Miwa et al. [27]	2017	Low	Low	Low	Low	Low	Moderate	Low	Moderate
Kreitman et al. [38]	2021	Low	Low	Low	Low	Low	Moderate	Low	Moderate

Table 2. *Cont.*

(B)							
Study		**Pre-Intervention**	**Post Intervention**				**Overall Risk of Bias**
First Author	**Year**	**Bias Arising from the Randomization Process**	**Bias Due to Deviations from Intended Interventions**	**Bias Due to Missing Outcome Data**	**Bias in Measurement of the Outcome**	**Bias in Selection of the Reported Result**	**Low, Some Concerns, High Risk of Bias**
Hui et al. [15]	2017	Some concerns	Some concerns	Low	Low	Low	Some concerns
Schmid et al. [18]	2020	Low	Some concerns	Low	Low	Low	Some concerns
Harper et al. [24]	2019	Some concerns	Low	Low	Low	Low	Some concerns
Ferris et al. [28]	2020	Some concerns	Some concerns	Low	Low	Low	Some concerns
Saba et al. [29]	2019	Some concerns	Some concerns	Low	Low	Low	Some concerns
Garbe et al. [34]	2008	Some concerns	Some concerns	Low	Low	Low	Some concerns
Heiss et al. [42]	2010	Some concerns	Some concerns	Low	Low	Low	Some concerns
Chumsri et al. [19]	2019	Some concerns	Some concerns	Low	Low	Low	Some concerns
Shore et al. [11]	2017	Low	Some concerns	Low	Low	Low	Some concerns
Liau et al. [21]	2018	Low	Some concerns	Low	Low	Low	Some concerns
Planchard et al. [14]	2020	Some concerns	Some concerns	Low	Low	Low	Some concerns
Hemstock et al. [36]	2020	Some concerns	Low	Low	Low	Low	Some concerns

4. Discussion

The results from the present study indicate that the use of immunotherapy, either alone or as a supportive therapy to the conventional cancer treatments, has enormous potential in improving the overall survival and progression-free survival rates of cancer patients, especially those who have failed on their first-line therapy, leading to disease recurrence. In addition, the results of the clinical trials have shown a minimal tolerable side effect of the immunotherapy used, unlike the usual treatment such as chemotherapy, whereby there is a higher prevalence of adverse effects, especially among elderly patients [29].

The use of immune checkpoint inhibitors showed a relatively improved response and survival rates of patients with high expression of PD-L1 on their tumor cells, especially in patients with non-small cell lung cancer. Biomarkers, such as PD-L1 and tumor infiltrating immune cells, and genetic mutations are important in cancer, as they help determine what may be the possible cause of the cancer to recur and metastasize. The PD-1 and PD-L1 pathways are rather important for the immune checkpoint inhibitors, as most cancer cells express PD-L1 as cell surface receptors, which play a major role in regulating T-cell exhaustion by binding onto PD-1 [46]. Therefore, targeting the PD-L1 pathway by immune checkpoint inhibitors will block the PD-L1 binding and enhance the immune response against cancer cells. However, despite the immense response seen in PD-L1 positive patients, there have been anti-tumor responses as well, in patients with low or negative PD-L1 expression, from using immune checkpoint inhibitors [13,14].

Additionally, cancer vaccines have shown improvements in the overall results of the studies, as seen in Table 1. The tumor burden elicits an immunosuppressive effect in a recurrent or metastatic cancer environment. Hence, a further approach has been completed to extend the response of the vaccines, such as including the influence of cytokines on the immune response or in combination with antibodies in the inhibition of the receptors, such as CTLA-4 and PD-1, used in downregulating the immune responses [17]. Overall, the main role of these cancer vaccines is to stimulate the immune responses and, thereby, reduce the disease process from either recurring or as a form of prophylaxis of cancer caused by infections.

Although there were effective treatments such as surgery, there have been cases of recurrences and their association with reproductive morbidities. Therefore, cancer vaccines were made to prevent cancer associated with human papillomavirus (HPV) without the need of surgery. One of the clinical trials involved the use of these vaccines in HPV patients associated with cervical intraepithelial neoplasia (CIN) grades 2 or 3. The study showed a reduction in the abnormal cells in the viral DNA, regardless of the high-risk HPV types [24].

Immunotherapy using dendritic cell (DC)-based vaccination has been used in an attempt to treat patients with recurrences after failing their first-line therapy. In cases of sarcoma, further treating these patients with chemotherapy would be insufficient due to the tumors being resistant to the treatment and the rise of multiorgan failure from the treatment. Although there are other possible treatments available, the results are inadequate. Thus, DC-based vaccination offers a much safer treatment, with fewer side effects. As seen in this study, DC-based vaccination has shown to increase the immune responses through the production of IFN-γ and IL-12 [46]. Besides that, the use of DC-based vaccination provided a longer overall survival rate in the treatment of acute myeloid leukemia patients, to further prevent or delay the disease recurrence. The use of this vaccine in the treatment of leukemia is an effective approach toward patients who were unable to carry out an allogeneic hematopoietic stem cell transplant, especially in elderly patients and also in younger patients who may not have compatible donors [37].

Lastly, the use of CAR T-cells therapy-based studies were not as effective as the other two, but they still had an effect on the overall survival rate. Since tumors are often resistant to standard treatment, CAR T-cells have shown some favorable results, especially in CD19-positive malignancies' clinical trials [26]. CD19 is a biomarker that is critically involved in the malignant tumors of the B-lymphocyte system. CARs bind onto antigens, which are expressed on the cell membrane of tumor cells, and there are a few possible CAR

target antigens identified in the case of sarcoma that include human epidermal growth factor receptor 2 (HER2). As there are many types of sarcomas, there happen to be some malignancies of the sarcomas that express low levels of HER2, e.g., osteosarcoma, which may not be so effective for HER2 monoclonal bodies to exert their effect. Overall, HER2 CAR T-cells did demonstrate antitumor activity in patients expressing low levels of HER2. Although the results were for HER2-negative patients, using CAR T-cells targeting HER2 could also be possible in malignancies that are HER2-positive, which have no effects on HER2 antibodies because they are not HER2-gene-amplified [26].

While the results from this systematic review have shown to be promising, there are still numerous ongoing clinical trials that have been performed using immunotherapy in the treatment of cancer. In fact, throughout the years, there have been several immunotherapy drugs that have been approved by the US Food and Drug Administration (FDA) for use in the treatment of a wide range of cancers. According to Benjamin et al. (2022), 42% of the cancer drugs approved by the US FDA between the 1 May 2016 and 31 May 2021 are used in combination with standard therapies or used as an adjuvant or maintenance treatment. Pembrolizumab, which is one of the approved cancer drugs, was used in the treatment of advanced non-small cell lung cancer (NSCLC) alongside chemotherapy, as a combination treatment [47]. Other approved uses of pembrolizumab includes the treatment of head and neck squamous cell carcinoma, gastrointestinal cancer, Hodgkin's lymphoma, melanoma, and bladder cancer, as an alternative source of treatment when the disease has progressed after standard treatment or where standard treatment is not appropriate enough to be carried out [48].

Also, durvalumab was approved as a maintenance treatment used in patients with unresectable stage 3 NSCLC whose disease remained stagnant after receiving simultaneous platinum-based chemotherapy and radiation therapy [47]. Cemiplimab was approved as a source of alternative treatment in patients with metastatic cutaneious squamous cell carcinoma (CSCC) or locally advanced CSCC who are unable to have curative surgery or radiation [49].

Besides immune checkpoint inhibitors, the US FDA approved CAR T-cell therapy such as tisagenlecleucel and axicabtagene ciloleucel to be used in the treatment of hematological malignancies, acute lymphoblastic leukemia (ALL), and large B-cell lymphomas, particularly in patients whose disease has relapsed and remained refractory despite multiple treatments [50]. In addition, tisagenlecleucel is used in the treatment of pediatric patients with ALL who had a history of refractory disease, though this disease is more commonly diagnosed in children compared to adults [50]. This helped overall in the remission of the disease among pediatric patients where standard treatment is not efficient enough to suppress and prevent the disease.

Regardless of how the FDA approved the use of immunotherapy, either as an alternative or adjuvant cancer therapy, there are immunotherapies that are used as the first line of treatment against cancer. Such examples include the use of pembrolizumab as the first line of treatment in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer that has metastasized [51]. Other uses of pembrolizumab as the first line of treatment include either as a monotherapy or in combination with chemotherapy in the treatment of patients with advanced NSCLC [52].

However, despite the promising results that immunotherapy may provide using the body's immune system to treat a broad range of malignancies, stimulating the immune system may lead to autoimmune toxicity, also known as an immune-related adverse event (irAE). An irAE will occur in about one in five patients receiving immunotherapy, and the risk increases with patients who are concurrently taking two immunotherapy drugs and have had a history of autoimmune disease [53]. The severity of these adverse events (AEs) ranges from mild to life-threatening and is influenced by the type of immunotherapy used, its route of administration, and the mechanism of action [54]. Compared with the AEs of standard chemotherapy, they have a much more predictable nadir or cyclic pattern after administration [54]. In contrast, immunotherapy's AEs are rather complicated, as they vary

in onset and resolution, are present during the first few weeks of administration, and may linger up to a few months after treatment [54].

Dermatologic toxicities are one of the most common irAEs from immunotherapy, which include maculopapular rash, pruritus, and psoriasiform and lichenoid eruptions [55,56]. About 30% to 40% of patients taking PD-1/PD-L1 inhibitors and 50% of patients taking CTLA-4 inhibitors experience dematologic irAEs [57]. After the initial dose of an immune checkpoint inhibitor, a maculopapular rash appears within the first six weeks, indicating there are cutaneous immune-related side effects. This rash can be managed with the use of topical corticosteroids for a mild to moderate rash, systemic corticosteroids for a severe rash, and immunotherapy treatment cessation for those with a potentially life-threatening rash such as Stevens-Johnson syndrome [55].

Another common type of irAEs are the gastrointestinal (GI) disorders that involve symptoms such as diarrhea and colitis. Up to 30% of patients receiving CTLA-4 inhibitors experience gastrointestinal-related AEs, and the percentage is even higher for patients receiving combination therapy, at 44% [58]. However, GI side effects are usually short-lived, about six weeks, and patients rarely suffer from ileal perforation. Symptomatic treatment alongside an adequate dietary adjustment to prevent dehydration is necessary for patients with grade 1 GI disorders, whereas those with grade 2 and colitis can be treated with oral or IV corticosteroids [58]. Hepatotoxicity induced by immune checkpoint inhibitors, on the other hand, is rather rare compared to GI AEs, but hepatitis still remains as part of the irAES. As hepatitis is usually asymptomatic, liver function tests are necessary for all patients before each treatment cycle, and once or twice a week if the aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are elevated [58,59]. Patients with grade 1 hepatitis can still proceed with immune checkpoint inhibitors, provided that they are monitored closely, and treatment should be ceased in those with grade 3 or higher liver disorders until it subsides to grade 1 [58].

Additionally, inflammation of the myocardium and pericardium from the use of immune checkpoint inhibitors is thought to be caused by the existence of T-cell receptor sequences that are identical in cardiac muscle and tumors [60]. Like immune checkpoint inhibitors, CAR T-cell therapy has a similar cause of the cardiotoxicity mechanism of action, whereby the cardiac tissues and tumor cells share the same common antigens [60]. Nevertheless, treatment of cardiotoxicity is possible by managing the overactive T-cell response with therapies that are used to suppress the immune system. However, before initiation of treatment, how persistent the symptoms are must be considered, if the immunosuppressive therapy needs to be ongoing and if there are any life-threatening side effects [61].

In addition to the irAEs, endocrine-related irAEs include acute hypophysitis and thyroid disease, with hypophysitis being diagnosed two to five times more often in men of more than 60 years of age compared to women [62]. Patients receiving CTLA-4 inhibitors have a higher risk of developing hypophysitis, while those receiving PD-1/PD-L1 inhibitors possess a higher risk of primary thyroid dysfunction and, rarely, type 1 diabetes mellitus, central diabetic insipidus, and hypoparathyroidism [62]. Rarely, other immunotherapies such as oncolytic viruses, adoptive T-cell transfer, and cancer vaccines lead to thyroid dysfunctions [63]. Nevertheless, hormone replacement therapy is an effective treatment strategy in treating irAEs, if the patient has not previously experienced higher grades of irAEs' toxicities.

Pulmonary irAEs derived from immunotherapy include interstitial lung disease and concomitant pneumonitis. Even though pulmonary toxicity is not the most common of AEs, it is nonetheless important, since it can be fatal [64]. Pneumonitis, the most common irAEs of the pulmonary system and the most common irAE-related cause of death, usually requires patients to discontinue immune checkpoint inhibitor therapy [65]. In most cases, immunotherapy is discontinued, and most patients are initiated with a low dose of corticosteroids accompanied by follow-up [64,66]. Restarting immunotherapy is possible if the patient recovers well without any complications.

Lastly, a significant number of irAEs have been recorded with CAR T-cell therapy, and the AEs include cytokine release syndrome (CRS), B-cell aplasia, anemia, thrombocytopenia, hypogammaglobulinemia, and neurological toxicities such as CAR T-cell related encephalopathy syndrome (CRES) [65,67,68]. CRS is clinically similar to sepsis and is driven by a significant release of pro-inflammatory cytokines. About 90% of patients on CAR T-cell treatment will experience CRS, with 50% requiring critical care and vasopressors and ventilation [65,68]. The start of the CRS symptoms usually occurs one to five days after CAR T-cell infusion, but it also varies depending on the agent and how severe the activation of the patient's immune cells is [65]. Additionally, greater symptoms may be present in patients with large tumor masses. CRS management involves symptomatic treatment and cytokine inhibition, depending on the patient's signs, symptoms, and hemodynamic status, as some might need IV fluids, vasopressors, and broad-spectrum antibiotics, when there is a possibility of sepsis [65]. Tocilizumab is effective in treating severe CRS, whereas corticosteroids are also considered but are often only used in combination with oncology consolation [65]. Otherwise, corticosteroids are often avoided, as they may have a negative impact on the antitumor effects. Meanwhile, tocilizumab in CRES is ineffective because it does not cross the blood–brain barrier, but anakinra, an IL-1 receptor antagonist, may help treat CRES [65]. IV corticosteroid dexamethasone is used to treat patients with severe neurologic symptoms, as it can cross the blood–brain barrier [65].

Cancer patients' quality of life (QOL) is essential, as it affects how well their treatments work [69]. As cancer treatment continues to become more precise and focused over the years, cancer patients will be able to receive even more improved treatment outcomes with minimal adverse effects. According to Ramirez et al. (2018), immunotherapy produces a higher quality of life than the chemotherapy regimens used to treat various types of cancer. The incidences of grade 3 and higher adverse events with immunotherapy are lower compared to chemotherapy, meaning it can be considered to be safer than chemotherapy [70]. However, there are still patients that experience a significant amount of therapy-related adverse effects due to their treatment regimen, despite attempts to improve the QOL [70]. Hence, besides improving the survival rate, optimizing a patient's QOL is crucial to reduce disease-related symptoms and therapy-related side effects.

5. Limitations

The sample size included in the clinical trials was small, as the studies were performed in small settings. Some of the studies did not provide any information on the median overall survival and progression free survival rates, as they were not assessed for the primary or secondary endpoints of the clinical trials, or there were not enough sufficient data to calculate the results, leading to limitations for the evaluation of the overall efficacy of the results.

6. Conclusions

In summary, more data are needed in order to comprehensively evaluate the overall efficacy of immunotherapy in cancer patients. Researchers who are designing new immunotherapy studies should ensure a larger group of patients' recruitment. Nevertheless, despite the sample size, the results indicate the effectiveness of the immunotherapy used in the treatment of cancer patients, in prolonging their life span. In addition, immunotherapy is considered as a secondary alternative treatment option, when the primary standard treatment cannot be performed on some patients, such as the elderly. Overall, with the increasing rate of the aging population, immunotherapy offers a promising approach in the overall treatment of cancer, as a stand-alone treatment or in combination with other conventional cancer treatments.

Author Contributions: Conceptualization, S.P.L., L.C.M., C.A. and N.S.; methodology, S.P.L., L.C.M., C.A. and N.S.; formal analysis; S.P.L., L.C.M., Z.H. and N.S., resources; C.A., K.W.G. and Z.H., data curation; S.P.L., L.C.M., J.S.D. and C.A.; Supervision: L.C.M., C.A. and N.S.; Visualization: S.P.L., L.C.M., J.S.D., M.G. and N.S.; Funding acquisition: L.C.M., C.A. and K.W.G.; writing original draft

preparation, S.P.L., L.C.M., C.A. and N.S.; writing, review and editing, S.P.L., L.C.M., J.S.D., M.G., C.A., Z.H. and N.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J. Clin.* **2021**, *71*, 209–249. [CrossRef] [PubMed]
2. Xiaomei, M.; Herbert, Y. Cancer Issue: Global Burden of Cancer. *Yale J. Biol. Med.* **2006**, *79*, 85.
3. Arruebo, M.; Vilaboa, N.; Sáez-Gutierrez, B.; Lambea, J.; Tres, A.; Valladares, M.; González-Fernández, Á. Assessment of the Evolution of Cancer Treatment Therapies. *Cancers* **2011**, *3*, 3279–3330. [CrossRef]
4. Whitaker, K. Earlier diagnosis: The importance of cancer symptoms. *Lancet Oncol.* **2019**, *21*, 6–8. [CrossRef]
5. Borghaei, H.; Smith, M.R.; Campbell, K.S. Immunotherapy of cancer. *Eur. J. Pharmacol.* **2009**, *625*, 41–54. [CrossRef]
6. Advances in Cancer Immunology and Cancer Immunotherapy—PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/27011048/ (accessed on 20 August 2021).
7. Mellman, I.; Coukos, G.; Dranoff, G. Cancer immunotherapy comes of age. *Nature* **2011**, *480*, 480–489. [CrossRef] [PubMed]
8. Sterne, J.A.C.; Hernán, M.A.; Reeves, B.C.; Savović, J.; Berkman, N.D.; Viswanathan, M.; Henry, D.; Altman, D.G.; Ansari, M.T.; Boutron, I.; et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* **2016**, *355*, i4919. [CrossRef]
9. Cochrane Handbook for Systematic Reviews and Interventions. Available online: http://training.cochrane.org/handbook (accessed on 3 June 2020).
10. Wang, F.H.; Wei, X.; Xu, N.; Shen, L.; Dai, G.; Yuan, X.; Chen, Y.; Yang, S.; Shi, J.; Hu, X.; et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. *Ann. Oncol.* **2019**, *30*, 1479–1486. [CrossRef]
11. Shore, N.D.; Boorjian, S.A.; Canter, D.J.; Ogan, K.; Karsh, L.I.; Downs, T.M.; Gomella, L.G.; Kamat, A.M.; Lotan, Y.; Svatek, R.S.; et al. Intravesical rAd–IFNα/Syn3 for Patients with High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. *J. Clin. Oncol.* **2017**, *35*, 3410–3416. [CrossRef]
12. Ding, X.; Cao, H.; Chen, X.; Zhao, Y.; Jin, H.; Niu, C.; Ma, K.; Liu, Z.; Chen, J.; Wang, X.; et al. Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer in extensive stage. *J. Cell. Immunother.* **2016**, *2*, 36–43. [CrossRef]
13. Cho, B.C.; Yoh, K.; Perets, R.; Nagrial, A.; Spigel, D.R.; Gutierrez, M.; Kim, D.-W.; Kotasek, D.; Rasco, D.; Niu, J.; et al. Anti–cytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer. *Lung Cancer* **2021**, *159*, 162–170. [CrossRef] [PubMed]
14. Planchard, D.; Reinmuth, N.; Orlov, S.; Fischer, J.; Sugawara, S.; Mandziuk, S.; Marquez-Medina, D.; Novello, S.; Takeda, Y.; Soo, R.; et al. ARCTIC: Durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. *Ann. Oncol.* **2020**, *31*, 609–618. [CrossRef] [PubMed]
15. Hui, R.; Garon, E.B.; Goldman, J.W.; Leighl, N.B.; Hellmann, M.D.; Patnaik, A.; Gandhi, L.; Eder, J.P.; Ahn, M.-J.; Horn, L.; et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: A phase 1 trial. *Ann. Oncol.* **2017**, *28*, 874–881. [CrossRef]
16. Spigel, D.R.; Chaft, J.E.; Gettinger, S.; Chao, B.H.; Dirix, L.; Schmid, P.; Chow, L.Q.; Hicks, R.J.; Leon, L.; Fredrickson, J.; et al. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC. *J. Thorac. Oncol.* **2018**, *13*, 1733–1742. [CrossRef]
17. Mittendorf, E.; Clifton, G.; Holmes, J.; Schneble, E.; van Echo, D.; Ponniah, S.; Peoples, G. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. *Ann. Oncol.* **2014**, *25*, 1735–1742. [CrossRef] [PubMed]
18. Schmid, P.; Salgado, R.; Park, Y.; Muñoz-Couselo, E.; Kim, S.; Sohn, J.; Im, S.-A.; Foukakis, T.; Kuemmel, S.; Dent, R.; et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: Results from the phase 1b open-label, multicohort KEYNOTE-173 study. *Ann. Oncol.* **2020**, *31*, 569–581. [CrossRef]
19. Chumsri, S.; Li, Z.; Serie, D.J.; Mashadi-Hossein, A.; Colon-Otero, G.; Song, N.; Pogue-Geile, K.L.; Gavin, P.; Paik, S.; Moreno-Aspitia, A.; et al. Incidence of Late Relapses in Patients with HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. *J. Clin. Oncol.* **2019**, *37*, 3425–3435. [CrossRef]
20. Antonilli, M.; Rahimi, H.; Visconti, V.; Napoletano, C.; Ruscito, I.; Zizzari, I.G.; Caponnetto, S.; Barchiesi, G.; Iadarola, R.; Pierelli, L.; et al. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial. *Int. J. Oncol.* **2016**, *48*, 1369–1378. [CrossRef]

21. Liau, L.M.; Ashkan, K.; Tran, D.D.; Campian, J.L.; Trusheim, J.E.; Cobbs, C.S.; Heth, J.A.; Salacz, M.; Taylor, S.; D'Andre, S.D.; et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. *J. Transl. Med.* **2018**, *16*, 142. [CrossRef]
22. Quispel-Janssen, J.; van der Noort, V.; de Vries, J.F.; Zimmerman, M.; Lalezari, F.; Thunnissen, E.; Monkhorst, K.; Schouten, R.; Schunselaar, L.; Disselhorst, M.; et al. Programmed Death 1 Blockade with Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. *J. Thorac. Oncol.* **2018**, *13*, 1569–1576. [CrossRef]
23. Rischin, D.; Gil-Martin, M.; González-Martin, A.; Braña, I.; Hou, J.Y.; Cho, D.; Falchook, G.S.; Formenti, S.; Jabbour, S.; Moore, K.; et al. PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. *Gynecol. Oncol.* **2020**, *159*, 322–328. [CrossRef] [PubMed]
24. Harper, D.M.; Nieminen, P.; Donders, G.; Einstein, M.H.; Garcia, F.; Huh, W.K.; Stoler, M.H.; Glavini, K.; Attley, G.; Limacher, J.-M.; et al. The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up. *Gynecol. Oncol.* **2019**, *153*, 521–529. [CrossRef]
25. Santin, A.D.; Deng, W.; Frumovitz, M.; Buza, N.; Bellone, S.; Huh, W.; Khleif, S.; Lankes, H.A.; Ratner, E.S.; O'Cearbhaill, R.E.; et al. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). *Gynecol. Oncol.* **2020**, *157*, 161–166. [CrossRef] [PubMed]
26. Ahmed, N.; Brawley, V.S.; Hegde, M.; Robertson, C.; Ghazi, A.; Gerken, C.; Liu, E.; Dakhova, O.; Ashoori, A.; Corder, A.; et al. Human Epidermal Growth Factor Receptor 2 (HER2)–Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. *J. Clin. Oncol.* **2015**, *33*, 1688–1696. [CrossRef] [PubMed]
27. Miwa, S.; Nishida, H.; Tanzawa, Y.; Takeuchi, A.; Hayashi, K.; Yamamoto, N.; Mizukoshi, E.; Nakamoto, Y.; Kaneko, S.; Tsuchiya, H. Phase 1/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma. *Cancer* **2017**, *123*, 1576–1584. [CrossRef] [PubMed]
28. Ferris, R.; Haddad, R.; Even, C.; Tahara, M.; Dvorkin, M.; Ciuleanu, T.; Clement, P.; Mesia, R.; Kutukova, S.; Zholudeva, L.; et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. *Ann. Oncol.* **2020**, *31*, 942–950. [CrossRef]
29. Saba, N.F.; Blumenschein, G., Jr.; Guigay, J.; Licitra, L.; Fayette, J.; Harrington, K.J.; Kiyota, N.; Gillison, M.L.; Ferris, R.L.; Jayaprakash, V.; et al. Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. *Oral Oncol.* **2019**, *96*, 7–14. [CrossRef]
30. Zandberg, D.P.; Algazi, A.P.; Jimeno, A.; Good, J.S.; Fayette, J.; Bouganim, N.; Ready, N.E.; Clement, P.M.; Even, C.; Jang, R.W.; et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. *Eur. J. Cancer* **2019**, *107*, 142–152. [CrossRef]
31. Zhang, B.; Qi, L.; Wang, X.; Xu, J.; Liu, Y.; Mu, L.; Wang, X.; Bai, L.; Huang, J. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma. *Cancer Commun.* **2020**, *40*, 711–720. [CrossRef]
32. Hansen, A.R.; Massard, C.; Ott, P.A.; Haas, N.B.; Lopez, J.S.; Ejadi, S.; Wallmark, J.M.; Keam, B.; Delord, J.-P.; Aggarwal, R.; et al. Pembrolizumab for advanced prostate adenocarcinoma: Findings of the KEYNOTE-028 study. *Ann. Oncol.* **2018**, *29*, 1807–1813. [CrossRef]
33. Schuhmacher, J.; Heidu, S.; Balchen, T.; Richardson, J.R.; Schmeltz, C.; Sonne, J.; Schweiker, J.; Rammensee, H.-G.; Straten, P.T.; Røder, M.A.; et al. Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: Results from a phase I/II clinical trial. *J. Immunother. Cancer* **2020**, *8*, e001157. [CrossRef] [PubMed]
34. Garbe, C.; Radny, P.; Linse, R.; Dummer, R.; Gutzmer, R.; Ulrich, J.; Stadler, R.; Weichenthal, M.; Eigentler, T.; Ellwanger, U.; et al. Adjuvant low-dose interferon α2a with or without dacarbazine compared with surgery alone: A prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. *Ann. Oncol.* **2008**, *19*, 1195–1201. [CrossRef] [PubMed]
35. Namikawa, K.; Kiyohara, Y.; Takenouchi, T.; Uhara, H.; Uchi, H.; Yoshikawa, S.; Takatsuka, S.; Koga, H.; Wada, N.; Minami, H.; et al. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study. *Eur. J. Cancer* **2018**, *105*, 114–126. [CrossRef] [PubMed]
36. Hemstock, M.; Amadi, A.; Kupas, K.; Roskell, N.; Kotapati, S.; Gooden, K.; Middleton, M.R.; Schadendorf, D. Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma. *Eur. J. Cancer* **2020**, *132*, 176–186. [CrossRef]
37. Anguille, S.; Van de Velde, A.L.; Smits, E.L.; Van Tendeloo, V.F.; Juliusson, G.; Cools, N.; Nijs, G.; Stein, B.; Lion, E.; Van Driessche, A.; et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. *Blood* **2017**, *130*, 1713–1721. [CrossRef]
38. Kreitman, R.J.; Dearden, C.; Zinzani, P.L.; Delgado, J.; Robak, T.; le Coutre, P.D.; Gjertsen, B.T.; Troussard, X.; Roboz, G.J.; Karlin, L.; et al. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): Long-term follow-up from the pivotal trial. *J. Hematol. Oncol.* **2021**, *14*, 1–11. [CrossRef]
39. Wang, M.; Munoz, J.; Goy, A.; Locke, F.L.; Jacobson, C.A.; Hill, B.T.; Timmerman, J.M.; Holmes, H.; Jaglowski, S.; Flinn, I.W.; et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. *N. Engl. J. Med.* **2020**, *382*, 1331–1342. [CrossRef]

40. Maruyama, D.; Hatake, K.; Kinoshita, T.; Fukuhara, N.; Choi, I.; Taniwaki, M.; Ando, K.; Terui, Y.; Higuchi, Y.; Onishi, Y.; et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. *Cancer Sci.* **2017**, *108*, 1007–1012. [CrossRef]
41. Fan, H.; Lu, X.; Wang, X.; Liu, Y.; Guo, B.; Zhang, Y.; Zhang, W.; Nie, J.; Feng, K.; Chen, M.; et al. Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report. *J. Immunol. Res.* **2014**, *2014*, 1–14. [CrossRef]
42. Heiss, M.M.; Murawa, P.; Koralewski, P.; Kutarska, E.; Kolesnik, O.O.; Ivanchenko, V.V.; Dudnichenko, A.S.; Aleknaviciene, B.; Razbadauskas, A.; Gore, M.; et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. *Int. J. Cancer* **2010**, *127*, 2209–2221. [CrossRef]
43. Burges, A.; Wimberger, P.; Kümper, C.; Gorbounova, V.; Sommer, H.; Schmalfeldt, B.; Pfisterer, J.; Lichinitser, M.; Makhson, A.; Moiseyenko, V.; et al. Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study. *Clin. Cancer Res.* **2007**, *13*, 3899–3905. [CrossRef] [PubMed]
44. Desai, K.; McManus, J.M.; Sharifi, N. Hormonal Therapy for Prostate Cancer. *Endocr. Rev.* **2021**, *42*, 354–373. [CrossRef] [PubMed]
45. Daniel, M.; Keefe, F.J.; Lyna, P.; Peterson, B.; Garst, J.; Kelley, M.; Bepler, G.; Bastian, L.A. Persistent Smoking After a Diagnosis of Lung Cancer Is Associated with Higher Reported Pain Levels. *J. Pain* **2009**, *10*, 323–328. [CrossRef] [PubMed]
46. Yanyan, H.; Dandan, L.; Lianhong, L. PD-1/PD-L1 Pathway: Current Researches in Cancer. *Am. J. Cancer Res.* **2020**, *10*, 727.
47. Benjamin, D.J.; Xu, A.; Lythgoe, M.P.; Prasad, V. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021. *JAMA Netw. Open* **2022**, *5*, e222265. [CrossRef]
48. Kichloo, A.; Albosta, M.; Dahiya, D.; Guidi, J.C.; Aljadah, M.; Singh, J.; Shaka, H.; Wani, F.; Kumar, A.; Lekkala, M. Systemic adverse effects and toxicities associated with immunotherapy: A review. *World J. Clin. Oncol.* **2021**, *12*, 150–163. [CrossRef]
49. Migden, M.R.; Rischin, D.; Schmults, C.D.; Guminski, A.; Hauschild, A.; Lewis, K.D.; Chung, C.H.; Hernandez-Aya, L.F.; Lim, A.M.; Chang, A.L.S.; et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. *N. Engl. J. Med.* **2018**, *379*, 341–351. [CrossRef]
50. Ahmad, A.; Uddin, S.; Steinhoff, M. CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas. *Int. J. Mol. Sci.* **2020**, *21*, 3906. [CrossRef]
51. Voelker, R. Immunotherapy Is Now First-line Therapy for Some Colorectal Cancers. *JAMA* **2020**, *324*, 433. [CrossRef]
52. Xiong, A.; Wang, J.; Zhou, C. Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China. *Front. Oncol.* **2021**, *11*. [CrossRef]
53. Brown, T.J.; Mamtani, R.; Bange, E.M. Immunotherapy Adverse Effects. *JAMA Oncol.* **2021**, *7*, 1908. [CrossRef]
54. Barber, F.D. Adverse Events of Oncologic Immunotherapy and Their Management. *Asia-Pac. J. Oncol. Nurs.* **2019**, *6*, 212–226. [CrossRef] [PubMed]
55. Geisler, A.N.; Phillips, G.S.; Barrios, D.M.; Wu, J.; Leung, D.Y.M.; Moy, A.P.; Kern, J.A.; Lacouture, M.E. Immune checkpoint inhibitor–related dermatologic adverse events. *J. Am. Acad. Dermatol.* **2020**, *83*, 1255–1268. [CrossRef] [PubMed]
56. Si, X.; He, C.; Zhang, L.; Liu, X.; Li, Y.; Wang, H.; Guo, X.; Zhou, J.; Duan, L.; Wang, M.; et al. Management of immune checkpoint inhibitor-related dermatologic adverse events. *Thorac. Cancer* **2019**, *11*, 488–492. [CrossRef]
57. Apalla, Z.; Rapoport, B.; Sibaud, V. Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management. *Int. J. Women's Dermatol.* **2021**, *7*, 625–635. [CrossRef] [PubMed]
58. Liu, Y.-H.; Zang, X.-Y.; Wang, J.-C.; Huang, S.-S.; Xu, J.; Zhang, P. Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy. *Biomed. Pharmacother.* **2019**, *120*, 109437. [CrossRef]
59. Rajha, E.; Chaftari, P.; Kamal, M.; Maamari, J.; Chaftari, C.; Yeung, S.-C.J. Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy. *Gastroenterol. Rep.* **2019**, *8*, 25–30. [CrossRef]
60. Ganatra, S.; Parikh, R.; Neilan, T.G. Cardiotoxicity of Immune Therapy. *Cardiol. Clin.* **2019**, *37*, 385–397. [CrossRef] [PubMed]
61. Ala, C.K.; Klein, A.L.; Moslehi, J.J. Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management. *Curr. Cardiol. Rep.* **2019**, *21*, 156. [CrossRef]
62. Del Rivero, J.; Cordes, L.M.; Klubo-Gwiezdzinska, J.; Madan, R.A.; Nieman, L.K.; Gulley, J.L. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management. *Oncologist* **2019**, *25*, 290–300. [CrossRef]
63. Chalan, P.; Di Dalmazi, G.; Pani, F.; De Remigis, A.; Corsello, A.; Caturegli, P. Thyroid dysfunctions secondary to cancer immunotherapy. *J. Endocrinol. Investig.* **2017**, *41*, 625–638. [CrossRef] [PubMed]
64. Delaunay, M.; Prévot, G.; Collot, S.; Guilleminault, L.; Didier, A.; Mazières, J. Management of pulmonary toxicity associated with immune checkpoint inhibitors. *Eur. Respir. Rev.* **2019**, *28*, 190012. [CrossRef] [PubMed]
65. Long, B.J.; Brem, E.; Koyfman, A. Oncologic Emergencies: Immune-Based Cancer Therapies and Complications. *West. J. Emerg. Med.* **2020**, *21*, 566–580. [CrossRef] [PubMed]
66. Chuzi, S.; Tavora, F.; Cruz, M.; Costa, R.; Chae, Y.K.; Carneiro, A.B.; Giles, F.J. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. *Cancer Manag. Res.* **2017**, *9*, 207–213. [CrossRef]
67. Lipe, D.N.; Shafer, S. CAR-T and checkpoint inhibitors: Toxicities and antidotes in the emergency department. *Clin. Toxicol.* **2021**, *59*, 376–385. [CrossRef]
68. Pallin, D.J.; Baugh, C.W.; Postow, M.A.; Caterino, J.M.; Erickson, T.B.; Lyman, G.H. Immune-related Adverse Events in Cancer Patients. *Acad. Emerg. Med.* **2018**, *25*, 819–827. [CrossRef] [PubMed]

69. Sibeoni, J.; Picard, C.; Orri, M.; Labey, M.; Bousquet, G.; Verneuil, L.; Revah-Levy, A. Patients' quality of life during active cancer treatment: A qualitative study. *BMC Cancer* **2018**, *18*, 951. [CrossRef]
70. Ramirez, R.A.; Lu, J.; Thomas, K.E.H. Quality of life for non-small cell lung cancer patients in the age of immunotherapy. *Transl. Lung Cancer Res.* **2018**, *7*, S149–S152. [CrossRef] [PubMed]

Cancers

COUNTRY

Switzerland

Universities and research institutions in Switzerland

Media Ranking in Switzerland

PUBLISHER

Multidisciplinary Digital Publishing Institute (MDPI)

H-INDEX

92

SUBJECT AREA AND CATEGORY

Biochemistry, Genetics and Molecular Biology
Cancer Research

Medicine
Oncology

PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
Journals	20726694	2009-2021	Homepage How to publish in this journal scmok@mdanderson.org

SCOPE

Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes article types including Research Papers, Reviews, Editorials, Communications, etc. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. The full experimental details must be provided so that the results can be reproduced. There is, in addition, a unique feature of this journal: we accept studies showing meaningful but negative results. While there are many journals that focus on cancer studies, none of them actively accepts negative results. As a result, most negative data end up not being in the public domain even if the data were meaningfully negative and the study well designed. By accepting those negative results, our journal encourages scientists to share those data so that they would not need to repeat the experiments that somebody else has already done. We publish high-quality articles including basic, translational, and clinical studies on all tumor types.

Quartiles

FIND SIMILAR JOURNALS

options

1	2	3	4	5
Oncotarget	**Frontiers in Oncology**	**Cancer Science**	**Journal of Oncology**	**Translational Oncology**
USA	CHE	USA	USA	USA
97% similarity	95% similarity	92% similarity	92% similarity	92% similarity

















← Show this widget in your own website

Just copy the code below and paste within your html code:

<a href="https://www.scimag

SCImago Graphica

Explore, visually communicate and make sense of data with our **new data visualization tool**.